U.S. patent application number 12/761080 was filed with the patent office on 2010-10-21 for 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2.
Invention is credited to Cuifen Hou, Heather Rae Hufnagel, Dana L. Johnson, Zhihua Sui, Xuqing Zhang.
Application Number | 20100267689 12/761080 |
Document ID | / |
Family ID | 42167720 |
Filed Date | 2010-10-21 |
United States Patent
Application |
20100267689 |
Kind Code |
A1 |
Zhang; Xuqing ; et
al. |
October 21, 2010 |
4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2
Abstract
The present invention comprises compounds of Formula (I):
##STR00001## wherein: X, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are
as defined in the specification. The invention also comprises a
method of preventing, treating or ameliorating a syndrome, disorder
or disease, wherein said syndrome, disorder or disease is type II
diabetes, obesity and asthma. The invention also comprises a method
of inhibiting CCR2 activity in a mammal by administration of a
therapeutically effective amount of at least one compound of
Formula (I).
Inventors: |
Zhang; Xuqing; (Audubon,
PA) ; Hufnagel; Heather Rae; (Glenmoore, PA) ;
Hou; Cuifen; (Spring House, PA) ; Johnson; Dana
L.; (Upper Black Eddy, PA) ; Sui; Zhihua;
(Spring House, PA) |
Correspondence
Address: |
PHILIP S. JOHNSON;JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933-7003
US
|
Family ID: |
42167720 |
Appl. No.: |
12/761080 |
Filed: |
April 15, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61170307 |
Apr 17, 2009 |
|
|
|
Current U.S.
Class: |
514/210.21 ;
514/210.19; 514/210.2; 548/171; 548/221; 548/524; 548/953 |
Current CPC
Class: |
A61P 9/04 20180101; A61P
11/00 20180101; A61P 31/04 20180101; A61P 35/02 20180101; C07D
205/04 20130101; A61P 1/04 20180101; A61P 11/02 20180101; A61P
17/00 20180101; A61P 35/00 20180101; A61P 43/00 20180101; A61P 1/02
20180101; A61P 27/02 20180101; A61P 11/06 20180101; C07D 417/08
20130101; A61P 17/06 20180101; A61P 29/00 20180101; C07D 403/10
20130101; A61P 37/08 20180101; A61P 9/10 20180101; A61P 3/04
20180101; A61P 3/10 20180101; A61P 37/06 20180101; A61P 27/14
20180101; C07D 413/08 20130101; C07D 403/08 20130101; A61P 13/12
20180101; A61P 25/00 20180101; A61P 31/06 20180101; A61P 17/04
20180101; C07D 405/08 20130101; A61P 19/02 20180101 |
Class at
Publication: |
514/210.21 ;
548/953; 548/221; 514/210.19; 548/171; 548/524; 514/210.2 |
International
Class: |
A61K 31/423 20060101
A61K031/423; C07D 205/04 20060101 C07D205/04; C07D 413/10 20060101
C07D413/10; A61K 31/397 20060101 A61K031/397; A61P 9/10 20060101
A61P009/10; A61P 27/02 20060101 A61P027/02; A61P 19/02 20060101
A61P019/02; A61P 17/06 20060101 A61P017/06; A61P 1/04 20060101
A61P001/04; A61P 13/12 20060101 A61P013/12; A61P 37/06 20060101
A61P037/06; A61P 3/10 20060101 A61P003/10; A61P 3/04 20060101
A61P003/04; A61P 31/04 20060101 A61P031/04; A61P 31/06 20060101
A61P031/06; A61P 29/00 20060101 A61P029/00; A61P 11/06 20060101
A61P011/06; A61P 1/02 20060101 A61P001/02; A61P 9/04 20060101
A61P009/04; A61P 35/00 20060101 A61P035/00; A61P 35/02 20060101
A61P035/02; C07D 417/10 20060101 C07D417/10; C07D 403/10 20060101
C07D403/10; A61K 31/4025 20060101 A61K031/4025 |
Claims
1. A compound of Formula (I) ##STR00268## wherein: X is NH.sub.2,
F, H, SH, S(O)CH.sub.3, SCH.sub.3, SO.sub.2CH.sub.3, or OH; R.sup.1
is phenyl optionally substituted with one or two substituents, one
of which is selected from the group consisting of:
OC.sub.(1-4)alkyl, SC.sub.(1-4)alkyl, SOC.sub.(1-4)alkyl,
SO.sub.2C.sub.(1-4)alkyl, --OSO.sub.2NH.sub.2,
--SO.sub.2NHC.sub.(1-4)alkyl, --OSO.sub.2NH.sub.2,
--SO.sub.2NH.sub.2, N(C.sub.(1-4)alkyl).sub.2, NH.sub.2,
NHC.sub.1-4)alkyl, NHSO.sub.2C.sub.(1-4)alkyl,
N(SO.sub.2CH.sub.3).sub.2, OH,
OC.sub.(1-4)alkylCO.sub.2C.sub.(1-4)alkyl,
OC.sub.(1-4)alkylCO.sub.2H,
OCH.sub.2CH.sub.2N(C.sub.(1-4)alkyl).sub.2, F, Cl, CH.sub.2CN, CN,
C.sub.(1-4)alkyl, NHCO.sub.2H, NHCO.sub.2C.sub.(1-4)alkyl,
NHCOC.sub.(1-4)alkyl, --C.ident.CH, CONH.sub.2, NHCONH.sub.2,
NHCONHC.sub.(1-4)alkyl, CONHC.sub.(1-4)alkyl,
CH.sub.2CONHC.sub.(1-4)alkyl, C.sub.(1-4)alkylCONH.sub.2,
C.sub.(1-4)alkylCO.sub.2C.sub.(1-4)alkyl,
C.sub.(1-4)alkylCO.sub.2H, CO.sub.2H, CH.sub.2C(NH)NH.sub.2,
CO.sub.2C.sub.(1-4)alkyl, CF.sub.3, OCHF.sub.2, CHF.sub.2,
OCF.sub.3, OCH.sub.2CF.sub.3, cycloalkyl, heterocyclyl, phenoxy,
phenyl, CH.sub.2phenyl, CH.sub.2heteroaryl, and heteroaryl; and the
second substituent, if present, is selected from the group
consisting of F, C.sub.(2-4)alkyl and OCH.sub.3, or said phenyl may
be substituted on two adjacent carbon atoms to form a fused
bicyclic system, selected from the group consisting of
benzothiazolyl, benzooxazolyl, benzofuranyl, indolyl, quinolinyl,
isoquinolinyl, benzo[b]thiophenyl, 3H-benzothiazol-2-onyl,
3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl,
1-methyl-1H-benzoimidazolyl, benzo[1,3]dioxolyl,
2,3-dihydro-benzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, wherein
said 3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl, and
1-methyl-1H-benzoimidazolyl, are optionally substituted on any
nitrogen atom with C.sub.(1-4)alkyl; R.sup.2 is H,
C.sub.(1-4)alkyl, NH.sub.2, NO.sub.2, NHCH.sub.2CH.sub.2OH,
N(C.sub.(1-4)alkyl).sub.2, N(SO.sub.2CH.sub.3).sub.2,
NHCONHC.sub.(1-4)alkyl, CN, F, Cl, Br, CF.sub.3, cycloalkyl,
heterocyclyl, OCF.sub.3, OCF.sub.2H, CF.sub.2H, or
OC.sub.(1-4)alkyl; R.sup.3 is F, Cl, CF.sub.3, or
OC.sub.(1-4)alkyl; alternatively, R.sup.2 and R.sup.3 may be taken
together with their attached phenyl to form a benzo[1,3]dioxolyl,
2,3-dihydro-benzofuranyl, or 2,3-dihydro-benzo[1,4]dioxinyl group;
R.sup.4 is H, OC.sub.(1-4)alkyl, or F; and solvates, hydrates,
tautomers, prodrugs, and pharmaceutically acceptable salts
thereof.
2. A compound of claim 1 wherein: X is NH.sub.2, F, H, or OH;
R.sup.1 is phenyl optionally substituted with one or two
substituents, one of which is selected from the group consisting
of: OC.sub.(1-4)alkyl, SC.sub.(1-4)alkyl, SOC.sub.(1-4)alkyl,
SO.sub.2C.sub.(1-4)alkyl, --OSO.sub.2NH.sub.2,
--SO.sub.2NHC.sub.(1-4)alkyl, --OSO.sub.2NH.sub.2,
--SO.sub.2NH.sub.2, N(C.sub.(1-4)alkyl).sub.2, NH.sub.2,
NHC.sub.(1-4)alkyl, NHSO.sub.2C.sub.(1-4)alkyl,
N(SO.sub.2CH.sub.3).sub.2, OH, OCH.sub.2CO.sub.2C.sub.(1-4)alkyl,
OCH.sub.2CO.sub.2H, OCH.sub.2CH.sub.2N(CH.sub.3).sub.2, F, Cl,
CH.sub.2CN, CN, C.sub.(1-4)alkyl, NHCO.sub.2H,
NHCO.sub.2C.sub.(1-4)alkyl, NHCOC.sub.(1-4)alkyl, --C.ident.CH,
CONH.sub.2, NHCONH.sub.2, NHCONHC.sub.(1-4)alkyl,
CONHC.sub.(1-4)alkyl, CH.sub.2CONHC.sub.(1-4)alkyl,
CH.sub.2CONH.sub.2, CH.sub.2CO.sub.2C.sub.(1-4)alkyl,
CH.sub.2CO.sub.2H, CO.sub.2H, CH.sub.2C(NH)NH.sub.2,
CO.sub.2C.sub.(1-4)alkyl, CF.sub.3, OCHF.sub.2, CHF.sub.2,
OCF.sub.3, cyclopentyl, cyclohexyl, morpholinyl, piperazinyl,
piperidinyl, phenoxy, CH.sub.2phenyl, phenyl, CH.sub.2pyridyl,
pyridyl, pyrrolidinyl, CH.sub.2tetrazolyl, and tetrazolyl; and the
second substituent, if present, is selected from the group
consisting of F, CH.sub.2CH.sub.3 and OCH.sub.3, or said phenyl may
be substituted on two adjacent carbon atoms to form a fused
bicyclic system, selected from the group consisting of
3H-benzothiazol-2-onyl, 3H-benzooxazol-2-onyl,
1,3-dihydro-benzoimidazol-2-onyl, 1-methyl-1H-benzoimidazolyl,
benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl,
2,3-dihydro-benzo[1,4]dioxinyl, wherein said 3H-benzooxazol-2-onyl,
1,3-dihydro-benzoimidazol-2-onyl, and 1-methyl-1H-benzoimidazolyl,
are optionally substituted on any nitrogen atom with
C.sub.(1-4)alkyl; R.sup.2 is H, C.sub.(1-4)alkyl, NH.sub.2,
NO.sub.2, NHCH.sub.2CH.sub.2OH, N(C.sub.(1-4)alkyl).sub.2,
N(SO.sub.2CH.sub.3).sub.2, NHCONHC.sub.(1-4)alkyl, CN, F, Cl, Br,
CF.sub.3, pyridinyl, pyrrolidinyl, OCF.sub.3, OCF.sub.2H,
CF.sub.2H, or OC.sub.(1-4)alkyl; R.sup.3 is F, Cl, CF.sub.3, or
OC.sub.(1-4)alkyl; alternatively, R.sup.2 and R.sup.3 may be taken
together with their attached phenyl to form a benzo[1,3]dioxolyl
group; R.sup.4 is H, OCH.sub.3, or F; and solvates, hydrates,
tautomers, prodrugs, and pharmaceutically acceptable salts
thereof.
3. A compound claim 2 wherein: R.sup.1 is phenyl optionally
substituted with one or two substituents, one of which is selected
from the group consisting of: OC.sub.(1-4)alkyl, SC.sub.(1-4)alkyl,
SO.sub.2CH.sub.3, N(C.sub.(1-4)alkyl).sub.2, NH.sub.2,
NHSO.sub.2C.sub.(1-4)alkyl, N(SO.sub.2CH.sub.3).sub.2, OH, F, Cl,
CH.sub.2CN, CN, C.sub.(1-4)alkyl, NHCO.sub.2C(CH.sub.3).sub.3,
OCH.sub.2CO.sub.2C.sub.(1-4)alkyl, OCH.sub.2CO.sub.2H,
OCH.sub.2CH.sub.2N(CH.sub.3).sub.2, --C.ident.CH, CONH.sub.2,
CO.sub.2H, CO.sub.2C.sub.(1-4)alkyl, CH.sub.2CO.sub.2H,
CH.sub.2CO.sub.2C.sub.(1-4)alkyl, CH.sub.2C(NH)NH.sub.2,
CH.sub.2CONH.sub.2, pyrrolidinyl, CH.sub.2tetrazolyl, and
tetrazolyl; and the second substituent, if present, is selected
from the group consisting of F, CH.sub.2CH.sub.3 and OCH.sub.3, or
said phenyl may be substituted on two adjacent carbon atoms to form
a fused bicyclic system, selected from the group consisting of
3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl,
1-methyl-1H-benzoimidazolyl, benzo[1,3]dioxolyl,
2,3-dihydro-benzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, wherein
said 3H-benzothiazol-2-onyl, 3H-benzooxazol-2-onyl,
1,3-dihydro-benzoimidazol-2-onyl, and 1-methyl-1H-benzoimidazolyl,
are optionally substituted on any nitrogen atom with
C.sub.(1-4)alkyl; R.sup.2 is H, NH.sub.2, NO.sub.2,
NHCH.sub.2CH.sub.2OH, N(CH.sub.3).sub.2, N(SO.sub.2CH.sub.3).sub.2,
NHCONHC.sub.(1-4)alkyl, CN, F, Cl, Br, CF.sub.3, pyridinyl,
pyrrolidinyl, or OCH.sub.3; R.sup.3 is F, Cl, CF.sub.3, or
OCH.sub.3; alternatively, R.sup.2 and R.sup.3 may be taken together
with their attached phenyl to form a benzo[1,3]dioxolyl group;
R.sup.4 is H, or F; and solvates, hydrates, tautomers, prodrugs,
and pharmaceutically acceptable salts thereof.
4. A compound claim 3 wherein: R.sup.1 is phenyl optionally
substituted with one substituent selected from the group consisting
of: OC.sub.(1-4)alkyl, SC.sub.(1-4)alkyl, SO.sub.2CH.sub.3,
N(C.sub.(1-4)alkyl).sub.2, NH.sub.2, NHSO.sub.2C.sub.(1-4)alkyl,
N(SO.sub.2CH.sub.3).sub.2, OH, F, Cl, CH.sub.2CN, CN,
C.sub.(1-4)alkyl, NHCO.sub.2C(CH.sub.3).sub.3,
OCH.sub.2CO.sub.2C.sub.(1-4)alkyl, OCH.sub.2CO.sub.2H,
OCH.sub.2CH.sub.2N(CH.sub.3).sub.2, --C.ident.CH, CONH.sub.2,
CO.sub.2H, CO.sub.2C.sub.(1-4)alkyl, CH.sub.2CO.sub.2H,
CH.sub.2CO.sub.2C.sub.(1-4)alkyl, CH.sub.2C(NH)NH.sub.2,
CH.sub.2CONH.sub.2, pyrrolidinyl, CH.sub.2tetrazolyl, and
tetrazolyl; or said phenyl may be substituted with one OCH.sub.3
group and one F, or said phenyl may be substituted on two adjacent
carbon atoms to form a fused bicyclic system, selected from the
group consisting of 3H-benzothiazol-2-onyl, 3H-benzooxazol-2-onyl,
1,3-dihydro-benzoimidazol-2-onyl, 1-methyl-1H-benzoimidazolyl,
benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl,
2,3-dihydro-benzo[1,4]dioxinyl, wherein said 3H-benzooxazol-2-onyl,
1,3-dihydro-benzoimidazol-2-onyl, and 1-methyl-1H-benzoimidazolyl,
are optionally substituted on any nitrogen atom with
C.sub.(1-4)alkyl. and solvates, hydrates, tautomers, prodrugs, and
pharmaceutically acceptable salts thereof.
5. A compound claim 4 wherein: R.sup.1 is phenyl, ##STR00269##
wherein said phenyl is optionally substituted with one substituent
selected from the group consisting of: OCH.sub.3, SCH.sub.3,
SO.sub.2CH.sub.3, N(CH.sub.3).sub.2, NH.sub.2, NHSO.sub.2CH.sub.3,
N(SO.sub.2CH.sub.3).sub.2, OH, F, Cl, CH.sub.2CN, CN, CH.sub.3,
NHCO.sub.2C(CH.sub.3).sub.3, OCH.sub.2CO.sub.2CH.sub.3,
OCH.sub.2CO.sub.2H, OCH.sub.2CH.sub.2N(CH.sub.3).sub.2,
--C.ident.CH, CH.sub.2CH.sub.3, CONH.sub.2, CO.sub.2H,
CO.sub.2CH.sub.3, CO.sub.2CH.sub.2CH.sub.3, CH.sub.2CO.sub.2H,
CH.sub.2CO.sub.2CH.sub.2CH.sub.3, CH.sub.2C(NH)NH.sub.2,
CH.sub.2CONH.sub.2, pyrrolidinyl, CH.sub.2tetrazolyl and
tetrazolyl; or said phenyl may be substituted with one OCH.sub.3
group and one F; R.sup.2 is H, F, Br, CF.sub.3, NO.sub.2, NH.sub.2,
NHCH.sub.2CH.sub.2OH, N(CH.sub.3).sub.2, N(SO.sub.2CH.sub.3).sub.2,
NHCONHC.sub.(1-4)alkyl, pyrrolidinyl, pyridinyl, OCH.sub.3; R.sup.3
is CF.sub.3; R.sup.4 is H; and solvates, hydrates, tautomers,
prodrugs, and pharmaceutically acceptable salts thereof.
6. A compound selected from the group consisting of: ##STR00270##
##STR00271## ##STR00272## ##STR00273## ##STR00274## ##STR00275##
##STR00276## ##STR00277## ##STR00278## ##STR00279## ##STR00280##
##STR00281## ##STR00282## ##STR00283## ##STR00284## ##STR00285##
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically
acceptable salts thereof.
7. A compound of claim 6 selected from the group consisting of:
##STR00286## ##STR00287## ##STR00288## and solvates, hydrates,
tautomers, prodrugs, and pharmaceutically acceptable salts
thereof.
8. A compound of claim 7, which is ##STR00289## and solvates,
hydrates, tautomers, prodrugs, and pharmaceutically acceptable
salts thereof.
9. A pharmaceutical composition, comprising a compound of claim 1
and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition made by mixing a compound of claim
1 and a pharmaceutically acceptable carrier.
11. A process for making a pharmaceutical composition comprising
mixing a compound of claim 1 and a pharmaceutically acceptable
carrier.
12. A process for the preparation of a compound of Formula (I) of
claim 1, comprising reacting a compound of Formula (V) ##STR00290##
with a compound of Formula (VI) ##STR00291## in the presence of a
reducing agent to provide the compound of Formula (I).
13. A product made by the process of claim 12.
14. A process for the preparation of a compound of Formula (I) of
claim 1, comprising reacting a compound of Formula (XIII)
##STR00292## where R.sub.a is OH or Cl, with ##STR00293## in the
presence of HOBt/EDCI or Et.sub.3N to provide the compound of
Formula (I).
15. A product made by the process of claim 14.
16. A method for preventing, treating or ameliorating a CCR2
mediated syndrome, disorder or disease comprising administering to
a subject in need thereof a therapeutically effective amount of a
compound of claim 1.
17. A method for preventing, treating or ameliorating a CCR2
mediated inflammatory syndrome, disorder or disease wherein the
syndrome, disorder or disease is associated with elevated MCP-1
expression or MCP-1 overexpression, or is an inflammatory condition
that accompanies syndromes, disorders or diseases associated with
elevated MCP-1 expression or MCP-1 overexpression comprising
administering to a subject in need thereof an effective amount of a
compound of claim 1.
18. A method of preventing, treating or ameliorating a syndrome,
disorder or disease, wherein said syndrome, disorder or disease is
selected from the group consisting of: Chronic Obstructive
Pulmonary Disease (COPD), ophthalmic disorders, uveitis,
atherosclerosis, rheumatoid arthritis, psoriasis, psoriatic
arthritis, atopic dermatitis, multiple sclerosis, Crohn's Disease,
ulcerative colitis, nephritis, organ allograft rejection, fibroid
lung, renal insufficiency, type-I diabetes, type II diabetes and
diabetic complications, diabetic nephropathy, diabetic retinopathy,
diabetic retinitis, diabetic microangiopathy, overweight, obesity,
obesity-associated insulin resistance, tuberculosis, chronic
obstructive pulmonary disease, sarcoidosis, invasive
staphyloccocia, inflammation after cataract surgery, allergic
rhinitis, allergic conjunctivitis, chronic urticaria, asthma,
allergic asthma, periodontal diseases, periodonitis, gingivitis,
gum disease, diastolic cardiomyopathies, cardiac infarction,
myocarditis, chronic heart failure, angiostenosis, restenosis,
reperfusion disorders, glomerulonephritis, solid tumors and
cancers, chronic lymphocytic leukemia, chronic myelocytic leukemia,
multiple myeloma, malignant myeloma, Hodgkin's disease, and
carcinomas of the bladder, breast, cervix, colon, lung, prostate,
or stomach comprising administering to a subject in need thereof an
effective amount of a compound of claim 1.
19. A method of preventing, treating or ameliorating a syndrome,
disorder or disease, wherein said syndrome, disorder or disease is
selected from the group consisting of: type II diabetes and
diabetic complications, diabetic nephropathy, diabetic retinopathy,
diabetic retinitis, diabetic microangiopathy, obesity, asthma, and
allergic asthma, comprising administering to a subject in need
thereof a therapeutically effective amount of a compound of claim
1.
20. A method of treating a disorder selected from the group
consisting of type II diabetes, obesity and asthma comprising
administering to a subject in need thereof a therapeutically
effective amount of a compound of claim 1.
21. A compound of claim 1, which is the less polar isomer of any of
Examples #1-88.
22. A compound of claim 1, which is the less polar isomer of
Example #30.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional
Applications Ser. No. 61/170,307 filed Apr. 17, 2009, the contents
of each of which are hereby incorporated by reference in their
entirety.
FIELD OF THE INVENTION
[0002] The invention is directed to substituted dipiperidine
compounds, which are antagonists to the chemoattractant cytokine
receptor 2 (CCR2), pharmaceutical compositions, and methods for use
thereof. More particularly, the CCR2 antagonists are substituted
piperidyl acrylamide compounds useful for preventing, treating or
ameliorating a CCR2 mediated syndrome, disorder or disease.
BACKGROUND OF THE INVENTION
[0003] CCR2 is a member of the GPCR family of receptors, as are all
known chemokine receptors, and are expressed by monocytes and
memory T-lymphocytes. The CCR2 signaling cascade involves
activation of phospholipases (PLC.beta.2), protein kinases (PKC),
and lipid kinases (PI-3 kinase).
[0004] Chemoattractant cytokines (i.e., chemokines) are relatively
small proteins (8-10 kD), which stimulate the migration of cells.
The chemokine family is divided into four subfamilies based on the
number of amino acid residues between the first and second highly
conserved cysteines.
[0005] Monocyte chemotactic protein-1 (MCP-1) is a member of the CC
chemokine subfamily (wherein CC represents the subfamily having
adjacent first and second cysteines) and binds to the cell-surface
chemokine receptor 2 (CCR2). MCP-1 is a potent chemotactic factor,
which, after binding to CCR2, mediates monocyte and lymphocyte
migration (i.e., chemotaxis) toward a site of inflammation. MCP-1
is also expressed by cardiac muscle cells, blood vessel endothelial
cells, fibroblasts, chondrocytes, smooth muscle cells, mesangial
cells, alveolar cells, T-lymphocytes, marcophages, and the
like.
[0006] After monocytes enter the inflammatory tissue and
differentiate into macrophages, monocyte differentiation provides a
secondary source of several proinflammatory modulators, including
tumor necrosis factor-.alpha. (TNF-.alpha.), interleukin-1 (IL-1),
IL-8 (a member of the CXC chemokine subfamily, wherein CXC
represents one amino acid residue between the first and second
cysteines), IL-12, arachidonic acid metabolites (e.g., PGE.sub.2
and LTB.sub.4), oxygen-derived free radicals, matrix
metalloproteinases, and complement components.
[0007] Animal model studies of chronic inflammatory diseases have
demonstrated that inhibition of binding between MCP-1 and CCR2 by
an antagonist suppresses the inflammatory response. The interaction
between MCP-1 and CCR2 has been implicated (see Rollins B J,
Monocyte chemoattractant protein 1: a potential regulator of
monocyte recruitment in inflammatory disease, Mol. Med. Today,
1996, 2:198; and Dawson J, et al., Targeting monocyte
chemoattractant protein-1 signaling in disease, Expert Opin. Ther.
Targets, 2003 Feb. 7 (1):35-48) in inflammatory disease pathologies
such as psoriasis, uveitis, atherosclerosis, rheumatoid arthritis
(RA), multiple sclerosis, Crohn's Disease, nephritis, organ
allograft rejection, fibroid lung, renal insufficiency, type II
diabetes and diabetic complications, diabetic nephropathy, diabetic
retinopathy, diabetic retinitis, diabetic microangiopathy,
tuberculosis, sarcoidosis, invasive staphylococcia, inflammation
after cataract surgery, allergic rhinitis, allergic conjunctivitis,
chronic urticaria, Chronic Obstructive Pulmonary Disease (COPD),
allergic asthma, periodontal diseases, periodonitis, gingivitis,
gum disease, diastolic cardiomyopathies, cardiac infarction,
myocarditis, chronic heart failure, angiostenosis, restenosis,
reperfusion disorders, glomerulonephritis, solid tumors and
cancers, chronic lymphocytic leukemia, chronic myelocytic leukemia,
multiple myeloma, malignant myeloma, Hodgkin's disease, and
carcinomas of the bladder, breast, cervix, colon, lung, prostate,
and stomach. Monocyte migration is inhibited by MCP-1 antagonists
(either antibodies or soluble, inactive fragments of MCP-1), which
have been shown to inhibit the development of arthritis, asthma,
and uveitis. Both MCP-1 and CCR2 knockout (KO) mice have
demonstrated that monocyte infiltration into inflammatory lesions
is significantly decreased. In addition, such KO mice are resistant
to the development of experimental allergic encephalomyelitis (EAE,
a model of human MS), cockroach allergen-induced asthma,
atherosclerosis, and uveitis. Rheumatoid arthritis and Crohn's
Disease patients have improved during treatment with TNF-.alpha.
antagonists (e.g., monoclonal antibodies and soluble receptors) at
dose levels correlated with decreases in MCP-1 expression and the
number of infiltrating macrophages.
[0008] MCP-1 has been implicated in the pathogenesis of seasonal
and chronic allergic rhinitis, having been found in the nasal
mucosa of most patients with dust mite allergies. MCP-1 has also
been found to induce histamine release from basophils in vitro.
During allergic conditions, both allergens and histamines have been
shown to trigger (i.e., to up-regulate) the expression of MCP-1 and
other chemokines in the nasal mucosa of people with allergic
rhinitis, suggesting the presence of a positive feedback loop in
such patients.
[0009] There remains a need for small molecule CCR2 antagonists for
preventing, treating or ameliorating a CCR2 mediated inflammatory
syndrome, disorder or disease resulting from MCP-1 induced monocyte
and lymphocyte migration to a site of inflammation. All documents
cited herein are incorporated by reference.
SUMMARY OF THE INVENTION
[0010] The present invention comprises compounds of Formula
(I).
##STR00002##
wherein:
X is NH.sub.2, F, H, SH, S(O)CH.sub.3, SCH.sub.3, SO.sub.2CH.sub.3,
or OH;
[0011] R.sup.1 is phenyl optionally substituted with one or two
substituents, one of which is selected from the group consisting
of: OC.sub.(1-4)alkyl, SC.sub.(1-4)alkyl, SOC.sub.(1-4)alkyl,
SO.sub.2C.sub.(1-4)alkyl, --OSO.sub.2NH.sub.2,
--SO.sub.2NHC.sub.(1-4)alkyl, --OSO.sub.2NH.sub.2,
--SO.sub.2NH.sub.2, N(C.sub.(1-4)alkyl).sub.2, NH.sub.2,
NHC.sub.(1-4)alkyl, NHSO.sub.2C.sub.(1-4)alkyl,
N(SO.sub.2CH.sub.3).sub.2, OH,
OC.sub.(1-4)alkylCO.sub.2C.sub.(1-4)alkyl,
OC.sub.(1-4)alkylCO.sub.2H,
OCH.sub.2CH.sub.2N(C.sub.(1-4)alkyl).sub.2, F, Cl, CH.sub.2CN, CN,
C.sub.(1-4)alkyl, NHCO.sub.2H, NHCO.sub.2C.sub.(1-4)alkyl,
NHCOC.sub.(1-4)alkyl, --C.ident.CH, CONH.sub.2, NHCONH.sub.2,
NHCONHC.sub.(1-4)alkyl, CONHC.sub.(1-4)alkyl,
CH.sub.2CONHC.sub.(1-4)alkyl, C.sub.(1-4)alkylCONH.sub.2,
C.sub.(1-4)alkylCO.sub.2C.sub.(1-4)alkyl,
C.sub.(1-4)alkylCO.sub.2H, CO.sub.2H, CH.sub.2C(NH)NH.sub.2,
CO.sub.2C.sub.(1-4)alkyl, CF.sub.3, OCHF.sub.2, CHF.sub.2,
OCF.sub.3, OCH.sub.2CF.sub.3, cycloalkyl, heterocyclyl, phenoxy,
phenyl, CH.sub.2phenyl, CH.sub.2heteroaryl, and heteroaryl; and the
second substituent, if present, is selected from the group
consisting of F, C.sub.(2-4)alkyl and OCH.sub.3, or said phenyl may
be substituted on two adjacent carbon atoms to form a fused
bicyclic system, selected from the group consisting of
benzothiazolyl, benzooxazolyl, benzofuranyl, indolyl, quinolinyl,
isoquinolinyl, benzo[b]thiophenyl, 3H-benzothiazol-2-onyl,
3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl,
1-methyl-1H-benzoimidazolyl, benzo[1,3]dioxolyl,
2,3-dihydro-benzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, wherein
said 3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl, and
1-methyl-1H-benzoimidazolyl, are optionally substituted on any
nitrogen atom with C.sub.(1-4)alkyl; R.sup.2 is H,
C.sub.(1-4)alkyl, NH.sub.2, NO.sub.2, NHCH.sub.2CH.sub.2OH,
N(C.sub.(1-4)alkyl).sub.2, N(SO.sub.2CH.sub.3).sub.2,
NHCONHC.sub.(1-4)alkyl, CN, F, Cl, Br, CF.sub.3, cycloalkyl,
heterocyclyl, OCF.sub.3, OCF.sub.2H, CF.sub.2H, or
OC.sub.(1-4)alkyl; R.sup.3 is F, Cl, CF.sub.3, or
OC.sub.(1-4)alkyl; alternatively, R.sup.2 and R.sup.3 may be taken
together with their attached phenyl to form a benzo[1,3]dioxolyl,
2,3-dihydro-benzofuranyl, or 2,3-dihydro-benzo[1,4]dioxinyl group;
R.sup.4 is H, OC.sub.(1-4)alkyl, or F; and solvates, hydrates,
tautomers, prodrugs, and pharmaceutically acceptable salts
thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0012] The present invention comprises compounds of Formula
(I):
##STR00003##
wherein X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described
above; and solvates, hydrates, tautomers, prodrugs, and
pharmaceutically acceptable salts thereof.
[0013] Another embodiment of the invention comprises the compounds
of Formula (Ia):
##STR00004##
wherein X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined
above for Formula (I); and solvates, hydrates, tautomers, prodrugs,
and pharmaceutically acceptable salts thereof.
[0014] Another embodiment of the invention comprises compounds of
Formula (I) and/or Formula (Ia) wherein:
X is NH.sub.2, F, H, or OH;
[0015] R.sup.1 is phenyl optionally substituted with one or two
substituents, one of which is selected from the group consisting
of: OC.sub.(1-4)alkyl, SC.sub.(1-4)alkyl, SOC.sub.(1-4)alkyl,
SO.sub.2C.sub.(1-4)alkyl, --OSO.sub.2NH.sub.2,
--SO.sub.2NHC.sub.(1-4)alkyl, --OSO.sub.2NH.sub.2,
--SO.sub.2NH.sub.2, N(C.sub.(1-4)alkyl).sub.2, NH.sub.2,
NHC.sub.1-4)alkyl, NHSO.sub.2C.sub.(1-4)alkyl,
N(SO.sub.2CH.sub.3).sub.2, OH, OCH.sub.2CO.sub.2C.sub.(1-4)alkyl,
OCH.sub.2CO.sub.2H, OCH.sub.2CH.sub.2N(CH.sub.3).sub.2, F, Cl,
CH.sub.2CN, CN, C.sub.(1-4)alkyl, NHCO.sub.2H,
NHCO.sub.2C.sub.(1-4)alkyl, NHCOC.sub.(1-4)alkyl, --C.ident.CH,
CONH.sub.2, NHCONH.sub.2, NHCONHC.sub.(1-4)alkyl,
CONHC.sub.(1-4)alkyl, CH.sub.2CONHC.sub.(1-4)alkyl,
CH.sub.2CONH.sub.2, CH.sub.2CO.sub.2C.sub.(1-4)alkyl,
CH.sub.2CO.sub.2H, CO.sub.2H, CH.sub.2C(NH)NH.sub.2,
CO.sub.2C.sub.(1-4)alkyl, CF.sub.3, OCHF.sub.2, CHF.sub.2,
OCF.sub.3, cyclopentyl, cyclohexyl, morpholinyl, piperazinyl,
piperidinyl, phenoxy, CH.sub.2phenyl, phenyl, CH.sub.2pyridyl,
pyridyl, pyrrolidinyl, CH.sub.2tetrazolyl, and tetrazolyl; and the
second substituent, if present, is selected from the group
consisting of F, CH.sub.2CH.sub.3 and OCH.sub.3, or said phenyl may
be substituted on two adjacent carbon atoms to form a fused
bicyclic system, selected from the group consisting of
3H-benzothiazol-2-onyl, 3H-benzooxazol-2-onyl,
1,3-dihydro-benzoimidazol-2-onyl, 1-methyl-1H-benzoimidazolyl,
benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl,
2,3-dihydro-benzo[1,4]dioxinyl, wherein said 3H-benzooxazol-2-onyl,
1,3-dihydro-benzoimidazol-2-onyl, and 1-methyl-1H-benzoimidazolyl,
are optionally substituted on any nitrogen atom with
C.sub.(1-4)alkyl; R.sup.2 is H, C.sub.(1-4)alkyl, NH.sub.2,
NO.sub.2, NHCH.sub.2CH.sub.2OH, N(C.sub.(1-4)alkyl).sub.2,
N(SO.sub.2CH.sub.3).sub.2, NHCONHC.sub.(1-4)alkyl, CN, F, Cl, Br,
CF.sub.3, pyridinyl, pyrrolidinyl, OCF.sub.3, OCF.sub.2H,
CF.sub.2H, or OC.sub.(1-4)alkyl; R.sup.3 is F, Cl, CF.sub.3, or
OC.sub.(1-4)alkyl; alternatively, R.sup.2 and R.sup.3 may be taken
together with their attached phenyl to form a benzo[1,3]dioxolyl
group;
R.sup.4 is H, OCH.sub.3, or F;
[0016] and solvates, hydrates, tautomers, prodrugs, and
pharmaceutically acceptable salts thereof.
[0017] Another embodiment of the invention comprises compounds of
Formula (I) and/or Formula (Ia) wherein:
X is NH.sub.2, F, H, or OH;
[0018] R.sup.1 is phenyl optionally substituted with one or two
substituents, one of which is selected from the group consisting
of: OC.sub.(1-4)alkyl, SC.sub.(1-4)alkyl, SO.sub.2CH.sub.3,
N(C.sub.(1-4)alkyl).sub.2, NH.sub.2, NHSO.sub.2C.sub.(1-4)alkyl,
N(SO.sub.2CH.sub.3).sub.2, OH, F, Cl, CH.sub.2CN, CN,
C.sub.(1-4)alkyl, NHCO.sub.2C(CH.sub.3).sub.3,
OCH.sub.2CO.sub.2C.sub.(1-4)alkyl, OCH.sub.2CO.sub.2H,
OCH.sub.2CH.sub.2N(CH.sub.3).sub.2, --C.ident.CH, CONH.sub.2,
CO.sub.2H, CO.sub.2C.sub.(1-4)alkyl, CH.sub.2CO.sub.2H,
CH.sub.2CO.sub.2C.sub.(1-4)alkyl, CH.sub.2C(NH)NH.sub.2,
CH.sub.2CONH.sub.2, pyrrolidinyl, CH.sub.2tetrazolyl, and
tetrazolyl; and the second substituent, if present, is selected
from the group consisting of F, CH.sub.2CH.sub.3 and OCH.sub.3, or
said phenyl may be substituted on two adjacent carbon atoms to form
a fused bicyclic system, selected from the group consisting of
3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl,
1-methyl-1H-benzoimidazolyl, benzo[1,3]dioxolyl,
2,3-dihydro-benzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, wherein
said 3H-benzothiazol-2-onyl, 3H-benzooxazol-2-onyl,
1,3-dihydro-benzoimidazol-2-onyl, and 1-methyl-1H-benzoimidazolyl,
are optionally substituted on any nitrogen atom with
C.sub.(1-4)alkyl; R.sup.2 is H, NH.sub.2, NO.sub.2,
NHCH.sub.2CH.sub.2OH, N(CH.sub.3).sub.2, N(SO.sub.2CH.sub.3).sub.2,
NHCONHC.sub.(1-4)alkyl, CN, F, Cl, Br, CF.sub.3, pyridinyl,
pyrrolidinyl, or OCH.sub.3; R.sup.3 is F, Cl, CF.sub.3, or
OCH.sub.3; alternatively, R.sup.2 and R.sup.3 may be taken together
with their attached phenyl to form a benzo[1,3]dioxolyl group;
R.sup.4 is H, or F;
[0019] and solvates, hydrates, tautomers, prodrugs, and
pharmaceutically acceptable salts thereof.
[0020] Another embodiment of the invention comprises compounds of
Formula (I) and/or Formula (Ia) wherein:
X is NH.sub.2, F, H, or OH;
[0021] R.sup.1 is phenyl optionally substituted with one
substituent selected from the group consisting of:
OC.sub.(1-4)alkyl, SC.sub.(1-4)alkyl, SO.sub.2CH.sub.3,
N(C.sub.(1-4)alkyl).sub.2, NH.sub.2, NHSO.sub.2C.sub.(1-4)alkyl,
N(SO.sub.2CH.sub.3).sub.2, OH, F, Cl, CH.sub.2CN, CN,
C.sub.(1-4)alkyl, NHCO.sub.2C(CH.sub.3).sub.3,
OCH.sub.2CO.sub.2C.sub.(1-4)alkyl, OCH.sub.2CO.sub.2H,
OCH.sub.2CH.sub.2N(CH.sub.3).sub.2, --C.ident.CH, CONH.sub.2,
CO.sub.2H, CO.sub.2C.sub.(1-4)alkyl, CH.sub.2CO.sub.2H,
CH.sub.2CO.sub.2C.sub.(1-4)alkyl, CH.sub.2C(NH)NH.sub.2,
CH.sub.2CONH.sub.2, pyrrolidinyl, CH.sub.2tetrazolyl, and
tetrazolyl; or said phenyl may be substituted with one OCH.sub.3
group and one F, or said phenyl may be substituted on two adjacent
carbon atoms to form a fused bicyclic system, selected from the
group consisting of 3H-benzothiazol-2-onyl, 3H-benzooxazol-2-onyl,
1,3-dihydro-benzoimidazol-2-onyl, 1-methyl-1H-benzoimidazolyl,
benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl,
2,3-dihydro-benzo[1,4]dioxinyl, wherein said 3H-benzooxazol-2-onyl,
1,3-dihydro-benzoimidazol-2-onyl, and 1-methyl-1H-benzoimidazolyl,
are optionally substituted on any nitrogen atom with
C.sub.(1-4)alkyl. R.sup.2 is H, NH.sub.2, NO.sub.2,
NHCH.sub.2CH.sub.2OH, N(CH.sub.3).sub.2, N(SO.sub.2CH.sub.3).sub.2,
NHCONHC.sub.(1-4)alkyl, CN, F, Cl, Br, CF.sub.3, pyridinyl,
pyrrolidinyl, or OCH.sub.3; R.sup.3 is F, Cl, CF.sub.3, or
OCH.sub.3; alternatively, R.sup.2 and R.sup.3 may be taken together
with their attached phenyl to form a benzo[1,3]dioxolyl group;
R.sup.4 is H, or F;
[0022] and solvates, hydrates, tautomers, prodrugs, and
pharmaceutically acceptable salts thereof.
[0023] Another embodiment of the invention comprises compounds of
Formula (I) and/or Formula (Ia) wherein:
X is NH.sub.2, F, H, or OH;
[0024] R.sup.1 is phenyl,
##STR00005##
wherein said phenyl is optionally substituted with one substituent
selected from the group consisting of: OCH.sub.3, SCH.sub.3,
SO.sub.2CH.sub.3, N(CH.sub.3).sub.2, NH.sub.2, NHSO.sub.2CH.sub.3,
N(SO.sub.2CH.sub.3).sub.2, OH, F, Cl, CH.sub.2CN, CN, CH.sub.3,
NHCO.sub.2C(CH.sub.3).sub.3, OCH.sub.2CO.sub.2CH.sub.3,
OCH.sub.2CO.sub.2H, OCH.sub.2CH.sub.2N(CH.sub.3).sub.2,
--C.ident.CH, CH.sub.2CH.sub.3, CONH.sub.2, CO.sub.2H,
CO.sub.2CH.sub.3, CO.sub.2CH.sub.2CH.sub.3, CH.sub.2CO.sub.2H,
CH.sub.2CO.sub.2CH.sub.2CH.sub.3, CH.sub.2C(NH)NH.sub.2,
CH.sub.2CONH.sub.2, pyrrolidinyl, CH.sub.2tetrazolyl and
tetrazolyl; or said phenyl may be substituted with one OCH.sub.3
group and one F; R.sup.2 is H, F, Br, CF.sub.3, NO.sub.2, NH.sub.2,
NHCH.sub.2CH.sub.2OH, N(CH.sub.3).sub.2, N(SO.sub.2CH.sub.3).sub.2,
NHCONHC.sub.(1-4)alkyl, pyrrolidinyl, pyridinyl, OCH.sub.3;
R.sup.3 is CF.sub.3;
R.sup.4 is H;
[0025] and solvates, hydrates, tautomers, prodrugs, and
pharmaceutically acceptable salts thereof.
[0026] Another embodiment of the invention is a compound which is
selected from the group consisting of:
##STR00006## ##STR00007## ##STR00008## ##STR00009## ##STR00010##
##STR00011## ##STR00012## ##STR00013## ##STR00014## ##STR00015##
##STR00016## ##STR00017## ##STR00018## ##STR00019## ##STR00020##
##STR00021##
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically
acceptable salts thereof.
[0027] Another embodiment of the invention is a compound which is
compound selected from the group consisting of:
##STR00022## ##STR00023## ##STR00024##
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically
acceptable salts thereof.
[0028] Another embodiment of the invention is a compound which
is
##STR00025##
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically
acceptable salts thereof.
[0029] Another embodiment of the invention is a compound selected
from the group consisting of:
##STR00026## ##STR00027## ##STR00028## ##STR00029## ##STR00030##
##STR00031## ##STR00032## ##STR00033## ##STR00034## ##STR00035##
##STR00036## ##STR00037## ##STR00038## ##STR00039## ##STR00040##
##STR00041##
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically
acceptable salts thereof.
[0030] Another embodiment of the invention is the compound:
##STR00042##
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically
acceptable salts thereof.
[0031] Another embodiment of the invention is a pharmaceutical
composition, comprising a compound of Formula (I) and/or (Ia) and a
pharmaceutically acceptable carrier.
[0032] Another embodiment of the invention is a pharmaceutical
composition, comprising a compound listed in the Examples section
of this specification and a pharmaceutically acceptable
carrier.
[0033] The present invention also provides a method for preventing,
treating or ameliorating a CCR2 mediated syndrome, disorder or
disease comprising administering to a subject in need thereof a
therapeutically effective amount of a compound of Formula (I)
and/or (Ia) or a form, composition or medicament thereof. In one
embodiment of the present invention, the CCR2 mediated syndrome,
disorder or disease is an inflammatory syndrome, disorder or
disease.
[0034] The present invention also provides a method for preventing,
treating or ameliorating a CCR2 mediated inflammatory syndrome,
disorder or disease wherein the syndrome, disorder or disease is
associated with elevated MCP-1 expression or MCP-1 overexpression,
or is an inflammatory condition that accompanies syndromes,
disorders or diseases associated with elevated MCP-1 expression or
MCP-1 overexpression comprising administering to a subject in need
thereof a therapeutically effective amount of a compound of Formula
(I) and/or (Ia) or a form, composition or medicament thereof.
[0035] The present invention also provides a method of preventing,
treating or ameliorating a syndrome, disorder or disease, wherein
said syndrome, disorder or disease is selected from the group
consisting of: Chronic Obstructive Pulmonary Disease (COPD),
ophthalmic disorders, uveitis, atherosclerosis, rheumatoid
arthritis, psoriasis, psoriatic arthritis, atopic dermatitis,
multiple sclerosis, Crohn's Disease, ulcerative colitis, nephritis,
organ allograft rejection, fibroid lung, renal insufficiency, type
II diabetes and diabetic complications, diabetic nephropathy,
obesity, weight disorders, diabetic retinopathy, diabetic
retinitis, diabetic microangiopathy, tuberculosis, chronic
obstructive pulmonary disease, sarcoidosis, invasive
staphyloccocia, inflammation after cataract surgery, allergic
rhinitis, allergic conjunctivitis, chronic urticaria, asthma,
allergic asthma, periodontal diseases, periodonitis, gingivitis,
gum disease, diastolic cardiomyopathies, cardiac infarction,
myocarditis, chronic heart failure, angiostenosis, restenosis,
reperfusion disorders, glomerulonephritis, solid tumors and
cancers, chronic lymphocytic leukemia, chronic myelocytic leukemia,
multiple myeloma, malignant myeloma, Hodgkin's disease, and
carcinomas of the bladder, breast, cervix, colon, lung, prostate,
or stomach comprising administering to a subject in need thereof a
therapeutically effective amount of a compound of Formula (I)
and/or (Ia) or a form, composition or medicament thereof.
[0036] In one embodiment, the present invention provides a method
of treating or ameliorating a syndrome, disorder or disease,
wherein said syndrome, disorder or disease is selected from the
group consisting of: ophthalmic disorders, rheumatoid arthritis,
psoriasis, psoriatic arthritis, atopic dermatitis, chronic
obstructive pulmonary disease, allergic rhinitis, asthma, allergic
asthma, and periodontal diseases comprising administering to a
subject in need thereof a therapeutically effective amount of a
compound of Formula (I) and/or (Ia) or a form, composition or
medicament thereof.
[0037] The invention also relates to methods of inhibiting CCR2
activity in a mammal by administration of an effective amount of at
least one compound of Formula (I) and/or (Ia).
[0038] In another embodiment, the invention relates to a product
made by the process of any of Examples from Example 1 to Example
87.
[0039] In another embodiment, the invention relates to a compound
which is the less polar isomer of any of Examples #1-87.
[0040] In another embodiment, the invention relates to a compound
which is the less polar isomer of Example #30.
[0041] In another embodiment, the invention relates to a process
for the preparation of a compound of Formula (I), comprising
reacting a compound of Formula (V)
##STR00043##
with a compound of Formula (VI)
##STR00044##
in the presence of a reducing agent to provide the compound of
Formula (I).
[0042] In another embodiment, the invention relates to a product
made by the above process.
[0043] In another embodiment, the invention relates to a process
for the preparation of a compound of Formula (I), comprising
reacting a compound of Formula (XIII)
##STR00045##
where R.sub.a is OH or Cl, with a compound of Formula (XII)
##STR00046##
in the presence of HOBt/EDCI or Et.sub.3N to provide the compound
of Formula (I).
[0044] In another embodiment, the invention relates to a product
made by the above process.
[0045] In another embodiment, the invention relates to the use of
hCCR2 knock-in mice to identify antagonists of CCR2 for use in the
treatment of asthma.
[0046] In another embodiment, the invention relates to the use of
hCCR2 knock-in mice to identify antagonists of CCR2 for use in the
treatment of obesity.
[0047] In another embodiment, the invention relates to the use of
hCCR2 knock-in mice to identify antagonists of CCR2 as described in
Example 93.
[0048] In another embodiment, the invention relates to the use of
hCCR2 knock-in mice to identify antagonists of CCR2 as described in
Example 94.
[0049] In another embodiment, the invention relates to the use of
hCCR2 knock-in mice to identify antagonists of CCR2 as described in
Example 95.
DEFINITIONS
[0050] The term "alkyl" refers to both linear and branched chain
radicals of up to 12 carbon atoms, preferably up to 6 carbon atoms,
unless otherwise indicated, and includes, but is not limited to,
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,
tert-butyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, octyl,
2,2,4-trimethylpentyl, nonyl, decyl, undecyl and dodecyl.
[0051] The term "C.sub.(a-b)" (where a and b are integers referring
to a designated number of carbon atoms) refers to an alkyl,
alkenyl, alkynyl, alkoxy or cycloalkyl radical or to the alkyl
portion of a radical in which alkyl appears as the prefix root
containing from a to b carbon atoms inclusive. For example,
C.sub.(1-4)denotes a radical containing 1, 2, 3 or 4 carbon
atoms.
[0052] The term "cycloalkyl" refers to a saturated or partially
unsaturated monocyclic or bicyclic hydrocarbon ring radical derived
by the removal of one hydrogen atom from a single ring carbon atom.
Typical cycloalkyl radicals include cyclopropyl, cyclobutyl,
cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl
and cyclooctyl. Additional examples include C.sub.(3-8)cycloalkyl,
C.sub.(5-8)cycloalkyl, C.sub.(3-12)cycloalkyl,
C.sub.(3-20)cycloalkyl, decahydronaphthalenyl, and
2,3,4,5,6,7-hexahydro-1H-indenyl.
[0053] The term "oxo" refers to the functional group
##STR00047##
[0054] The term "heterocyclyl" refers to a saturated or partially
unsaturated monocyclic cycloalkyl ring radical wherein from 1 to 3
ring carbon atoms have been replaced with heteroatoms selected from
N, O, or S. Said heteroatoms may exist in any allowed oxidation
state. The radical may be derived from the removal of a hydrogen
atom from a carbon or a nitrogen atom. Typical heterocyclyl
radicals include, but are not limited to, 2H-pyrrolyl,
2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1,3-dioxolanyl,
2-imidazolinyl (also referred to as 4,5-dihydro-1H-imidazolyl),
imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, tetrazolyl,
piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl,
thiomorpholinyl, piperazinyl, azepanyl, hexahydro-1,4-diazepinyl
and the like.
[0055] The term "heteroaromatic" or "heteroaryl" refers to 5- to
7-membered mono- or 8- to 10-membered bicyclic aromatic ring
systems, containing from one to four heteroatoms selected from N,
O, or S where the nitrogen and sulfur atoms can exist in any
allowed oxidation state. Examples include, but are not limited to,
benzimidazolyl, benzothiazolyl, benzothienyl, benzoxazolyl, furyl,
imidazolyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl,
pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, thiazolyl
and thienyl.
[0056] The term "heteroatom" refers to a nitrogen atom, an oxygen
atom or a sulfur atom wherein the nitrogen and sulfur atoms can
exist in any allowed oxidation states.
[0057] For use in medicines, the salts of the compounds of this
invention refer to non-toxic "pharmaceutically acceptable salts."
FDA approved pharmaceutically acceptable salt forms (Ref
International J. Pharm. 1986, 33, 201-217; J. Pharm. Sci., 1977,
Jan, 66(1), p1) include pharmaceutically acceptable acidic/anionic
or basic/cationic salts.
[0058] Throughout this specification, compounds are described as
being separated, usually by silica gel column, although preporatory
thin layer chromatography, or high or low pressure liquid
choromatography may also be used. It is generally accepted that
when eluting compounds through a silica gel-type separation medium,
that the least polar compounds elute before the more polar
compounds. Therefore, the term "less polar isomer", refers to the
isomer that will elute first from a silica gel type separation
medium.
Abbreviations
[0059] Herein and throughout this application, the following
abbreviations may be used. [0060] BOC or Boc tert-butyloxycarbonyl
[0061] Bu butyl [0062] DAST diethylaminosulfur trifluoride [0063]
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene [0064] DCC
dicyclohexylcarbodiimide [0065] DCM dicholomethane [0066] DMF
dimethylformamide [0067] EDCI
1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide [0068] Et ethyl
[0069] EtOAc ethyl acetate [0070] HOBt hydroxybenzotriazole [0071]
IPA isopropyl alcohol [0072] Me methyl [0073] Ms mesylate [0074]
OAc acetate [0075] OXONE registered trademark of Dupont, the active
ingredient of which is potassium monopersulfate (KHSO.sub.5) [0076]
PdCl.sub.2(dppf)
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) [0077]
PPh.sub.3 triphenylphosphine [0078] iPr isopropyl [0079] PyBrop
bromo-tris-pyrrolidinophosphonium hexafluorophosphate [0080] TBAF
tetrabutylammonium fluoride [0081] TEA triethylamine [0082] TFA
trifluoroacetic acid [0083] THF tetrahydrofuran [0084] Ts
tosylate
[0085] Pharmaceutically acceptable acidic/anionic salts include,
and are not limited to acetate, benzenesulfonate, benzoate,
bicarbonate, bitartrate, bromide, calcium edetate, camsylate,
carbonate, chloride, citrate, dihydrochloride, edetate, edisylate,
estolate, esylate, fumarate, glyceptate, gluconate, glutamate,
glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide,
hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate,
lactobionate, malate, maleate, mandelate, mesylate, methylbromide,
methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate,
pantothenate, phosphate/diphosphate, polygalacturonate, salicylate,
stearate, subacetate, succinate, sulfate, tannate, tartrate,
teoclate, tosylate and triethiodide. Organic or inorganic acids
also include, and are not limited to, hydriodic, perchloric,
sulfuric, phosphoric, propionic, glycolic, methanesulfonic,
hydroxyethanesulfonic, oxalic, 2-naphthalenesulfonic,
p-toluenesulfonic, cyclohexanesulfamic, saccharinic or
trifluoroacetic acid.
[0086] Pharmaceutically acceptable basic/cationic salts include,
and are not limited to aluminum,
2-amino-2-hydroxymethyl-propane-1,3-diol (also known as
tris(hydroxymethyl)aminomethane, tromethane or "TRIS"), ammonia,
benzathine, t-butylamine, calcium, calcium gluconate, calcium
hydroxide, chloroprocaine, choline, choline bicarbonate, choline
chloride, cyclohexylamine, diethanolamine, ethylenediamine,
lithium, LiOMe, L-lysine, magnesium, meglumine, NH.sub.3,
NH.sub.4OH, N-methyl-D-glucamine, piperidine, potassium,
potassium-t-butoxide, potassium hydroxide (aqueous), procaine,
quinine, sodium, sodium carbonate, sodium-2-ethylhexanoate (SEH),
sodium hydroxide, triethanolamine or zinc.
Methods of Use
[0087] The present invention is directed to a method for
preventing, treating or ameliorating a CCR2 mediated syndrome,
disorder or disease comprising administering to a subject in need
thereof an effective amount of a compound of Formula (I) and/or
(Ia) or a form, composition or medicament thereof.
[0088] Examples of a CCR2 mediated syndrome, disorder or disease
for which the compounds of Formula (I) and/or (Ia) are useful
include chronic obstructive pulmonary disorder (COPD), ophthalmic
disorders, uveitis, atherosclerosis, rheumatoid arthritis,
psoriasis, psoriatic arthritis, atopic dermatitis, multiple
sclerosis, Crohn's Disease, ulcerative colitis, nephritis, organ
allograft rejection, fibroid lung, renal insufficiency, type-I
diabetes, type II diabetes and diabetic complications, diabetic
nephropathy, diabetic retinopathy, diabetic retinitis, diabetic
microangiopathy, overweight, obesity, obesity-associated insulin
resistance, tuberculosis, chronic obstructive pulmonary disease,
sarcoidosis, invasive staphyloccocia, inflammation after cataract
surgery, allergic rhinitis, allergic conjunctivitis, chronic
urticaria, asthma, allergic asthma, periodontal diseases,
periodonitis, gingivitis, gum disease, diastolic cardiomyopathies,
cardiac infarction, myocarditis, chronic heart failure,
angiostenosis, restenosis, reperfusion disorders,
glomerulonephritis, solid tumors and cancers, chronic lymphocytic
leukemia, chronic myelocytic leukemia, multiple myeloma, malignant
myeloma, Hodgkin's disease, and carcinomas of the bladder, breast,
cervix, colon, lung, prostate, or stomach.
[0089] The term "administering" with respect to the methods of the
invention, means a method for therapeutically or prophylactically
preventing, treating or ameliorating a syndrome, disorder or
disease as described herein by using a compound of Formula (I)
and/or (Ia) or a form, composition or medicament thereof. Such
methods include administering an effective amount of said compound,
compound form, composition or medicament at different times during
the course of a therapy or concurrently in a combination form. The
methods of the invention are to be understood as embracing all
known therapeutic treatment regimens.
[0090] The term "subject" refers to a patient, which may be animal,
typically a mammal, typically a human, which has been the object of
treatment, observation or experiment. In one aspect of the
invention, the subject is at risk of (or susceptible to) developing
a syndrome, disorder or disease that is associated with elevated
MCP-1 expression or MCP-1 overexpression, or a patient with an
inflammatory condition that accompanies syndromes, disorders or
diseases associated with elevated MCP-1 expression or MCP-1
overexpression.
[0091] The term "therapeutically effective amount" means that
amount of active compound or pharmaceutical agent that elicits the
biological or medicinal response in a tissue system, animal or
human, that is being sought by a researcher, veterinarian, medical
doctor, or other clinician, which includes preventing, treating or
ameliorating the symptoms of a syndrome, disorder or disease being
treated.
[0092] The term "uveitis" generically refers to any inflammatory
disease involving the eye.
[0093] Uveitis can be divided into clinically distinct subtypes
based on the part of the eye in which the inflammation is present
(percentages correspond to patients known to fit these categories):
anterior (51%), intermediate (13%), posterior (20%), or panuveitis
(16%) and, according to the course of the disease, as either acute
(16%), recurring (26%), or chronic (58%). Those with anterior
uveitis (0.19%) eventually develop irreparable vision damage
despite aggressive treatment such as unilateral blindness (9%),
bilateral blindness (2%), or unilateral or bilateral vision
impairment (8%). Most cases of uveitis are idiopathic, but known
causes include infection (e.g., toxoplasmosis, cytomegalovirus, and
the like) or development as a component of a systemic inflammatory
and/or autoimmune disorder (e.g., juvenile RA, HLA-B27 associated
spondyloarthropathies, sarcoidosis, and the like). (HLA-B27: Human
Leukocyte Antigen B*27--is a class I surface antigen encoded by the
B locus in the major histocompatibility complex (MHC) on chromosome
6 and presents micobial antigens to T cells. HLA-B27 is strongly
associated with a certain set of autoimmune diseases referred to as
the seronegative spondyloarthropathies.)
[0094] When employed as CCR2 inhibitors, the compounds of the
invention may be administered in an effective amount within the
dosage range of about 0.5 mg to about 10 g, preferably between
about 0.5 mg to about 5 g, in single or divided daily doses. The
dosage administered will be affected by factors such as the route
of administration, the health, weight and age of the recipient, the
frequency of the treatment and the presence of concurrent and
unrelated treatments.
[0095] It is also apparent to one skilled in the art that the
therapeutically effective dose for compounds of the present
invention or a pharmaceutical composition thereof will vary
according to the desired effect. Therefore, optimal dosages to be
administered may be readily determined by one skilled in the art
and will vary with the particular compound used, the mode of
administration, the strength of the preparation, and the
advancement of the disease condition. In addition, factors
associated with the particular subject being treated, including
subject age, weight, diet and time of administration, will result
in the need to adjust the dose to an appropriate therapeutic level.
The above dosages are thus exemplary of the average case. There
can, of course, be individual instances where higher or lower
dosage ranges are merited, and such are within the scope of this
invention.
[0096] The compounds of Formula (I) and/or (Ia) may be formulated
into pharmaceutical compositions comprising any known
pharmaceutically acceptable carriers. Exemplary carriers include,
but are not limited to, any suitable solvents, dispersion media,
coatings, antibacterial and antifungal agents and isotonic agents.
Exemplary excipients that may also be components of the formulation
include fillers, binders, disintegrating agents and lubricants.
[0097] The pharmaceutically-acceptable salts of the compounds of
Formula (I) and/or (Ia) include the conventional non-toxic salts or
the quaternary ammonium salts which are formed from inorganic or
organic acids or bases. Examples of such acid addition salts
include acetate, adipate, benzoate, benzenesulfonate, citrate,
camphorate, dodecylsulfate, hydrochloride, hydrobromide, lactate,
maleate, methanesulfonate, nitrate, oxalate, pivalate, propionate,
succinate, sulfate and tartrate. Base salts include ammonium salts,
alkali metal salts such as sodium and potassium salts, alkaline
earth metal salts such as calcium and magnesium salts, salts with
organic bases such as dicyclohexylamino salts and salts with amino
acids such as arginine. Also, the basic nitrogen-containing groups
may be quaternized with, for example, alkyl halides.
[0098] The pharmaceutical compositions of the invention may be
administered by any means that accomplish their intended purpose.
Examples include administration by parenteral, subcutaneous,
intravenous, intramuscular, intraperitoneal, transdermal, buccal or
ocular routes. Alternatively or concurrently, administration may be
by the oral route. Suitable formulations for parenteral
administration include aqueous solutions of the active compounds in
water-soluble form, for example, water-soluble salts, acidic
solutions, alkaline solutions, dextrose-water solutions, isotonic
carbohydrate solutions and cyclodextrin inclusion complexes.
[0099] The present invention also encompasses a method of making a
pharmaceutical composition comprising mixing a pharmaceutically
acceptable carrier with any of the compounds of the present
invention. Additionally, the present invention includes
pharmaceutical compositions made by mixing a pharmaceutically
acceptable carrier with any of the compounds of the present
invention. As used herein, the term "composition" is intended to
encompass a product comprising the specified ingredients in the
specified amounts, as well as any product which results, directly
or indirectly, from combinations of the specified ingredients in
the specified amounts.
Polymorphs and Solvates
[0100] Furthermore, the compounds of the present invention may have
one or more polymorph or amorphous crystalline forms and as such
are intended to be included in the scope of the invention. In
addition, the compounds may form solvates, for example with water
(i.e., hydrates) or common organic solvents. As used herein, the
term "solvate" means a physical association of the compounds of the
present invention with one or more solvent molecules. This physical
association involves varying degrees of ionic and covalent bonding,
including hydrogen bonding. In certain instances the solvate will
be capable of isolation, for example when one or more solvent
molecules are incorporated in the crystal lattice of the
crystalline solid. The term "solvate" is intended to encompass both
solution-phase and isolatable solvates. Non-limiting examples of
suitable solvates include ethanolates, methanolates, and the
like.
[0101] It is intended that the present invention include within its
scope polymorphs and solvates of the compounds of the present
invention. Thus, in the methods of treatment of the present
invention, the term "administering" shall encompass the means for
treating, ameliorating or preventing a syndrome, disorder or
disease described herein with the compounds of the present
invention or a polymorph or solvate thereof, which would obviously
be included within the scope of the invention albeit not
specifically disclosed.
[0102] In another embodiment, the invention relates to a compound
as described in the Examples or Formula (I) and/or Formula (Ia) for
use as a medicament, in particular, for use as a medicament for
treating a CCR2 mediated syndrome disorder or disease.
[0103] In another embodiment, the invention relates to the use of a
compound as described in the Examples of Formula (I) and/or Formula
(Ia) for the preparation of a medicament for the treatment of a
disease associated with an elevated or inappropriate CCR2
activity.
[0104] The present invention includes within its scope prodrugs of
the compounds of this invention. In general, such prodrugs will be
functional derivatives of the compounds which are readily
convertible in vivo into the required compound. Thus, in the
methods of treatment of the present invention, the term
"administering" shall encompass the treatment of the various
disorders described with the compound specifically disclosed or
with a compound which may not be specifically disclosed, but which
converts to the specified compound in vivo after administration to
the patient. Conventional procedures for the selection and
preparation of suitable prodrug derivatives are described, for
example, in "Design of Prodrugs", Ed. H. Bundgaard, Elsevier,
1985.
[0105] Where the compounds according to this invention have at
least one chiral center, they may accordingly exist as enantiomers.
Where the compounds possess two or more chiral centers, they may
additionally exist as diastereomers. It is to be understood that
all such isomers and mixtures thereof are encompassed within the
scope of the present invention.
[0106] Where the processes for the preparation of the compounds
according to the invention give rise to mixture of stereoisomers,
these isomers may be separated by conventional techniques such as
preparative chromatography. The compounds may be prepared in
racemic form, or individual enantiomers may be prepared either by
enantiospecific synthesis or by resolution. The compounds may, for
example, be resolved into their component enantiomers by standard
techniques, such as the formation of diastereomeric pairs by salt
formation with an optically active acid, such as
(-)-di-p-toluoyl-D-tartaric acid and/or (+)-di-p-toluoyl-L-tartaric
acid followed by fractional crystallization and regeneration of the
free base. The compounds may also be resolved by formation of
diastereomeric esters or amides, followed by chromatographic
separation and removal of the chiral auxiliary. Alternatively, the
compounds may be resolved using a chiral HPLC column.
[0107] During any of the processes for preparation of the compounds
of the present invention, it may be necessary and/or desirable to
protect sensitive or reactive groups on any of the molecules
concerned. This may be achieved by means of conventional protecting
groups, such as those described in Protective Groups in Organic
Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W.
Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis,
John Wiley & Sons, 1991. The protecting groups may be removed
at a convenient subsequent stage using methods known from the
art.
General Reaction Scheme
[0108] Representative compounds of the present invention can be
synthesized in accordance with the general synthetic methods
described below. Compounds of Formula (I) can be prepared by
methods known to those who are skilled in the art. The following
reaction schemes are only meant to represent examples of the
invention and are in no way meant to be a limit of the
invention.
[0109] Compounds of Formula (I) may be prepared according to the
processes outlined in Scheme 1.
##STR00048##
[0110] Scheme 1 illustrates a synthetic route leading to compounds
of Formula (I). Commercially available azetidine (II) is reacted
with acid (III), wherein (III) is prepared according to the
procedure described by Ingersoll, A. W. et. al., Organic Syntheses
1932, XII, 40-2 substituting commercially available
##STR00049##
for benzoyl chloride, in the presence of a coupling reagent such as
EDCI/HOBt, PyBrop, or DCC, in an organic solvent such as THF,
dichloromethane or 1,2-dichloroethane, at a temperature in the
range of about 0.degree. C. to about 25.degree. C., to yield the
corresponding amide (IV). Amide (IV) is treated with an acid such
as 1N HCl, 1N H.sub.2SO.sub.4 or trifluoroacetic acid in an organic
solvent such as diethyl ether, THF, dichloromethane or dioxane, at
a temperature in the range of about 0.degree. C. to about
25.degree. C. to yield amine (V). Amine (V) is reacted with a
suitably substituted ketone (VI), in the presence of a reducing
reagent such as NaBH.sub.4, NaBH(CN).sub.3 or NaBH(OAc).sub.3, in
an organic base such as triethylamine, diethylpropylamine or
N-methylmorpholine with or without molecule sieves, in an organic
solvent such as dichloromethane, 1,2-dichloroethane or THF, at a
temperature in the range of 0.degree. C. to about 25.degree. C., to
yield the corresponding azetidine (I).
[0111] Alternatively, compounds of Formula (I) may be prepared
according to the processes outlined in Scheme 2.
##STR00050##
[0112] Commercially available azetidine (VII) is reacted with a
suitably substituted ketone (VI), in the presence of a reducing
reagent such as NaBH.sub.4, NaBH(CN).sub.3 or NaBH(OAc).sub.3, in
an organic base such as triethylamine, diethylpropylamine or
N-methylmorpholine, with or without molecule sieves, in an organic
solvent such as dichloromethane, 1,2-dichloroethane or THF at a
temperature in the range of 0.degree. C. to about 25.degree. C., to
yield the corresponding azetidine (VIII).
[0113] Azetidine (VIII) is treated with 1N HCl, 1N H.sub.2SO.sub.4
or trifluoroacetic acid in an organic solvent such as diethyl
ether, THF, dioxane or dichloromethane, at a temperature in the
range of about 0.degree. C. to about 25.degree. C., to yield the
corresponding amine (IX). Amine (IX) is reacted with acid (X), in
the presence of a coupling reagent such as EDCI/HOBt, PyBrop or
DCC, in an organic solvent such as THF, dichloromethane or
1,2-dichloroethane, at a temperature in the range of about
0.degree. C. to about 25.degree. C., to yield the corresponding
azetidine (XI).
[0114] Azetidine (XI) is treated with 1N HCl or H.sub.2SO.sub.4 or
trifluoroacetic acid, in an organic solvent such as diethyl ether,
THF or dioxane, at a temperature in the range of about 0.degree. C.
to about 25.degree. C., to yield the corresponding amine (XII).
[0115] Amine (XII) is reacted with acid (XIII). When R.sup.a is OH,
the reaction is performed in the presence of a coupling reagent
such as EDCI/HOBt, PyBrop or DCC, in an organic solvent such as
THF, dichloromethaneor 1,2-dichloroethane, at a temperature in the
range of about 0.degree. C. to about 25.degree. C. When R.sup.a is
Cl, the reaction is performed in the presence of an organic base
such triethylamine, diethylpropylamine or N-methylmorpholine, in an
organic solvent such as THF, dichloromethane or 1,2-dichloroethane,
at a temperature in the range of about 0.degree. C. to about
25.degree. C., to yield the corresponding azetidine (I).
[0116] Compounds of Formula (I) may be derived from ketone (VI).
Preparation of (VI) is outlined in Scheme 3.
##STR00051##
[0117] Commercially available aryl halide or aryl alkane R'Z (where
R.sup.1 is as defined in Formula (I)) is reacted with commercially
available ketone (XIV) in the presence of organometalic agent such
as n-BuLi, i-PrMgBr or i-PrMgCl, in an organic solvent such as
ether, THF or dioxane, at a temperature in the range of about
-78.degree. C. to about 0.degree. C., to yield the corresponding
ketal (XV).
[0118] Ketal (XV) is treated with an acid such as 1N HCl or 1N
H.sub.2SO.sub.4 in an organic solvent such as acetone, acetonitrile
or THF, at a temperature in the range of about 0.degree. C. to
about 25.degree. C., to yield the corresponding ketone (VI).
[0119] Compounds of Formula (I) may be derived from ketone (XIX).
Preparation of (XIX) is outlined in Scheme 4.
##STR00052##
[0120] Ketal (XVI) is treated with a dehydrating agent such as
Burgess' reagent, in an organic solvent such as ether, THF or
dioxane, at a temperature in the range of about 0.degree. C. to
about 25.degree. C., to yield the corresponding alkene (XVII).
[0121] Alkene (XVII) is treated with hydrogen gas under pressure
from 5 to 50 psi catalyzed by 5-10% Pd/C, in an organic solvent
such as methanol, at a temperature in the range of about 25.degree.
C. to about 50.degree. C., to yield the corresponding alkane
(XVIII). Alkane (XVIII) is treated with 1N HCl or 1N
H.sub.2SO.sub.4, in an organic solvent such as acetone,
acetonitrile or THF, at a temperature in the range of about
0.degree. C. to about 25.degree. C., to yield the corresponding
ketone (XIX).
[0122] Alternatively compound (XVII) may be prepared according to
the processes outlined in Scheme 5.
##STR00053##
[0123] Commercially available aryl boronic acid (XX), (wherein
R.sup.1 is as defined in Formula (I)) is reacted with vinyl
triflate (XXI) prepared according to the procedure of Pearson, W.
et. al., J. Org. Chem. 2004, 69, 9109-9122, in the presence of a
catalyst such as Pd(Ph.sub.3P).sub.4, PdCl.sub.2(Ph.sub.3P).sub.2
or PdCl.sub.2(dppf) and a base such as 2N Na.sub.2CO.sub.3 or
K.sub.2CO.sub.3, in an organic solvent such as toluene, dioxane or
THF, at a temperature in the range of about 80.degree. C. to about
120.degree. C., to yield the corresponding alkene (XVII).
[0124] Alternatively, commercially available aryl or heteroaryl
halide R.sup.1Z is reacted with vinyl boronic ester (XXII) prepared
according to Birch, A. M. et. al., PCT Int. Appl. 2006, WO
2006064189, in the presence of a catalyst such as
Pd(Ph.sub.3P).sub.4, PdCl.sub.2(Ph.sub.3P).sub.2 or PdCl.sub.2
(dppf) and a base such as 2N Na.sub.2CO.sub.3 or K.sub.2CO.sub.3,
in an organic solvent such as toluene, dioxane or THF, at a
temperature in the range of about 80.degree. C. to about
120.degree. C., to yield the corresponding alkene (XVII).
[0125] Compounds of Formula (I) may be derived from ketone (XXIII).
Ketone (XXIII) may be prepared according to the processes outlined
in Scheme 6.
##STR00054##
[0126] Ketal (XVI) is treated with a fluorinating agent such as
DAST or trifluorosulfonyl fluoride, in an organic solvent such as
dichloromethane, THF or dioxane, at a temperature in the range of
about -78.degree. C. to about 0.degree. C., to yield the
corresponding fluoride (XXIV). Fluoride (XXIV) is treated with an
acid such as 1N HCl or 1N H.sub.2SO.sub.4, in an organic solvent
such as acetone, acetonitrile or THF, at a temperature in the range
of about 0.degree. C. to about 25.degree. C., to yield the
corresponding ketone (XXIII).
[0127] Compounds of Formula (I) may be derived from ketone (XXV).
Ketone (XXV) may be prepared according to the processes outlined in
Scheme 7.
##STR00055##
[0128] Commercially available 2-methyl-propane-2-sulfinic acid
amide is reacted with commercially available
1,4-dioxa-spiro[4.5]decan-8-one in the presence of a coupling agent
such as Ti(OEt).sub.4 or CuSO.sub.4, in an organic solvent such as
dichloromethane, THF or dioxane, at a temperature in the range of
about 25.degree. C. to about 80.degree. C., to yield
2-methyl-propane-2-sulfinic acid
(1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide.
[0129] 2-Methyl-propane-2-sulfinic acid
(1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide is treated with an
organometalic agent such as R.sup.1MgBr or R.sup.1Li, in an organic
solvent such as ether, THF or dioxane, at a temperature in the
range of about -78.degree. C. to about 25.degree. C., to yield the
corresponding sulfonamide (XXVI).
[0130] Sulfinamide (XXVI) is treated with an acid such as 1N HCl or
1N H.sub.2SO.sub.4 in an organic solvent such as acetone,
acetonitrile or THF, at a temperature in the range of about
0.degree. C. to about 25.degree. C., to yield the corresponding
ketone (XXV).
[0131] Compounds of Formula (I) where R.sup.1 is linked with the
cyclohexyl ring through N or O may be prepared according to the
process outlined in Scheme 8.
##STR00056##
[0132] Commercially available OH or NH substituted R.sup.1 is
reacted with alkyl tosylate or alkyl mesylate (XXVII) in the
presence of inorganic base such as K.sub.2CO.sub.3,
Cs.sub.2CO.sub.3 or NaH, in an organic solvent such as DMF or THF,
at a temperature in the range of about 25.degree. C. to about
80.degree. C., to yield the corresponding ketal (XVIII).
EXAMPLES
[0133] Representative compounds of the present invention can be
synthesized in accordance with the general synthetic methods
described herein. Compounds of Formula (I) can be prepared by
methods known to those who are skilled in the art. The following
examples are only meant to represent examples of the invention and
are in no way meant to be a limit of the invention.
Example 1
N-{[1-(4-Benzo[1,3]dioxol-5-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-
-3-trifluoromethyl-benzamide
Step A
8-Benzo[1,3]dioxol-5-yl-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00057##
[0135] A solution of n-BuLi (2.5 M in hexanes, 24 mL, 60 mmol) was
dropped slowly into a solution of 5-bromo-benzo[1,3]dioxole
(Aldrich, 10.0 g, 50 mmol) in THF (100 mL) at -78.degree. C. over
10 min. The reaction was stirred for additional 20 min. at
-78.degree. C. A solution of 1,4-dioxa-spiro[4.5]decan-8-one
(Aldrich, 8.60 g, 55 mmol) in THF (20 mL) was slowly dropped into
the reaction. After addition, the reaction was stirred for
additional 2 hours at -78.degree. C. The reaction was then quenched
with diluted NH.sub.4Cl solution and warmed to room temperature.
The solvent was removed in vacuo and the residue was partitioned
between ethyl acetate and water. The organic layer was washed with
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give a yellow solid, which was then purified by
silica gel column on a CombiFlash.RTM. system (Teledyne Isco, Inc,
Lincoln, Nebr.) using hexanes and ethyl acetate (from 10% ethyl
acetate to 100% ethyl acetate) to afford the title compound as a
white solid.
[0136] .sup.1H-NMR (CDCl.sub.3): .delta. 7.03 (s, 1H), 6.96 (d,
J=6.5 Hz, 1H), 6.74 (d, J=6.4 Hz, 1H), 5.91 (s, 2H), 3.96 (s, 4H),
2.17 (m, 1H), 2.10 (m, 2H), 1.99 (m, 2H), 1.86 (m, 2H), 1.64 (m,
2H).
Step B
4-Benzo[1,3]-dioxol-5-yl-4-hydroxy-cyclohexanone
##STR00058##
[0138] A solution of
8-benzo[1,3]dioxol-5-yl-1,4-dioxa-spiro[4.5]decan-8-ol (as prepared
in the previous step, 4.50 g, 16.2 mmol) in acetone (40 mL) was
treated with 1N HCl (.about.15 mL) at room temperature for 4 hours.
The reaction was neutralized with saturated NaHCO.sub.3 solution
and the solvent was removed. The residue was partitioned between
ethyl acetate and water. The organic layer was washed with brine,
dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to
give a yellow solid, which was then purified by silica gel column
on a CombiFlash.RTM. system using hexanes and ethyl acetate (from
10% ethyl acetate to 100% ethyl acetate) to afford the title
compound as a white solid.
[0139] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.10 (s, 1H), 6.95
(d, J=6.0 Hz, 1H), 6.75 (d, J=6.4 Hz, 1H), 5.98 (s, 2H), 2.86 (m,
2H), 2.42 (m, 2H), 2.26 (m, 4H).
Step C
4-Benzo[1,3]-dioxol-5-yl-cyclohex-3-enone
##STR00059##
[0141] A solution of
4-benzo[1,3]dioxol-5-yl-4-hydroxy-cyclohexanone (as prepared in the
previous step, 3.5 g, 15 mmol) in THF (10 mL) was treated with 6N
HCl (5 mL) overnight under argon at room temperature. The resulting
solution was quenched with sufficient 1N NaOH to neutralize the
reaction. The solvent was removed and the residue was partitioned
between DCM and water. The organic layer was washed with brine,
dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to
give a yellow oil, which was then purified by silica gel column on
a CombiFlash.RTM. system using hexanes and ethyl acetate (from 10%
ethyl acetate to 100% ethyl acetate) to afford the title compound
as a white solid.
[0142] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.85 (s, 1H), 7.80
(d, J=7.0 Hz, 1H), 7.75 (d, J=6.8 Hz, 1H), 5.95 (m, 1H), 5.90 (s,
2H), 3.05 (s, 2H), 2.85 (t, J=6.5 Hz, 2H), 2.58 (t, J=6.8 Hz,
2H).
Step D
[1-(4-Benzo[1,3]-dioxol-5-yl-cyclohex-3-enyl)-azetidin-3-yl]-carbamic
acid tent-butyl ester
##STR00060##
[0144] A solution of 4-benzo[1,3]dioxol-5-yl-cyclohex-3-enone (as
prepared in the previous step, 680 mg, 3.15 mmol) and
azetidin-3-yl-carbamic acid tert-butyl ester (BetaPharma, 542 mg,
3.15 mmol) in DCM (10 mL) was treated with NaBH(OAc).sub.3
(Aldrich, 2.0 g, 9.45 mmol) at room temperature. The reaction was
stirred for 4 hours and quenched with saturated sodium bicarbonate.
The organic layer was separated and the aqueous layer was extracted
3 times with DCM. The combined organic layers were dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give the
crude product, which was then purified by a CombiFlash.RTM. system
using hexanes and ethyl acetate as eluent (from pure hexanes to
pure ethyl acetate) to afford the title compound as a white
solid.
[0145] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.85 (s, 1H), 7.82
(d, J=7.0 Hz, 1H), 7.75 (d, J=6.8 Hz, 1H), 5.95 (s, 2H0, 5.90 (s,
br, 1H), 4.35 (s, br, 1H), 3.76 (m, 2H), 3.18 (s, br, 2H), 2.45 (m,
1H), 2.35 (m, 4H0, 2.02 (m, 2H), 1.45 (s, 9H).
Step E
1-(4-Benzo[1,3]-dioxol-5-yl-cyclohex-3-enyl)-azetidin-3-ylamine TFA
salt
##STR00061##
[0147] A solution of
[1-(4-Benzo[1,3]dioxol-5-yl-cyclohex-3-enyl)-azetidin-3-yl]-carbamic
acid tert-butyl ester (as prepared in the previous step, 750 mg,
2.02 mmol) in DCM (5 mL) and TFA (5 mL) was stirred at room
temperature for 2 hours. The solvent was removed under vacuum to
give the title compound as colorless oil.
[0148] ESI-MS (m/z): Calcd. For C.sub.16H.sub.20N.sub.2O.sub.2,
272; found: 273 (M+H).
Step F
N-{[1-(4-Benzo[1,3]-dioxol-5-yl-cyclohex-3-enyl)-azetidin-3-ylcarbamoyl]-m-
ethyl}-3-trifluoromethyl-benzamide
##STR00062##
[0150] A solution of
1-(4-benzo[1,3]dioxol-5-yl-cyclohex-3-enyl)-azetidin-3-ylamine TFA
salt (as prepared in the previous step, 550 mg, 1.10 mmol) and
(3-trifluoromethyl-benzoylamino)-acetic acid (Bionet, 272 mg, 1.10
mmol) in DCM (10 mL) was treated with TEA (770 .mu.L, 5.5 mmol) at
room temperature. The mixture was treated with EDCI (Aldrich, 252
mg, 1.32 mmol), HOBT (Aldrich 149 mg, 1.10 mmol), and the reaction
was stirred at room temperature for additional 6 hours. The
reaction was partitioned between DCM and water. The organic layer
was washed with brine, dried over anhydrous Na.sub.2SO.sub.4,
filtered and concentrated to give the crude product, which was then
purified by CombiFlash.RTM. system using ethyl acetate and 7N
NH.sub.3 in MeOH as eluent (from pure ethyl acetate to 5% 7N
NH.sub.3 in MeOH in ethyl acetate) to afford the title compound as
a white solid.
[0151] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.85 (d, J=6.5 Hz,
2H), 7.55 (t, J=6.5 Hz, 1H), 7.45 (d, J=7.0 Hz, 2H), 6.85 (s, 1H),
6.75 (d, J=6.5 Hz, 1H), 6.72 (d, J=6.6 Hz, 1H), 5.98 (s, 2H), 5.85
(m, 1H), 4.52 (m, 1H), 4.10 (d, J=3.5 Hz, 2H), 3.65 (t, J=7.0 Hz,
2H), 3.08 (t, J=7.0 Hz, 2H), 2.80 (m, 1H), 2.42 (m, 4H), 1.90 (m,
2H).
Step G
N-{[1-(4-Benzo[1,3]-dioxol-5-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl-
}-3-trifluoromethyl-benzamide
##STR00063##
[0153] A solution of
N-{[1-(4-Benzo[1,3]dioxol-5-yl-cyclohex-3-enyl)-azetidin-3-ylcarbamoyl]-m-
ethyl}-3-trifluoromethyl-benzamide (as prepared in the previous
step, 250 mg, 0.5 mmol) in MeOH (20 mL) was driven through an
H-Cube.RTM. Continuous-flow Hydrogenation reactor (ThalesNano,
Budapest, Hungary) under full hydrogen mode at room temperature
using a 5% Pd/C cartridge. The resulting solution was concentrated
and purified by silica gel column on a CombiFlash.RTM. system using
ethyl acetate and 7N NH.sub.3 in MeOH as eluent (from pure ethyl
acetate to 5% 7N NH.sub.3 in MeOH in ethyl acetate) to afford the
two title compounds as white solids.
[0154] 1a: Less Polar Fraction from Silica Gel Column
[0155] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.8 Hz, 1H), 7.85 (m, 1H), 7.74 (d, J=7.0 Hz, 2H), 7.55 (t,
J=6.8 Hz, 1H), 7.40 (d, J=7.0 Hz, 1H), 6.72 (d, J=6.5 Hz, 1H), 6.70
(s, 1H), 6.62 (d, J=6.2 Hz, 1H), 5.92 (s, 2H), 4.53 (m, 1H), 4.20
(d, J=3.5 Hz, 2H), 3.60 (t, J=7.0 Hz, 2H), 2.85 (t, J=7.0 Hz, 2H),
2.42 (m, 1H), 2.30 (s, br, 1H), 1.85 (m, 2H), 1.70 (m, 2H), 1.52
(m, 2H), 1.42 (m, 2H).
[0156] 1b: More Polar Fraction from Silica Gel Column
[0157] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.12 (s, 1H), 8.05
(d, J=6.5 Hz, 1H), 7.80 (d, J=6.6 Hz, 1H), 7.58 (t, J=6.8 Hz, 1H),
7.50 (m, 1H), 7.10 (d, J=6.2 Hz, 1H), 6.75 (d, J=6.8 Hz, 1H), 6.60
(s, 1H), 5.90 (s, 2H), 4.52 (m, 1H), 4.20 (d, J=4.6 Hz, 2H), 3.64
(t, J=7.5 Hz, 2H), 2.98 (t, J=7.5 Hz, 2H), 2.35 (m, 1H), 2.02 (m,
2H), 1.85 (m, 2H), 1.35 (m, 2H), 1.15 (m, 2H).
Example 2
N-{[1-(4-Benzo[1,3]dioxol-5-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-
-benzamide
##STR00064##
[0159] The title compounds were prepared as white solids by an EDCI
coupling between
1-(4-benzo[1,3]dioxol-5-yl-cyclohex-3-enyl)-azetidin-3-ylamine (as
prepared in Example 1, Step E) and benzoylamino-acetic acid
(Hippuric acid, Aldrich) followed by hydrogenation of the
corresponding alkene using the procedures described in Steps F and
G of Example 1.
[0160] 2a: Less Polar Fraction from Silica Gel Column
[0161] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.85 (d, J=6.0 Hz,
2H), 7.51 (t, J=6.8 Hz, 1H), 7.41 (d, J=7.0 Hz, 2H), 7.25 (m, 1H),
7.10 (d, J=7.0 Hz, 1H), 6.72 (d, J=6.5 Hz, 1H), 6.70 (s, 1H), 6.62
(d, J=6.2 Hz, 1H), 5.90 (s, 2H), 4.52 (m, 1H), 4.20 (d, J=3.5 Hz,
2H), 3.60 (t, J=7.0 Hz, 2H), 2.85 (t, J=7.0 Hz, 2H), 2.42 (m, 1H),
2.30 (s, br, 1H), 1.85 (m, 2H), 1.70 (m, 2H), 1.52 (m, 2H), 1.40
(m, 2H).
[0162] 2b: More Polar Fraction from Silica Gel Column
[0163] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.85 (d, J=6.5 Hz,
2H), 7.55 (t, J=6.6 Hz, 1H), 7.52 (t, J=6.8 Hz, 2H), 7.30 (m, 2H),
6.72 (d, J=6.8 Hz, 1H), 6.66 (s, 1H), 6.60 (d, J=5.8 Hz, 1H), 4.52
(m, 1H), 4.20 (d, J=4.6 Hz, 2H), 3.65 (t, J=7.5 Hz, 2H), 3.00 (t,
J=7.5 Hz, 2H), 2.35 (m, 1H), 2.02 (m, 2H), 1.85 (m, 2H), 1.35 (m,
2H), 1.15 (m, 2H).
Example 3
N-({1-[4-(2,3-Dihydro-benzofuran-6-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-
-methyl)-3-trifluoromethylbenzamide
Step A
8-(2,3-Dihydro-benzofuran-6-yl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00065##
[0165] The title compound was prepared as a white solid from
6-bromo-2,3-dihydro-benzofuran (Milestone) and
1,4-dioxa-spiro[4.5]decan-8-one using the procedure described in
Step A of Example 1.
[0166] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.38 (s, 1H), 7.25
(d, J=6.0 Hz, 1H), 6.72 (d, J=6.1 Hz, 1H), 4.55 (t, J=7.5 Hz, 2H),
4.01 (s, 4H), 3.20 (t, J=7.4 Hz, 2H), 2.51 (s, 1H), 2.15 (m, 2H),
2.06 (m, 2H), 1.85 (m, 2H), 1.70 (m, 2H).
Step B
4-(2,3-Dihydro-benzofuran-6-yl)-4-hydroxy-cyclohexanone
##STR00066##
[0168] The title compound was prepared as a white solid from
8-(2,3-dihydro-benzofuran-6-yl)-1,4-dioxa-spiro[4.5]decan-8-ol (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0169] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.38 (s, 1H), 7.25
(d, J=6.0 Hz, 1H), 6.75 (d, J=6.4 Hz, 1H), 4.55 (t, J=7.0 Hz, 2H),
3.20 (d, J=7.2 Hz, 2H), 2.90 (m, 2H), 2.31 (m, 2H), 2.20 (m,
4H).
Step C
4-(2,3-Dihydro-benzofuran-6-yl)-cyclohex-3-enone
##STR00067##
[0171] The title compound was prepared as a white solid from
4-(2,3-dihydro-benzofuran-6-yl)-4-hydroxy-cyclohexanone (as
prepared in the previous step) using the procedure described in
Step C of Example 1.
[0172] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.25 (s, 1H), 7.16
(d, J=6.6 Hz, 1H), 6.75 (d, J=7.0 Hz, 1H), 5.95 (m, 1H), 4.55 (t,
J=6.6 Hz, 2H), 3.22 (t, J=6.6 Hz, 2H), 3.08 (s, 2H), 2.88 (t, J=5.5
Hz, 2H), 2.66 (t, J=6.6 Hz, 2H).
Step D
1-[4-(2,3-Dihydro-benzofuran-6-yl)-cyclohex-3-enyl]-azetidin-3-ylamine
##STR00068##
[0174] The title compound was prepared as colorless oil from
4-(2,3-dihydro-benzofuran-6-yl)-cyclohex-3-enone (as prepared in
the previous step) using the procedures described in Steps D and E
of Example 1.
[0175] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.20 (s, 1H), 7.12
(d, J=6.0 Hz, 1H), 6.70 (d, J=6.3 Hz, 1H), 4.55 (t, J=6.8 Hz, 2H),
3.72 (t, J=6.8 Hz, 2H), 3.66 (m, 1H), 3.20 (t, J=6.5 Hz, 2H), 2.65
(t, J=6.4 Hz, 2H), 2.45 (m, 1H), 2.30 (m, 2H), 1.90 (m, 2H), 1.65
(m, 2H), 1.37 (m 2H).
Step E
N-({1-[4-(2,3-Dihydro-benzofuran-6-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-
-methyl)-3-trifluoromethylbenzamide
##STR00069##
[0177] The title compounds were prepared as white solids from the
EDCI coupling between the amine (from step D) and
(3-trifluoromethyl-benzoylamino)-acetic acid followed by H-Cube
hydrogenation using the procedures described in Steps E and F of
Example 1.
[0178] 3a: Less Polar Fraction from Silica Gel Column
[0179] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.8 Hz, 1H), 7.80 (d, J=6.2 Hz, 1H), 7.60 (t, J=7.0 Hz, 2H),
7.35 (m, 1H), 7.10 (s, 1H), 6.92 (d, J=6.5 Hz, 1H), 6.80 (d, J=6.5
Hz, 1H), 6.68 (d, J=6.8 Hz, 1H), 4.55 (t, J=6.2 Hz, 2H), 4.52 (m,
1H), 4.20 (s, 2H), 3.60 (t, J=6.8 Hz, 2H), 3.15 (t, J=6.6 Hz, 2H),
2.45 (m, 1H), 2.31 (m, 1H), 1.80 (m, 2H), 1.73 (m, 2H), 1.45 (m,
4H).
[0180] 3b: More Polar Fraction from Silica Gel Column
[0181] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.12 (s, 1H), 8.05
(d, J=6.5 Hz, 1H), 7.78 (d, J=6.6 Hz, 1H), 7.58 (t, J=6.8 Hz, 1H),
7.50 (m, 1H), 7.08 (d, J=6.2 Hz, 1H), 7.01 (s, 1H), 6.90 (d, J=6.8
Hz, 1H), 6.70 (d, J=6.6 Hz, 1H), 4.55 (t, J=6.8 Hz, 2H), 4.52 (m,
1H), 4.20 (d, J=4.6 Hz, 2H), 3.68 (t, J=7.5 Hz, 2H), 3.21 (t, J=6.7
Hz, 2H), 2.98 (t, J=7.5 Hz, 2H), 2.45 (m, 1H), 2.02 (m, 1H), 1.85
(m, 4H), 1.45 (m, 2H), 1.15 (m, 2H).
Example 4
N-{[1-(4-Phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromet-
hyl-benzamide
Step A
3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidine-1-carboxylic
acid tert-butyl ester
##STR00070##
[0183] A solution of 3-amino-azetidine-1-carboxylic acid tert-butyl
ester (BetaPharma, 1.2 g, 6.97 mmol) and
(3-trifluoromethyl-benzoylamino)-acetic acid (Bionet, 1.57 g, 6.36
mmol) in DCM (10 mL) was treated with EDCI (Aldrich, 1.57 g, 6.36
mmol) and HOBT (Aldrich, 1.22 g, 6.36 mmol) at room temperature for
4 hours. The reaction solution was partitioned between DCM and
water. The organic layer was washed with brine, dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give a
yellow oil, which was then purified by silica gel column on a
CombiFlash.RTM. system using hexanes and ethyl acetate (from 10%
ethyl acetate to 100% ethyl acetate) to afford the title compound
as a white solid.
[0184] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.10 (s, 1H), 8.02
(d, J=6.6 Hz, 1H), 7.80 (d, J=6.8 Hz, 1H), 7.56 (t, J=6.5 Hz, 1H),
4.61 (m, 1H), 4.25 (t, J=7.2 Hz, 2H), 4.18 (d, J=5.5 Hz, 2H), 3.82
(t, J=7.5 Hz, 2H), 1.41 (s, 9H).
Step B
N-(Azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide free
base, HCl and TFA salt
##STR00071##
[0186] A solution of
3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetidine-1-carboxylic
acid tert-butyl ester (as prepared in the previous step, 7.5 g,
18.7 mmol) in dioxane (5 mL) and MeOH (20 mL) was treated with 4N
HCl at room temperature. The reaction was stirred for 4 hours. The
solvent was removed and the residue was dried to give the title
compound as an HCl salt (yellow foam).
[0187] A solution of
3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetidine-1-carboxylic
acid tert-butyl ester (as prepared in Step A of this Example, 2.10
g, 5.24 mmol) in 1:1 TFA and DCM (10 mL) was stirred for 2 hours at
room temperature. The solvent was removed to give the title
compound as a TFA salt containing extra TFA (colorless oil).
[0188] The free base was obtained by treating the salt in MeOH with
solid Na.sub.2CO.sub.3 overnight. The solid was filtered and
residue was dried to give the title compound for analytical
characterization.
[0189] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.10 (s, 1H), 8.05
(d, J=6.0 Hz, 1H), 7.78 (d, J=6.2 Hz, 1H), 7.55 (m, 2H), 4.78 (m,
1H), 4.15 (d, J=3.2 Hz, 2H), 3.95 (t, J=7.0 Hz, 2H), 3.52 (t, J=7.0
Hz, 2H).
Step C
N-{[1-(4-Phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trifluoromet-
hyl-benzamide
##STR00072##
[0191] A solution of 4-phenyl-cyclohexanone (Aldrich, 1.5 g, 8.62
mmol) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide TFA
salt (as prepared in the previous step, 3.89 g, 12.9 mmol) in DCM
(20 mL) was treated with TEA (6 mL, 43 mmol) for 10 min followed by
NaBH(OAc).sub.3 (Aldrich, 3.65 g, 17.2 mmol) for another 4 hours at
room temperature. The reaction was quenched with saturated sodium
bicarbonate. The organic layer was separated and the aqueous layer
was extracted 3 times with a chloroform/IPA "cocktail" (.about.3:1,
v/v). The combined organic layers were dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give the crude
product, which was then purified by a CombiFlash.RTM. system using
ethyl acetate and 7N NH.sub.3 in MeOH as eluent (from pure ethyl
acetate to 5% 7N NH.sub.3 in MeOH in ethyl acetate) to afford the
two title compounds as white solids.
[0192] 4a: Less Polar Fraction from Silica Gel Column
[0193] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.8 Hz, 1H), 7.80 (d, J=7.0 Hz, 1H), 7.55 (t, J=6.8 Hz, 1H),
7.30 (m, 2H), 7.20 (m, 4H), 6.72 (d, J=6.5 Hz, 1H), 4.33 (m, 1H),
4.30 (d, J=3.5 Hz, 2H), 3.55 (t, J=7.0 Hz, 2H), 2.85 (t, J=7.0 Hz,
2H), 2.45 (m, 1H), 2.10 (m, 1H), 1.95 (m, 2H), 1.70 (m, 2H), 1.52
(m, 2H), 1.22 (m, 2H).
[0194] 4b: More Polar Fraction from Silica Gel Column
[0195] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.12 (s, 1H), 8.05
(d, J=6.5 Hz, 1H), 7.80 (d, J=6.6 Hz, 1H), 7.58 (t, J=6.8 Hz, 1H),
7.40 (m, 2H), 7.15 (m, 4H), 6.75 (d, J=6.8 Hz, 1H), 4.42 (m, 1H),
4.25 (d, J=4.6 Hz, 2H), 3.64 (t, J=7.5 Hz, 2H), 3.10 (t, J=7.5 Hz,
2H), 2.35 (m, 1H), 2.08 (s, 1H), 2.02 (m, 2H), 1.85 (m, 2H), 1.35
(m, 2H), 1.15 (m, 2H).
Example 5
N-({1-[4-(2-Oxo-2,3-dihydro-benzooxazol-5-yl)-cyclohexyl]-azetidin-3-ylcar-
bamoyl}-methyl)-3-trifluoromethyl-benzamide
Step A
5-(1-Hydroxy-4-oxo-cyclohexyl)-3H-benzooxazol-2-one
##STR00073##
[0197] The title compound was prepared as a white solid from
5-bromo-3H-benzooxazol-2-one (Aldrich) using the procedures
described in Steps A and B of Example 1.
[0198] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 7.35 (d, J=6.5
Hz, 1H), 7.23 (d, J=4.5 Hz, 1H), 7.12 (d, J=6.0 Hz, 1H), 2.90 (m,
2H), 2.30 (m, 4H), 2.08 (m, 2H).
Step B
5-(4-Oxo-cyclohex-1-enyl)-3H-benzooxazol-2-one
##STR00074##
[0200] A solution of
5-(1-hydroxy-4-oxo-cyclohexyl)-3H-benzooxazol-2-one (230 mg, 0.93
mmol) in THF (10 mL) was treated with Burgess' reagent (Aldrich,
334 mg, 1.40 mmol) at room temperature. The reaction was stirred
overnight. The solvent was removed and the residue was partitioned
between ethyl acetate and water. The organic layer was washed with
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered,
concentrated and then purified by silica gel column on a
CombiFlash.RTM. system using hexanes and ethyl acetate (from 10%
ethyl acetate to 100% ethyl acetate) to afford the title compound
as a white solid.
[0201] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 7.25 (d, J=6.0
Hz, 1H), 7.18 (d, J=5.8 Hz, 1H), 7.05 (d, J=6.0 Hz, 1H), 5.98 (m,
1H), 2.95 (s, 1H), 2.82 (t, J=5.2 Hz, 1H), 2.49 (t, J=6.5 Hz,
2H).
Step C
5-(4-Oxo-cyclohexyl)-3H-benzooxazol-2-one
##STR00075##
[0203] To a Parr hydrogenation flask was added a solution of
5-(4-oxo-cyclohex-1-enyl)-3H-benzooxazol-2-one (as prepared in the
previous step, 180 mg, 0.79 mmol) in MeOH (10 mL) followed by 5%
Pd/C (Aldrich, .about.100 mg). The reaction was charged with 40 psi
H.sub.2 gas for 10 hours at room temperature. The catalyst was
removed by passing the reaction solution through a pad of Celite.
MeOH was added to washed the Celite column three times. The
combined organic layers were concentrated in vacuo to give the
title compound as a white solid.
[0204] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.05 (s, br, 1H),
7.15 (d, J=5.8 Hz, 1H), 7.05 (m, 2H), 3.05 (m, 1H), 2.55 (m, 4H),
2.20 (m, 2H), 1.90 (m, 2H).
Step D
N-({1-[4-(2-Oxo-2,3-dihydro-benzooxazol-5-yl)-cyclohexyl]-azetidin-3-ylcar-
bamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00076##
[0206] The title compounds were prepared as white solids from
reductive amination of 5-(4-oxo-cyclohexyl)-3H-benzooxazol-2-one
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0207] 5a: Less Polar Fraction from Silica Gel Column
[0208] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.21 (s, 1H),
8.15 (d, J=6.3 Hz, 1H), 7.88 (d, J=6.5 Hz, 1H), 7.70 (t, J=6.6 Hz,
1H), 7.13 (d, J=6.6 Hz, 1H), 7.05 (m, 2H), 4.52 (m, 1H), 4.05 (s,
2H), 3.85 (m, 2H), 3.18 (m, 2H), 2.65 (m, 1H), 1.85 (m, 4H), 1.62
(m, 4H).
[0209] 5b: More Polar Fraction from Silica Gel Column
[0210] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.25 (s, 1H),
8.16 (d, J=5.5 Hz, 1H), 7.87 (d, J=6.0 Hz, 1H), 7.68 (t, J=6.0 Hz,
1H), 7.11 (d, J=6.6 Hz, 1H), 6.95 (m, 2H), 4.45 (m, 1H), 4.05 (s,
2H), 3.70 (t, J=6.2 Hz, 2H), 3.10 (t, J=6.5 Hz, 2H), 2.55 (m, 1H),
1.95 (m, 4H), 1.52 (m, 2H), 1.20 (m, 2H).
Example 6
N-({1-[4-(2-Oxo-2,3-dihydro-benzothiazol-5-yl)-cyclohexyl]-azetidin-3-ylca-
rbamoyl}-methyl)-3-trifluoromethyl-benzamide
Step A
5-(1-Hydroxy-4-oxo-cyclohexyl)-3H-benzothiazol-2-one
##STR00077##
[0212] The title compound was prepared as a white solid from
6-bromo-3H-benzothiazol-2-one (Aldrich) using the procedures
described in Steps A and B of Example 1.
[0213] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.41 (d, J=5.5 Hz,
1H), 7.20 (d, J=6.0 Hz, 1H), 7.10 (s, 1H), 2.85 (m, 2H), 2.63 (m,
2H), 2.48 (m, 2H). 2.10 (m, 2H).
Step B
5-(4-Oxo-cyclohex-1-enyl)-3H-benzothiazol-2-one
##STR00078##
[0215] The title compound was prepared as a white solid from
5-(1-hydroxy-4-oxo-cyclohexyl)-3H-benzothiazol-2-one (as prepared
in the previous step) using the procedure described in Step B of
Example 5.
[0216] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.50 (s, br, 1H),
7.41 (s, 1H), 7.30 (d, J=6.0 Hz, 1H), 7.08 (d, J=6.4 Hz, 1H), 6.05
(m, 1H), 2.90 (m, 2H), 2.65 (m, 2H), 2.50 (m, 2H).
Step C
N-({1-[4-(2-Oxo-2,3-dihydro-benzothiazol-5-yl)-cyclohexyl]-azetidin-3-ylca-
rbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00079##
[0218] The title compounds were prepared as white solids from
hydrogenation of 5-(4-oxo-cyclohex-1-enyl)-3H-benzothiazol-2-one
(as prepared in the previous step) followed by reductive amination
of the corresponding ketone with
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedures described in
Step C of Example 5 and Step C of Example 4.
[0219] 6a: Less Polar Fraction from Silica Gel Column
[0220] .sup.1H NMR (400 MHz, d.sub.6-DMSO) .delta. 8.15 (s, 1H),
8.10 (d, J=4.5 Hz, 1H), 7.95 (d, J=5.5 Hz, 1H), 7.75 (t, J=6.0 Hz,
1H), 7.35 (s, 1H), 7.10 (d, J=6.0 Hz, 1H), 7.05 (d, J=6.0 Hz, 1H),
4.38 (m, 1H), 3.95 (m, 2H), 3.56 (t, J=6.5 Hz, 2H), 2.80 (t, J=6.4
Hz, 2H), 3.02 (m, 1H), 1.80.about.1.65 (m, 4H), 1.45 (m, 4H).
[0221] 6b: More Polar Fraction from Silica Gel Column
[0222] ESI-MS (m/z): Calcd. For
C.sub.26H.sub.27F.sub.3N.sub.4O.sub.3S, 532; found: 533 (M+H).
Example 7
N-({1-[4-(4-Methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3--
trifluoromethyl-benzamide
Step A
8-(4-Methoxy-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00080##
[0224] The title compound was prepared as a white solid from
1-bromo-4-methoxy-benzene (Aldrich) using the procedure described
in Step A of Example 1.
[0225] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.51 (d, J=7.0 Hz,
2H), 6.85 (d, J=7.1 Hz, 2H), 3.98 (s, 4H), 3.79 (s, 3H), 2.10 (m,
4H), 1.80 (m, 2H), 1.65 (m, 2H).
Step B
4-Hydroxy-4-(4-methoxy-phenyl)-cyclohexanone
##STR00081##
[0227] The title compound was prepared as a white solid from
8-(4-methoxy-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (as prepared in
the previous step) using the procedure described in Step B of
Example 1.
[0228] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.55 (d, J=6.8 Hz,
2H), 6.90 (d, J=6.8 Hz, 2H), 3.85 (s, 3H), 2.95 (m, 2H), 2.33 (m,
4H), 2.20 (m, 2H).
Step C
4-(4-Methoxy-phenyl)-cyclohex-3-enone
##STR00082##
[0230] The title compound was prepared as a white solid from
4-hydroxy-4-(4-methoxy-phenyl)-cyclohexanone (as prepared in the
previous step) using the procedure described in Step B of Example
5.
[0231] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.35 (d, J=6.8 Hz,
2H), 6.85 (d, J=6.8 Hz, 2H), 5.98 (m, 1H), 3.80 (s, 3H), 3.05 (s,
2H), 2.85 (m, 2H), 2.65 (t, J=7.0 Hz, 2H).
Step D
N-({1-[4-(4-Methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3--
trifluoromethyl-benzamide
##STR00083##
[0233] The title compounds were prepared as white solids from the
hydrogenation of 4-(4-methoxy-phenyl)-cyclohex-3-enone (as prepared
in the previous step) followed by reductive amination of the
corresponding ketone with
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedures described in
Step C of Example 5 and Step C of Example 4.
[0234] 7a: Less Polar Fraction from Silica Gel Column
[0235] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (s, 1H), 8.05
(d, J=6.8 Hz, 1H), 7.80 (d, J=6.2 Hz, 1H), 7.65 (t, J=7.0 Hz, 2H),
7.45 (d, J=6.5 Hz, 1H), 6.92 (d, J=6.5 Hz, 2H), 4.52 (m, 1H), 4.18
(d, J=3.5 Hz, 2H), 3.85 (s, 3H), 3.60 (t, J=7.0 Hz, 2H), 2.90 (t,
J=7.0 Hz, 2H), 2.52 (m, 1H), 2.30 (s, br, 1H), 1.95 (m, 2H), 1.75
(m, 2H), 1.50 (m, 2H), 1.35 (m, 2H).
[0236] 7b: More Polar Fraction from Silica Gel Column
[0237] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.12 (s, 1H), 8.05
(d, J=6.5 Hz, 1H), 7.75 (d, J=6.6 Hz, 1H), 7.68 (d, J=6.8 Hz, 2H),
7.60 (t, J=6.8 Hz, 1H), 7.50 (d, J=6.8 Hz, 2H), 4.52 (m, 1H), 4.20
(d, J=4.6 Hz, 2H), 3.82 (s, 3H), 3.64 (t, J=7.5 Hz, 2H), 2.98 (t,
J=7.5 Hz, 2H), 2.55 (m, 1H), 2.40 (s, 1H), 2.02 (m, 2H), 1.85 (m,
2H), 1.35 (m, 2H), 1.15 (m, 2H).
Example 8
N-({1-[4-(3-Cyano-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-tr-
ifluoromethyl-benzamide
Step A
3-(8-Hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-benzonitrile
##STR00084##
[0239] A solution of iso-propyl-magnesium bromide (Aldrich, 2.0 M
in THF, 8 mL, 16 mmol) was slowly dropped into a solution of
3-iodo-benzonitrile (Aldrich, 3.25 g, 14.2 mmol) in THF (20 mL) at
0.degree. C. After addition, the reaction was stirred for another
30 min. A solution of 1,4-dioxa-spiro[4.5]decan-8-one (2.22 g, 14.2
mmol) in THF (5 mL) was added to the reaction mixture at 0.degree.
C. The reaction was then stirred for additional 2 hours. The
reaction was quenched with diluted NH.sub.4Cl solution and warmed
to room temperature. The solvent was removed in vacuo and the
residue was partitioned between ethyl acetate and water. The
organic layer was washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to give a yellow solid,
which was purified by silica gel column on a CombiFlash.RTM. system
using hexanes and ethyl acetate (from 10% ethyl acetate to 100%
ethyl acetate) to afford the title compound as a white solid.
[0240] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.82 (s, 1H), 7.75
(d, J=6.8 Hz, 1H), 7.51 (d, J=6.5 Hz, 2H), 7.42 (t, J=6.6 Hz, 1H),
3.98 (m, 4H), 2.12 (m, 4H), 1.78 (m, 2H), 1.65 (m, 2H).
Step B
3-(1-Hydroxy-4-oxo-cyclohexyl)-benzonitrile
##STR00085##
[0242] The title compound was prepared as a white solid from
3-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-benzonitrile (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0243] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.80 (s, 1H), 7.68
(d, J=6.7 Hz, 1H), 7.50 (d, J=6.8 Hz, 2H), 7.41 (t, J=6.6 Hz, 1H),
2.90 (m, 2H), 2.35 (m, 2H), 2.25 (m, 2H), 2.14 (m, 2H).
Step C
3-(4-Oxo-cyclohex-1-enyl)-benzonitrile
##STR00086##
[0245] The title compound was prepared as a white solid from
3-(1-hydroxy-4-oxo-cyclohexyl)-benzonitrile (as prepared in the
previous step) using the procedure described in Step B of Example
5.
[0246] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.90 (s, 1H), 7.78
(d, J=6.5 Hz, 1H), 7.65 (m, 1H), 7.48 (t, J=-6.6 Hz, 1H), 6.20 (m,
1H), 3.10 (s, 2H), 2.85 (m, 2H), 2.68 (t, J=6.8 Hz, 2H).
Step D
N-({1-[4-(3-Cyano-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-tr-
ifluoromethyl-benzamide
##STR00087##
[0248] The title compounds were prepared as white solids from
hydrogenation of 3-(4-oxo-cyclohex-1-enyl)-benzonitrile (as
prepared in the previous step) followed by reductive amination of
the corresponding ketone with
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedures described in
Step C of Example 5 and Step C of Example 4.
[0249] 8a: Less Polar Fraction from Silica Gel Column
[0250] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (s, 1H), 8.02
(d, J=6.4 Hz, 1H), 7.85 (s, 1H), 7.78 (t, J=7.0 Hz, 2H), 7.60 (d,
J=6.4 Hz, 1H), 7.58 (t, J=6.8 Hz, 1H), 7.40 (d, J=7.5 Hz, 1H), 4.60
(m, 1H), 4.18 (d, J=4.5 Hz, 2H), 3.66 (t, J=7.0 Hz, 2H), 3.10 (t,
J=5.7 Hz, 2H), 2.52 (m, 1H), 2.32 (s, br, 1H), 2.20 (m, 2H), 1.95
(m, 2H), 1.60 .about.1.45 (m, 4H).
[0251] 8b: More Polar Fraction from Silica Gel Column,
[0252] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.6 Hz, 1H), 7.90 (s, 1H), 7.75 (d, J=6.5 Hz, 2H), 7.60 (d,
J=6.8 Hz, 1H), 7.45 (t, J=6.5 Hz, 1H), 7.35 (d, J=5.8 Hz, 1H), 4.55
(m, 1H), 4.20 (d, J=3.5 Hz, 2H), 3.65 (t, J=7.0 Hz, 2H), 2.95 (s,
br, 2H), 2.55 (m, 1H), 2.30 (s, br, 1H), 2.05 (m, 2H), 1.90 (m,
2H), 1.75 (m, 4H).
Example 9
4-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cy-
clohexyl)-benzoic acid methyl ester
Step A
4-(8-Hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-benzoic acid methyl
ester
##STR00088##
[0254] The title compound was prepared as a white solid from
4-iodo-benzoic acid methyl ester (Aldrich) using the procedure
described in Step A of Example 8.
[0255] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.95 (d, J=7.0 Hz,
2H), 6.85 (d, J=7.3 Hz, 2H), 4.08 (s, 4H), 2.51 (t, J=6.0 Hz, 4H),
2.03 (t, J=6.0 Hz, 4H).
Step B
4-(1-Hydroxy-4-oxo-cyclohexyl)-benzoic acid methyl ester
##STR00089##
[0257] The title compound was prepared as a white solid from
4-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-benzoic acid methyl
ester (as prepared in the previous step) using the procedure
described in Step B of Example 1.
[0258] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.05 (d, J=6.8 Hz,
2H), 7.60 (d, J=6.8 Hz, 2H), 4.01 (m, 4H), 3.90 (s, 3H), 2.95 (m,
2H), 2.38 (m, 2H), 2.30 (m, 2H), 2.20 (m, 2H).
Step C
4-(4-Oxo-cyclohex-1-enyl)-benzoic acid methyl ester
##STR00090##
[0260] The title compound was prepared as a white solid from
4-(1-hydroxy-4-oxo-cyclohexyl)-benzoic acid methyl ester (as
prepared in the previous step) using the procedure described in
Step B of Example 5.
[0261] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.01 (d, J=6.5 Hz,
2H), 7.46 (d, J=6.6 Hz, 2H), 6.21 (m, 1H), 3.95 (s, 3H), 3.15 (s,
2H), 2.95 (t, J=5.6 Hz, 2H), 2.70 (t, J=6.3 Hz, 2H).
Step D
4-(4-Oxo-cyclohexyl)-benzoic acid methyl ester
##STR00091##
[0263] The title compound was prepared as a white solid from
4-(4-oxo-cyclohex-1-enyl)-benzoic acid methyl ester (as prepared in
the previous step) using the procedure described in Step C of
Example 5.
[0264] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.05 (d, J=8.0 Hz,
2H), 7.58 (d, J=8.0 Hz, 2H), 3.92 (s, 3H), 2.70 (m, 1H), 2.35-2.00
(8H).
Step E
4-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cy-
clohexyl)-benzoic acid methyl ester
##STR00092##
[0266] The title compound was prepared as a white solid by
reductive amination of 4-(4-oxo-cyclohexyl)-benzoic acid methyl
ester (as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0267] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.4 Hz, 1H), 7.95 (d, J=7.0 Hz, 2H), 7.80 (d, J=6.4 Hz, 1H),
7.58 (t, J=6.8 Hz, 1H), 7.30 (d, J=7.5 Hz, 2H), 6.56 (s, br, 1H),
4.55 (m, 1H), 4.18 (d, J=3.5 Hz, 2H), 3.62 (t, J=7.0 Hz, 2H), 2.95
(s, br, 2H), 2.62 (m, 1H), 1.95 (m, 2H), 1.80.about.1.55 (m,
6H).
Example 10
4-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cy-
clohexyl)-benzoic acid
##STR00093##
[0269] A solution of
4-(4-{3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-c-
yclohexyl)-benzoic acid methyl ester (less polar fraction from
Example 9, 250 mg, 0.48 mmol) in THF (1 mL), MeOH (1 mL) and
H.sub.2O (1 mL) was treated with LiOH.H.sub.2O (50 mg, 1.2 mmol) at
room temperature. The reaction was then heated to 50.degree. C. for
2 hours. The reaction was allowed to cool and solvent was removed
in vacuo. 1 N HCl solution was added to adjust the solution to
pH=6.about.7. The white precipitate was collected by filtration and
washed with water. The solid was dried in vacuo, re-dissolved in
ethyl acetate and re-crystallization to afford the title
compound.
[0270] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.10 (s, 1H),
8.01 (d, J=6.4 Hz, 1H), 7.72 (d, J=6.0 Hz, 1H), 7.70 (d, J=7.5 Hz,
2H), 7.55 (t, J=6.0 Hz, 1H), 7.18 (d, J=7.6 Hz, 2H), 4.56 (m, 1H),
4.15 (t, J=6.0 Hz, 2H), 4.08 (d, J=3.2 Hz, 2H), 3.81 (s, br, 2H),
2.65 (m, 1H), 1.95 (m, 2H), 1.80 (m, 2H), 1.66 (m, 4H).
Example 11
3-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cy-
clohexyl)-benzoic acid ethyl ester
Step A
3-(8-Hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-benzoic acid ethyl
ester
##STR00094##
[0272] The title compound was prepared as a white solid from
3-iodo-benzoic acid ethyl ester (Aldrich) using the procedure
described in Step A of Example 8.
[0273] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.20 (s, 1H), 7.95
(d, J=6.8 Hz, 1H), 7.75 (d, J=6.6 Hz, 1H), 7.40 (t, J=6.4 Hz, 1H),
4.35 (q, J=6.2 Hz, 2H), 4.05 (m, 4H), 2.20 (m, 4H), 1.85 (m, 2H),
1.72 (m, 2H), 1.40 (t, J=7.8 Hz, 3H).
Step B
3-(1-Hydroxy-4-oxo-cyclohexyl)-benzoic acid ethyl ester
##STR00095##
[0275] The title compound was prepared as a white solid from
3-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-benzoic acid ethyl ester
(as prepared in the previous step) using the procedure described in
Step B of Example 1.
[0276] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.20 (s, 1H), 8.00
(d, J=6.0 Hz, 1H), 7.78 (d, J=6.2 Hz, 1H), 7.45 (t, J=6.5 Hz, 1H),
4.35 (q, J=7.1 Hz, 2H), 2.95 (m, 2H), 2.40 (m, 4H), 2.21 (m, 2H),
1.38 (t, J=7.2 Hz, 3H).
Step C
3-(4-Oxo-cyclohex-1-enyl)-benzoic acid ethyl ester
##STR00096##
[0278] The title compound was prepared as a white solid from
3-(1-hydroxy-4-oxo-cyclohexyl)-benzoic acid ethyl ester (as
prepared in the previous step) using the procedure described in
Step B of Example 5.
[0279] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.10 (s, 1H), 7.96
(d, J=7.2 Hz, 1H), 7.59 (d, J=6.5 Hz, 1H), 7.42 (t, J=6.5 Hz, 1H),
6.20 (m, 1H), 4.37 (q, J=7.5 Hz, 2H), 3.10 (s, 2H), 2.95 (t, J=6.8
Hz, 2H), 2.68 (t, J=7.7 Hz, 2H), 1.40 (t, J=8.2 Hz, 3H).
Step D
3-(4-Oxo-cyclohexyl)-benzoic acid ethyl ester
##STR00097##
[0281] The title compound was prepared as a white solid from
3-4-oxo-cyclohex-1-enyl)-benzoic acid ethyl ester (as prepared in
the previous step) using the procedure described in Step C of
Example 5.
[0282] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.00 (s, 1H), 7.90
(d, J=6.8 Hz, 1H), 7.48 (d, J=6.5 Hz, 1H), 7.36 (t, J=6.6 Hz, 1H),
4.35 (q, J=7.2 Hz, 2H), 2.61 (m, 1H), 2.45 (m, 2H), 2.30 (m, 2H),
2.25 (m, 2H0, 2.05 (m, 2H), 1.35 (t, J=7.9 Hz, 3H).
Step E
3-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cy-
clohexyl)-benzoic acid ethyl ester
##STR00098##
[0284] The title compound was prepared as a white solid by the
reductive amination of 3-(4-oxo-cyclohexyl)-benzoic acid ethyl
ester (as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0285] 11a: Less Polar Isomer
[0286] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.26 (s, 1H),
8.18 (d, J=5.6 Hz, 1H), 7.85 (m, 3H), 7.71 (t, J=6.5 Hz, 1H), 7.55
(d, J=6.0 Hz, 1H), 7.38 (t, J=6.5 Hz, 1H), 4.55 (m, 1H), 4.32 (q,
J=6.8 Hz, 2H), 4.09 (s, 2H), 4.04 (t, J=6.0 Hz, 2H), 3.70 (d, J=6.0
Hz, 2H), 2.72 (m, 1H), 2.60 (m, 1H), 2.10 (m, 2H), 2.02 (m, 2H),
1.65 (m, 2H), 1.36 (t, J=6.0 Hz, 3H), 1.28 (m, 2H).
[0287] 11b: More Polar Isomer
[0288] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.20 (s, 1H),
8.10 (d, J=3.6 Hz, 1H), 8.02 (d, J=6.5 Hz, 1H), 7.80 (m, 2H), 7.65
(t, J=6.0 Hz, 1H), 7.50 (d, J=6.0 Hz, 1H), 7.29 (t, J=6.5 Hz, 1H),
4.50 (m, 1H), 4.30 (q, J=6.5 Hz, 2H), 4.10 (s, 2H), 3.85 (t, J=6.0
Hz, 2H), 3.35 (d, J=6.0 Hz, 2H), 2.72 (m, 1H), 2.30 (m, 2H), 2.08
(m, 2H), 1.75 (m, 4H), 1.50 (2H), 1.35 (t, J=6.0 Hz, 3H).
Example 12
3-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cy-
clohexyl)-benzoic acid
##STR00099##
[0290] The title compound was prepared as a white solid by
hydrolysis of
3-(4-{3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-c-
yclohexyl)-benzoic acid ethyl ester (less polar fraction, as
prepared in Example 11, Step E) using the procedure described in
Example 10.
[0291] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.15 (s, 1H),
8.10 (d, J=6.0 Hz, 1H), 8.85 (s, 1H), 7.80 (d, J=6.5 Hz, 1H), 7.71
(d, J=6.0 Hz, 1H), 7.65 (t, J=6.5 Hz, 1H), 7.32 (d, J=6.4
[0292] Hz, 1H), 7.20 (t, J=6.7 Hz, 1H), 4.55 (m, 1H), 4.20 (s, 2H),
4.15 (t, J=6.0 Hz, 2H), 3.02 (s, br, 2H), 3.69 (t, J=6.0 Hz, 2H),
2.68 (m, 1H), 1.80 (m, 4H), 1.72 (m, 4H).
Example 13
N-({1-[4-(4-Pyrrolidin-1-yl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
Step A
8-(4-Pyrrolidin-1-yl-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00100##
[0294] The title compound was prepared as a white solid from
1-(4-bromo-phenyl)-pyrrolidine (Ryan Scientific) using the
procedure described in Step A of Example 1.
[0295] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.36 (d, J=7.1 Hz,
2H), 6.51 (d, J=7.2 Hz, 2H), 4.01 (s, 4H), 3.95 (m, 2H), 3.30 (m,
2H), 2.11 (m, 2H), 2.05 (m, 6H), 1.88 (m, 2H), 1.70 (m, 2H).
Step B
1-[4-(1,4-Dioxa-spiro[4.5]dec-7-en-8-yl)-phenyl]-pyrrolidine
##STR00101##
[0297] The title compound was prepared as a white solid from
8-(4-pyrrolidin-1-yl-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (as
prepared in the previous step) using the procedure described in
Step B of Example 5.
[0298] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.26 (d, J=7.5 Hz,
2H), 6.55 (d, J=7.6 Hz, 2H), 5.85 (m, 1H), 4.10 (s, 4H), 3.25 (t,
J=5.6 Hz, 4H), 2.62 (m, 2H), 2.53 (t, J=6.4 Hz, 2H), 2.42 (s, 2H),
2.05 (t, J=5.8 Hz, 4H).
Step C
1-[4-(1,4-Dioxa-spiro[4.5]dec-8-yl)-phenyl]-pyrrolidine
##STR00102##
[0300] The title compound was prepared as a white solid from
1-[4-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-phenyl]-pyrrolidine (as
prepared in the previous step) using the procedure described in
Step C of Example 5.
[0301] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.10 (d, J=7.5 Hz,
2H), 6.48 (d, J=7.8 Hz, 2H), 3.96 (s, 4H), 3.25 (t, J=5.6 Hz, 4H),
2.45 (m, 1H), 2.00 (t, J=6.0 Hz, 4H), 1.85 (m, 4H), 1.75.about.1.60
(m, 4H).
Step D
4-(4-Pyrrolidin-1-yl-phenyl)-cyclohexanone
##STR00103##
[0303] The title compound was prepared as a white solid from
1-[4-(1,4-dioxa-spiro[4.5]dec-8-yl)-phenyl]-pyrrolidine (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0304] ESI-MS (m/z): Calcd. for C.sub.16H.sub.21NO, 243; found: 244
(M+H).
Step E
N-({1-[4-(4-Pyrrolidin-1-yl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
##STR00104##
[0306] The title compound was prepared as a white solid from the
reductive amination of 4-(4-pyrrolidin-1-yl-phenyl)-cyclohexanone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0307] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.8 Hz, 1H), 7.82 (d, J=6.0 Hz, 1H), 7.58 (t, J=6.5 Hz, 2H),
7.45 (d, J=6.5 Hz, 1H), 6.85 (d, J=6.5 Hz, 2H), 4.52 (m, 1H), 4.18
(d, J=3.5 Hz, 2H), 3.60 (t, J=6.0 Hz, 2H), 3.20 (t, J=7.0 Hz, 4H),
2.95 (t, J=6.0 Hz, 2H), 2.50 (m, 1H), 2.30 (s, br, 1H), 1.96 (t,
J=7.5 Hz, 4H), 1.90 (m, 2H), 1.75 (m, 2H), 1.55 (m, 2H), 1.30 (m,
2H).
Example 14
N-({1-[4-(3-Methanesulfonyl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
Step A
8-(3-Methylsulfanyl-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00105##
[0309] The title compound was prepared as a white solid from
1-bromo-3-methylsulfanyl-benzene (Aldrich) using the procedure
described in Step A of Example 1.
[0310] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.45 (s, 1H), 7.25
(d, J=4.5 Hz, 2H), 7.14 (t, J=5.2 Hz, 1H), 4.01 (m, 4H), 2.46 (s,
3H), 2.10 (m, 4H), 1.78 (d, J=8.2 Hz, 2H), 1.70 (d, J=8.2 Hz,
2H).
Step B
4-Hydroxy-4-(3-methylsulfanyl-phenyl)-cyclohexanone
##STR00106##
[0312] The title compound was prepared as a white solid from
8-(3-methylsulfanyl-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0313] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.41 (s, 1H), 7.25
(m, 2H), 7.19 (d, J=7.0 Hz, 1H), 2.92 (m, 2H), 2.49 (s, 3H), 2.32
(m, 2H), 2.25 (m, 2H), 2.20 (m, 2H).
Step C
4-(3-Methanesulfonyl-phenyl)-cyclohex-3-enone
##STR00107##
[0315] A solution of
4-hydroxy-4-(3-methylsulfanyl-phenyl)-cyclohexanone (as prepared in
the previous step, 1.10 g, 4.66 mmol) in THF (10 mL) was treated
with Burgess' reagent (1.20 g, 5.00 mmol) at room temperature
overnight. The solvent was removed and the residue was partitioned
between ethyl acetate and water. The organic layer was washed with
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered,
concentrated to give a white solid. To this white solid in MeOH (5
mL) and water (5 mL) was added OXONE (Aldrich, 6.10 g, 10 mmol) at
room temperature. The reaction mixture was stirred overnight and
quenched with saturated NaHCO.sub.3. The solvent was removed in
vacuo and the residue was partitioned between ethyl acetate and
water. The organic layer was washed with brine, dried over
anhydrous Na.sub.2SO.sub.4, filtered, concentrated and purified by
silica gel column on a CombiFlash.RTM. system using hexanes and
ethyl acetate (from 10% ethyl acetate to 100% ethyl acetate) to
afford the title compound as a white solid.
[0316] ESI-MS (m/z): Calcd. for C.sub.13H.sub.14O.sub.3S, 250;
found: 251 (M+H).
Step D
N-({1-[4-(3-Methanesulfonyl-phenyl)-cyclohex-3-enyl]-azetidin-3-ylcarbamoy-
l}-methyl)-3-trifluoromethyl-benzamide
##STR00108##
[0318] The title compound was prepared as a white solid from
4-(3-methanesulfonyl-phenyl)-cyclohex-3-enone (as prepared in the
previous step) using the procedure described in Step C of Example
4.
[0319] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.10 (s, 1H), 8.02
(d, J=6.0 Hz, 1H), 7.90 (s, 1H), 7.82 (d, J=6.2 Hz, 1H), 7.60 (t,
J=6.2 Hz, 1H), 7.55 (d, J=6.1 Hz, 1H), 7.45 (t, J=6.2 Hz, 1H), 6.85
(d, J=6.0 Hz, 1H), 6.11 (m, 1H), 4.53 (m, 1H), 4.15 (d, J=3.5 Hz,
2H), 3.65 (t, J=6.5 Hz, 2H), 3.05 (s, 3H), 3.02 (t, J=6.5 Hz, 2H),
2.42 (m, 1H), 2.33 (m, 2H), 2.20 (m, 1H), 2.01 (m, 1H), 1.90 (m,
1H), 1.83 (m, 1H).
Step E
N-({1-[4-(3-Methanesulfonyl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
##STR00109##
[0321] The title compound was prepared as a white solid from
N-({1-[4-(3-methanesulfonyl-phenyl)-cyclohex-3-enyl]-azetidin-3-ylcarbamo-
yl}-methyl)-3-trifluoromethyl-benzamide (as prepared in the
previous step) using the procedure described in Step G of Example
1.
[0322] 14a: Less Polar Fraction from Silica Gel Column
[0323] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.20 (s, 1H), 8.10
(d, J=6.2 Hz, 1H), 7.90 (s, 1H), 7.75 (m, 2H), 7.54 (m, 1H), 7.40
(m, 1H), 7.30 (s, 1H), 4.58 (m, 1H), 4.20 (d, J=3.5 Hz, 2H), 3.75
(s, br, 2H), 3.10 (s, 3H), 2.01 (m, 1H), 1.80 (m, 2H),
1.75.about.1.50 (m, 5H).
[0324] 14b: More Polar Fraction from Silica Gel Column
[0325] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.18 (s, 1H), 8.05
(d, J=6.0 Hz, 1H), 7.85 (s, 1H), 7.76 (m, 2H), 7.55 (m, 2H), 7.42
(m, 1H), 5.51 (s, br, 1H), 4.55 (m, 1H), 4.20 (d, J=3.0 Hz, 2H),
3.68 (t, J=5.5 Hz, 2H), 3.11 (s, 3H), 3.05 (m, 2H), 1.98 (m, 4H),
1.80 (m, 2H), 1.55 (m, 2H).
Example 15
N-({1-[4-(4-Amino-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-tr-
ifluoromethyl-benzamide
Step A
[4-(8-Hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-phenyl]-carbamic acid
tert-butyl ester
##STR00110##
[0327] The title compound was prepared as a white solid from
(4-bromo-phenyl)-carbamic acid tert-butyl ester (Aldrich) using the
procedure described in Step A of Example 1.
[0328] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.42 (d, J=6.5 Hz,
2H), 7.30 (d, J=6.6 Hz, 2H), 3.98 (m, 4H), 2.12 (m, 4H), 1.80 (m,
2H), 1.65 (M, 2H), 1.51 (s, 9H).
Step B
[4-(4-Oxo-cyclohex-1-enyl)-phenyl]-carbamic acid tert-butyl
ester
##STR00111##
[0330] The title compound was prepared as a white solid from
[4-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-phenyl]-carbamic acid
tert-butyl ester (as prepared in the previous step) using the
procedure described in Step B of Example 1 followed by dehydration
of the alcohol using the procedure described in Step B of Example
5.
[0331] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.35 (s, 4H), 6.51
(s, br, 1H), 6.03 9m, 1H), 3.08 (s, 2H), 2.90 (t, J=4.5 Hz, 2H),
2.64 (t, J=6.8 Hz, 2H), 1.48 (s, 9H).
Step C
[4-(4-Oxo-cyclohexyl)-phenyl]-carbamic acid tert-butyl ester
##STR00112##
[0333] The title compound was prepared as a white solid from
[4-(4-oxo-cyclohex-1-enyl)-phenyl]-carbamic acid tert-butyl ester
(as prepared in the previous step) using the procedure described in
Step C of Example 5.
[0334] ESI-MS (m/z): Calcd. for C.sub.17H.sub.23NO.sub.3, 289;
found: 290 (M+H).
Step D
{1-[4-(4-tert-Butoxycarbonylamino-phenyl)-cyclohexyl]-azetidin-3-yl}-carba-
mic acid tent-butyl ester
##STR00113##
[0336] The title compound was prepared as a white solid from
[4-(4-oxo-cyclohexyl)-phenyl]-carbamic acid tert-butyl ester (as
prepared in the previous step) using the procedure described in
Step D of Example 1.
[0337] Less polar fraction from silica gel column, .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.25 (d, J=6.5 Hz, 2H), 7.14 (d, J=6.5 Hz,
2H), 6.38 (s, br, 1H), 4.88 (s, br, 1H), 4.25 (m, 1H), 3.55 (t,
J=6.8 Hz, 2H), 2.72 (t, J=4.0 Hz, 2H), 2.42 (m, 1H), 1.85 (m, 4H),
1.63 (m, 4H), 1.51 (s, 9H), 1.43 (s, 9H).
[0338] More polar fraction from silica gel column, .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.26 (d, J=6.8 Hz, 2H), 7.10 (d, J=6.6 Hz,
2H), 6.42 (s, br, 1H), 4.95 (s, br, 1H), 4.26 (m, 1H), 3.60 (t,
J=6.5 Hz, 2H), 2.87 (s, br, 2H), 2.38 (m, 1H), 2.00 (m, 2H), 1.85
(m, 2H), 1.45 (s, 9H), 1.40 (s, 9H), 1.38 (m, 2H), 1.18 (m,
2H).
Step E
1-[4-(4-Amino-phenyl)-cyclohexyl]-azetidin-3-ylamine TFA salt
##STR00114##
[0340] The title compound was prepared as colorless oil from
{1-[4-(4-tert-butoxycarbonylamino-phenyl)-cyclohexyl]-azetidin-3-yl}-carb-
amic acid tert-butyl ester (as prepared in the previous step, less
polar fraction) using the procedure described in Step E of Example
1.
[0341] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.01 (d, J=6.6 Hz,
2H), 6.60 (d, J=6.8 Hz, 2H), 3.60 (t, J=7.0 Hz, 2H), 3.55 (m, 1H),
2.50 (t, J=7.0 Hz, 2H), 2.40 (m, 1H), 1.80 (m, 2H), 1.65 (m, 2H),
1.55.about.1.30 (m, 4H).
Step F
N-({1-[4-(4-Amino-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-tr-
ifluoromethyl-benzamide
##STR00115##
[0343] The title compound was prepared as a white solid from an
EDCI coupling of
1-[4-(4-amino-phenyl)-cyclohexyl]-azetidin-3-ylamine TFA salt (as
prepared in the previous step) and
(3-trifluoromethyl-benzoylamino)-acetic acid using the procedure
described in Step F of Example 1.
[0344] ESI-MS (m/z): Calcd. For
C.sub.25H.sub.29F.sub.3N.sub.4O.sub.2, 474; found: 475 (M+H).
Example 16, 17
N-({1-[4-(4-Methanesulfonylamino-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoy-
l}-methyl)-3-trifluoromethyl-benzamide and
N-({1-[4-(4,4-bis-Methanesulfonylamino-phenyl)-cyclohexyl]-azetidin-3-ylc-
arbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00116##
[0346]
N-({1-[4-(4-Amino-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methy-
l)-3-trifluoromethyl-benzamide (as prepared in example 15, 450 mg,
0.95 mmol) in DCM (8 mL) was treated with TEA (200 .mu.L, 1.42
mmol) followed by MsCl (Aldrich, 130 mg, 1.14 mmol) at 0.degree. C.
for 2 hours. The reaction was warmed to room temperature and
partitioned between DCM and saturated NaHCO.sub.3. The organic
layer was separated and the aqueous layer was extracted 3 times
with a chloroform/IPA "cocktail" (.about.3:1, v/v). The combined
organic layers were dried over anhydrous Na.sub.2SO.sub.4, filtered
and concentrated to give the crude product, which was then purified
by a CombiFlash.RTM. system using ethyl acetate and 7N NH.sub.3 in
MeOH as eluent (from pure ethyl acetate to 5% 7N NH.sub.3 in MeOH
in ethyl acetate) to afford two title compounds as white solids: a
less polar fraction,
N-({1-[4-(4,4-bis-methanesulfonylamino-phenyl)-cyclohexyl]-azetidin-3-ylc-
arbamoyl}-methyl)-3-trifluoromethyl-benzamide; and a more polar
isomer,
N-({1-[4-(4-methanesulfonylamino-phenyl)-cyclohexyl]-azetidin-3-ylcarbamo-
yl}-methyl)-3-trifluoromethyl-benzamide.
[0347] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.25 (s, 1H), 8.10
(d, J=6.8 Hz, 1H), 7.80 (d, J=6.2 Hz, 1H), 7.65 (d, J=7.5 Hz, 1H),
7.60 (t, J=6.6 Hz, 1H), 7.36 (d, J=6.2 Hz, 1H), 7.10 (abq, J=9.5
Hz, 2H), 4.55 (m, 1H), 4.18 (d, J=3.5 Hz, 2H), 3.70 (t, J=6.8 Hz,
2H), 3.40 (s, 3H), 2.90 (t, J=6.6 Hz, 2H), 2.55 (m, 1H), 2.30 (m,
1H), 1.90.about.1.65 (4H), 1.50 (m, 4H).
[0348] 17,
[0349] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (s, 1H), 8.05
(d, J=6.0 Hz, 1H), 7.75 (d, J=6.0 Hz, 1H), 7.60 (m, 1H), 7.54 (d,
J=7.0 Hz, 1H), 7.25 (abq, J=9.5 Hz, 4H), 4.51 (m, 1H), 4.15 (d,
J=5.0 Hz, 2H), 3.58 (t, J=6.6 Hz, 2H), 3.35 (s, 6H), 2.85 (s, br,
2H), 2.55 (m, 1H), 2.33 (s, br, 1H), 1.80 (m, 2H), 1.65 (m, 2H),
1.50 (m, 2H), 1.43 (m, 2H).
Example 18
N-[(1-[1-{4-[4-(3-tert-Butyl-ureido)-phenyl]-cyclohexyl}-azetidin-3-ylcarb-
amoyl)-methyl]-3-trifluoromethyl-benzamide
##STR00117##
[0351]
N-({1-[4-(4-Amino-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methy-
l)-3-trifluoromethyl-benzamide (as prepared in Example 15, 100 mg,
0.21 mmol) in DMF (2 mL) was treated with t-butyl-isocyanate
(Aldrich, 25 mg, 0.25 mmol) at room temperature for 48 hours. The
reaction mixture was directly purified on a silica gel column using
a CombiFlash.RTM. system using ethyl acetate and 7N NH.sub.3 in
MeOH as eluent (from pure ethyl acetate to 5% 7N NH.sub.3 in MeOH
in ethyl acetate) to afford the title compound as a white
solid.
[0352] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.25 (s, 1H),
8.20 (d, J=6.8 Hz, 1H), 7.90 (d, J=6.5 Hz, 1H), 7.70 (d, J=6.8 Hz,
1H), 7.20 (abq, J=10.5 Hz, 4H), 4.48 (m, 1H), 4.05 (s, 2H), 3.65
(t, J=7.0 Hz, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.55 (m, 1H), 2.40 (s,
br, 1H), 1.95.about.1.65 (4H), 1.55 (m, 2H), 1.35 (s, 9H).
Example 19
3-Trifluoromethyl-N-({1-[4-(4-ureido-phenyl)-cyclohexyl]-azetidin-3-ylcarb-
amoyl}-methyl)-benzamide
##STR00118##
[0354]
N-[(1-{-4-[4-(3-tert-Butyl-ureido)-phenyl]-cyclohexyl}-azetidin-3-y-
lcarbamoyl)-methyl]-3-trifluoromethyl-benzamide (prepared as
described in Example 18, 50 mg, 0.087 mmol) was treated with TFA (1
mL) at room temperature overnight. The reaction was quenched with
saturated NaHCO.sub.3. The reaction solution was extracted with a
chloroform/IPA "cocktail" (.about.3:1, v/v). The organic layer was
dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to
give the crude product, which was then purified by a
CombiFlash.RTM. system using ethyl acetate and 7N NH.sub.3 in MeOH
as eluent (from pure ethyl acetate to 5% 7N NH.sub.3 in MeOH in
ethyl acetate) to afford two title compound as white solid.
[0355] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.11 (s, 1H),
8.05 (d, J=6.5 Hz, 1H), 7.75 (d, J=6.0 Hz, 1H), 7.70 (d, J=7.5 Hz,
1H), 7.58 (t, J=6.5 Hz, 1H), 7.30 (d, J=6.0 Hz, 1H), 7.15 (abq,
J=10.5 Hz, 2H), 4.45 (m, 1H), 3.95 (s, 2H), 3.55 (t, J=6.8 Hz, 2H),
2.85 (t, J=6.6 Hz, 2H), 2.35 (m, 1H), 1.80.about.1.55 (6H), 1.45
(m, 2H).
Example 20
N-({1-[4-(3H-Benzoimidazol-5-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methy-
l)-3-trifluoromethyl-benzamide
Step A
8-(3H-Benzoimidazol-5-yl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00119##
[0357] The title compound was prepared as a white solid from
6-bromo-1H-benzoimidazole (Ryan Scientific) using the procedure
described in Step A of Example 1.
[0358] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.03 (s, 1H), 7.88
(s, 1H), 7.65 (d, J=6.8 Hz, 1H), 7.45 (d, J=6.5 Hz, 1H), 4.02 (s,
4H), 2.20 (m, 2H), 2.10 (m, 2H), 1.90 (d, J=6.8 Hz, 2H), 1.72 (m,
2H).
Step B
4-(3H-Benzoimidazol-5-yl)-4-hydroxy-cyclohexanone
##STR00120##
[0360] The title compound was prepared as a white solid from
8-(3H-benzoimidazol-5-yl)-1,4-dioxa-spiro[4.5]decan-8-ol (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0361] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.05 (s, 1H), 7.80
(s, br, 1H), 7.36 (d, J=6.5 Hz, 1H), 7.25 (d, J=6.4 Hz, 1H), 7.01
(s, 1H), 2.98 (m, 2H), 2.35 (m, 2H), 2.28 (m, 2H), 2.20 (m,
2H).
Step C
4-(3H-Benzoimidazol-5-yl)-cyclohex-3-enone
##STR00121##
[0363] The title compound was prepared as a white solid from
4-(3H-benzoimidazol-5-yl)-4-hydroxy-cyclohexanone (as prepared in
the previous step) using the procedure described in Step C of
Example 1.
[0364] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.30 (s, 1H),
7.65 (d, J=6.8 Hz, 1H), 7.50 (d, J=6.5 Hz, 1H), 7.38 (s, 1H), 6.10
(m, 1H), 3.10 (s, br, 2H), 2.95 (d, J=6.1 Hz, 2H), 2.65 (t, J=6.5
Hz, 2H).
Step D
N-({1-[4-(3H-Benzoimidazol-5-yl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methy-
l)-3-trifluoromethyl-benzamide
##STR00122##
[0366] The title compound was prepared as a white solid by
hydrogenation of 4-(3H-benzoimidazol-5-yl)-cyclohex-3-enone (as
prepared in the previous step) using the procedure described in
Step C of Example 5 followed by reductive amination of the ketone
with N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide
(as prepared in step B of Example 4) using the procedure described
in Step C of Example 4.
[0367] 20a: Less Polar Fraction from Silica Gel Column
[0368] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.15 (s, 1H),
8.10 (d, J=6.0 Hz, 1H), 7.85 (s, 1H), 7.72 (d, J=6.5 Hz, 1H), 7.63
(t, J=6.0 Hz, 1H), 7.55 (s, 1H), 7.40 (d, J=6.5 Hz, 1H), 7.12 (d,
J=6.4 Hz, 1H), 4.45 (m, 1H), 3.98 (s, 2H), 3.60 (t, J=6.0 Hz, 2H),
2.95 (t, J=5.4 Hz, 2H), 2.69 (t, J=3.0 Hz, 2H), 2.48 (m, 1H), 1.85
(m, 4H), 1.48 (m, 4H).
[0369] 20b: More Polar Fraction from Silica Gel Column
[0370] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.13 (s, 1H),
8.08 (d, J=6.3 Hz, 1H), 8.01 (s, 1H), 7.80 (d, J=6.5 Hz, 1H), 7.70
(s, 1H), 7.59 (d, J=6.1 Hz, 1H), 7.65 (d, J=5.5 Hz, 1H), 7.30 (d,
J=6.4 Hz, 1H), 4.40 (m, 1H), 3.95 (s, 2H), 3.90 (t, J=5.0 Hz, 2H),
3.10 (t, J=4.5 Hz, 2H), 2.59 (m, 1H), 2.25 (m, 1H), 2.00 (m, 2H),
1.80 (m, 2H), 1.62 (m, 2H), 1.35 (m, 2H).
Example 21
N-({1-[4-(4-Cyanomethyl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl-
)-3-trifluoromethyl-benzamide
Step A
[4-(1,4-Dioxa-spiro[4.5]dec-7-en-8-yl)-phenyl]-acetonitrile
##STR00123##
[0372] A solution of
8-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,4-dioxa-spiro[4.5]dec--
7-ene (as prepared by PCT Int. Appl. WO2006064189, 1.81 g, 6.80
mmol), 4-bromo-phenyl-acetonitrile (Aldrich, 1.40 g, 7.10 mmol),
and tetrakis(triphenylphosphino)-palladium(0) (Aldrich, 350 mg,
0.34 mmol) in 1,4-dioxane (20 mL), was treated with 2M aqueous
Na.sub.2CO.sub.3 (7 mL, 14.0 mmol), bubbled with argon for a few
minutes, and heated to 100.degree. C. under reflux condenser for 24
h. After cooling to ambient temperature, the reaction was diluted
with water (30 mL) and extracted thrice with dichloromethane. The
combined organic layers were washed with brine, dried over
anhydrous Na.sub.2SO.sub.4, filtered, and the filtrate concentrated
in vacuo to give a colorless oil. Purification by silica gel
column, using a CombiFlash.RTM. system using hexanes and ethyl
acetate as eluent (from pure hexanes to pure ethyl acetate),
afforded the title compound as a white solid.
[0373] ESI-MS (m/z): Calcd. For C.sub.16H.sub.17NO.sub.2, 255;
found: 256 (M+H).
Step B
[4-(4-Oxo-cyclohex-1-enyl)-phenyl]-acetonitrile
##STR00124##
[0375] The title compound was prepared as a white solid from
[4-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-phenyl]-acetonitrile (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0376] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.28 (d, J=6.5 Hz,
2H), 7.12 (d, J=6.5 Hz, 2H), 5.98 (m, 1H), 3.12 (s, 2H), 2.88 (t,
J=6.0 Hz, 2H), 2.64 (d, J=6.0 Hz, 2H).
Step C
[4-(4-Oxo-cyclohexyl)-phenyl]-acetonitrile
##STR00125##
[0378] The title compound was prepared as a white solid from
[4-(4-oxo-cyclohex-1-enyl)-phenyl]-acetonitrile (as prepared in the
previous step) using the procedure described in Step C of Example
5.
[0379] ESI-MS (m/z): Calcd. For C.sub.14H.sub.15NO, 213; found: 214
(M+H).
Step D
N-({1-[4-(4-Cyanomethyl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl-
)-3-trifluoromethyl-benzamide
##STR00126##
[0381] The title compound was prepared as a white solid by the
reductive amination of [4-(4-oxo-cyclohexyl)-phenyl]-acetonitrile
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0382] 21a: Less Polar Fraction from Silica Gel Column
[0383] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.25 (s, 1H),
8.12 (d, J=6.5 Hz, 1H), 8.01 (s, 1H), 7.86 (d, J=6.2 Hz, 1H), 7.68
(t, J=6.8 Hz, 1H), 7.35.about.7.22 (m, 4H), 4.52 (m, 1H), 4.10 (s,
2H), 3.80 (s, 2H), 3.68 (t, J=6.6 Hz, 2H), 2.95 (t, J=6.9 Hz, 3H),
2.65 (m, 1H), 2.45 (s, br, 1H), 1.90 (m, 2H), 1.75 (m, 2H), 1.58
(m, 4H).
[0384] 21b: More Polar Fraction from Silica Gel Column
[0385] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (s, 1H), 8.05
(d, J=6.5 Hz, 1H), 7.80 (d, J=6.2 Hz, 1H), 7.71 (m, 1H), 7.61 (t,
J=6.8 Hz, 1H), 7.30.about.7.20 (m, 4H), 4.52 (m, 1H), 4.15 (d,
J=5.4 Hz, 2H), 3.71 (s, 2H), 3.68 (t, J=6.6 Hz, 2H), 3.01 (t, J=6.9
Hz, 3H), 2.45 (m, 1H), 2.30 (s, br, 1H), 2.05 (m, 2H), 1.90 (m,
2H), 1.45 (m, 2H), 1.15 (m, 2H).
Example 22
N-({1-[4-(4-Carbamimidoylmethyl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl-
}-methyl)-3-trifluoromethyl-benzamide
##STR00127##
[0387] A solution of
N-({1-[4-(4-cyanomethyl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methy-
l)-3-trifluoromethyl-benzamide (as prepared in Example 21, 250 mg,
0.50 mmol) in dioxane (2 mL) and saturated NH.sub.4Cl (2 mL) was
heated in a sealed tube to 120.degree. C. overnight. The solvent
was removed in vacuo and the residue was purified on a silica gel
column using a CombiFlash.RTM. system using ethyl acetate and 7N
NH.sub.3 in MeOH as eluent (from pure ethyl acetate to 5% 7N
NH.sub.3 in MeOH in ethyl acetate) to afford the title compound as
yellow solid.
[0388] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.15 (s, 1H),
8.10 (d, J=6.5 Hz, 1H), 7.81 (d, J=6.0 Hz, 1H), 7.66 (d, J=6.5 Hz,
1H), 7.20 (m, 4H), 4.42 (m, 1H), 3.98 (s, 2H), 3.60 (t, J=6.8 Hz,
2H), 2.98 (t, J=6.6 Hz, 2H), 2.80 (m, 1H), 2.35 (m, 1H), 2.05 (m,
2H), 1.85 (m, 2H), 1.65 (m, 2H), 1.50 (m, 2H).
Example 23
N-[(1-{4-1-[4-(2H-Tetrazol-5-ylmethyl)-phenyl]-cyclohexyl}-azetidin-3-ylca-
rbamoyl)-methyl]-3-trifluoromethyl-benzamide
##STR00128##
[0390] A solution of
N-({1-[4-(4-cyanomethyl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methy-
l)-3-trifluoromethyl-benzamide (as prepared in Example 21, 250 mg,
0.50 mmol), sodium azide (Aldrich, 160 mg, 2.50 mmol), and
Et.sub.3N HCl salt (350 mg, 2.50 mmol) in dioxane (5 mL) was heated
in a sealed tube to 120.degree. C. overnight. The solvent was
removed in vacuo and the residue was purified on a silica gel
column using a CombiFlash.RTM. system using ethyl acetate and 7N
NH.sub.3 in MeOH as eluent (from pure ethyl acetate to 5% 7N
NH.sub.3 in MeOH in ethyl acetate) to afford the title compound as
a white solid.
[0391] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.11 (s, 1H),
8.02 (d, J=6.5 Hz, 1H), 7.78 (d, J=6.5 Hz, 1H), 7.55 (t, J=6.5 Hz,
1H), 7.20 (d, J=6.8 Hz, 2H), 7.08 (d, J=7.0 Hz, 2H), 4.15 (m, 1H),
3.95 (q, J=11.5 Hz, 2H), 3.75 (s, 2H), 3.42 (d, J=3.5 Hz, 2H), 2.80
(m, 1H), 2.65 (m, 2H), 2.45 (m, 1H), 1.86 (m, 4H), 1.55 (m,
4H).
Example 24
[4-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-c-
yclohexyl)-phenyl]-acetic acid ethyl ester
Step A
[4-(1,4-Dioxa-spiro[4.5]dec-7-en-8-yl)-phenyl]-acetic acid ethyl
ester
##STR00129##
[0393] The title compound was prepared as a white solid from
(4-bromo-phenyl)-acetic acid ethyl ester (Aldrich) using the
procedure described in Step A of Example 21.
[0394] ESI-MS (m/z): Calcd. for C.sub.18H.sub.22O.sub.4, 302;
found: 303 (M+H).
Step B
[4-(1,4-Dioxa-spiro[4.5]dec-8-yl)-phenyl]-acetic acid ethyl
ester
##STR00130##
[0396] The title compound was prepared as a white solid from
[4-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-phenyl]-acetic acid ethyl
ester (as prepared in the previous step) using the procedure
described in Step C of Example 5.
[0397] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.20 (m, 4H), 4.16
(q, J=6.5 Hz, 2H), 3.98 (s, 4H), 3.58 (s, 2H), 2.52 (m, 1H), 1.85
(m, 4H), 1.68 (m, 4H), 1.28 (t, J=7.0 Hz, 3H).
Step C
[4-(4-Oxo-cyclohexyl)-phenyl]-acetic acid ethyl ester
##STR00131##
[0399] The title compound was prepared as a white solid from
[4-(1,4-dioxa-spiro[4.5]dec-8-yl)-phenyl]-acetic acid ethyl ester
(as prepared in the previous step) using the procedure described in
Step B of Example 1.
[0400] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.21 (q, J=6.5 Hz,
4H), 4.15 (q, J=6.0 Hz, 2H), 3.59 (s, 2H), 3.05 (m, 1H), 2.46 (m,
4H), 2.21 (m, 2H), 1.95 (m, 2H).
Step D
[4-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-c-
yclohexyl)-phenyl]-acetic acid ethyl ester
##STR00132##
[0402] The title compound was prepared as a white solid by the
reductive amination of [4-(4-oxo-cyclohexyl)-phenyl]-acetic acid
ethyl ester (as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0403] 24a: Less Polar Fraction from Silica Gel Column
[0404] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.20 (s, 1H), 8.12
(d, J=6.5 Hz, 1H), 7.90 (m, 1H), 7.76 (d, J=6.2 Hz, 1H), 7.55 (t,
J=6.8 Hz, 1H), 7.35.about.7.15 (abq, J=9.5, 5.0 Hz, 4H), 4.68 (m,
1H), 4.15 (m, 2H), 4.10 (q, J=7.0 Hz, 2H), 3.90 (t, J=6.6 Hz, 2H),
3.05 (t, J=4.5 Hz, 3H), 2.91 (s, 1H), 2.65 (m, 1H), 1.90 (m, 2H),
1.75 (m, 2H), 1.58 (m, 4H), 1.32 (t, J=7.5 Hz, 3H).
[0405] 24b: More Polar Fraction from Silica Gel Column
[0406] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.21 (s, 1H), 8.10
(d, J=6.5 Hz, 1H), 7.90 (d, J=6.2 Hz, 1H), 7.75 (m, 1H), 7.59 (t,
J=6.8 Hz, 1H), 7.25.about.7.05 (abq, J=9.0, 4.5 Hz, 4H), 4.65 (m,
1H), 4.18 (d, J=5.4 Hz, 2H), 4.15 (q, J=6.2 Hz, 2H), 3.75 (t, J=6.6
Hz, 2H), 3.10 (t, J=6.9 Hz, 3H), 2.65 (m, 1H), 2.35 (s, br, 1H),
2.05 (m, 2H), 1.90 (m, 2H), 1.45 (m, 2H), 1.30 (t, J=6.5 Hz, 3H),
1.25 (m, 2H).
Example 25
[4-(4-{3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-c-
yclohexyl)-phenyl]-acetic acid
##STR00133##
[0408] The title compound was prepared as a white solid by
hydrolysis of
[4-(4-{3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}--
cyclohexyl)-phenyl]-acetic acid ethyl ester (as prepared in Example
24, less polar fraction) using the procedure described in Example
10.
[0409] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.25 (s, 1H),
8.15 (d, J=6.5 Hz, 1H), 7.89 (d, J=6.0 Hz, 1H), 7.72 (t, J=7.2 Hz,
1H), 7.18 (abq, J=10.5, 5.0 Hz, 4H), 4.60 (m, 1H), 4.10 (s, 2H),
3.98 (t, J=5.6 Hz, 2H), 3.55 (m, 2H), 3.50 (s, 2H), 2.85 (s, 1H),
2.55 (m, 1H), 1.80 (m, 4H), 1.65 (m, 4H).
Example 26
N-({1-[4-(4-Carbamoylmethyl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
##STR00134##
[0411] A solution of
[4-(4-{3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}--
cyclohexyl)-phenyl]-acetic acid (as prepared in Example 25, 450 mg,
0.87 mmol), EDCI (240 mg, 1.25 mmol), HOBT (130 mg, 0.96 mmol) and
TEA (610 .mu.L, 4.35 mmol) in DCM (10 mL) was treated with 2N
NH.sub.3 in dioxane (5 mL) at room temperature overnight. The
solvent was removed in vacuo and the residue was purified by a
CombiFlash.RTM. system using ethyl acetate and 7N NH.sub.3 in MeOH
as eluent (from pure ethyl acetate to 5% 7N NH.sub.3 in MeOH in
ethyl acetate) to afford the two title compound as white
solids.
[0412] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.11 (s, 1H),
8.05 (d, J=6.5 Hz, 1H), 7.75 (d, J=6.0 Hz, 1H), 7.60 (d, J=6.5 Hz,
1H), 7.10 (s, 4H), 4.35 (m, 1H), 3.95 (s, 2H), 3.58 (t, J=6.8 Hz,
2H), 3.05 (t, J=6.6 Hz, 2H), 2.75 (m, 1H), 2.45 (m, 1H), 2.20 (m,
2H), 1.80 (m, 2H), 1.65 (m, 2H), 1.45 (m, 2H).
Example 27
N-({1-[4-(4-Cyano-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-tr-
ifluoromethyl-benzamide
Step A
4-(1,4-Dioxa-spiro[4.5]dec-7-en-8-yl)-benzonitrile
##STR00135##
[0414] The title compound was prepared as a white solid from
4-bromophenylnitrile (Aldrich) using the procedure described in
Step A of Example 21.
[0415] ESI-MS (m/z): Calcd. For C.sub.15H.sub.15NO.sub.2, 241;
found: 242 (M+H).
Step B
4-(1,4-Dioxa-spiro[4.5]dec-8-yl)-benzonitrile
##STR00136##
[0417] The title compound was prepared as a white solid from
4-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-benzonitrile (as prepared in
the previous step) using the procedure described in Step C of
Example 5.
[0418] ESI-MS (m/z): Calcd. For C.sub.15H.sub.17NO.sub.2, 243;
found: 244 (M+H).
Step C
4-(4-Oxo-cyclohexyl)-benzonitrile
##STR00137##
[0420] The title compound was prepared as a white solid from
4-(1,4-dioxa-spiro[4.5]dec-8-yl)-benzonitrile (as prepared in the
previous step) using the procedure described in Step B of Example
1.
[0421] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.75 (d, J=6.8 Hz,
2H), 7.34 (d, J=6.8 Hz, 2H), 3.10 (m, 1H), 2.58 (m, 4H), 2.20 (m,
2H), 1.95 (m, 2H).
Step D
N-({1-[4-(4-Cyano-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-tr-
ifluoromethyl-benzamide
##STR00138##
[0423] The title compound was prepared as a white solid by the
reductive amination of 4-(4-oxo-cyclohexyl)-benzonitrile and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0424] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.21 (s, 1H),
8.15 (d, J=6.5 Hz, 1H), 7.85 (d, J=6.0 Hz, 1H), 7.70 (t, J=7.0 Hz,
1H), 7.58 (d, J=6.5 Hz, 2H), 7.42 (d, J=6.0 Hz, 2H), 4.48 (m, 1H),
4.05 (s, 2H), 3.65 (t, J=6.8 Hz, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.65
(m, 1H), 2.42 (s, 1H), 1.95 (m, 2H), 1.90 (m, 2H), 1.65 (m,
4H).
Example 28
N-[(1-{4-[4-(2H-Tetrazol-5-yl)-phenyl]-cyclohexyl}-azetidin-3-ylcarbamoyl)-
-methyl]-3-trifluoromethyl-benzamide
##STR00139##
[0426] The title compound was prepared as a white solid from
N-({1-[4-(4-cyano-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-t-
rifluoromethyl-benzamide (as prepared in Example 27) using the
procedure described in Example 23.
[0427] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.20 (s, 1H),
8.15 (d, J=6.5 Hz, 1H), 7.75 (d, J=6.0 Hz, 1H), 7.70 (t, J=7.0 Hz,
1H), 7.58 (d, J=6.5 Hz, 2H), 7.45 (d, J=6.0 Hz, 2H), 4.24 (m, 1H),
4.05 (m, 1H), 4.06 (q, J=9.0 Hz, 2H), 3.55 (t, J=6.8 Hz, 2H), 2.90
(s, 1H), 2.80 (t, J=6.6 Hz, 2H), 2.65 (m, 2H), 1.95 (m, 4H), 1.65
(m, 4H).
Example 29
N-({1-[4-(4-Methanesulfonyl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
Step A
8-(4-Methylsulfanyl-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00140##
[0429] The title compound was prepared as a white solid from
4-bromo-1-methylsulfanyl-benzene (Aldrich) using the procedure
described in Step A of Example 1.
[0430] .sup.1H NMR (CHLOROFORM-d) .delta.: 7.45 (d, J=8.6 Hz, 2H),
7.24-7.29 (m, 2H), 7.23 (s, 1H), 3.99 (dd, J=4.8, 3.3 Hz, 4H), 2.48
(s, 3H), 2.05-2.21 (m, 4H), 1.80 (d, J=11.6 Hz, 2H), 1.69 (d,
J=11.1 Hz, 2H).
Step B
4-(4-Methylsulfanyl-phenyl)-cyclohex-3-enone
##STR00141##
[0432] De-protection followed by dehydration occurred when
8-(4-methylsulfanyl-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (as
prepared in the previous step) was subjected to the reaction
conditions described in Step B of Example 1. The title compound was
prepared as a white solid.
[0433] .sup.1H NMR (CHLOROFORM-d) .delta.: 7.32 (d, J=8.6 Hz, 2H),
7.22 (d, J=8.8 Hz, 2H), 6.02-6.09 (m, 1H), 3.00-3.09 (m, 2H),
2.81-2.91 (m, 2H), 2.59-2.69 (m, 2H), 2.48 (s, 3H).
Step C
N-({1-[4-(4-Methylsulfanyl-phenyl)-cyclohex-3-enyl]-azetidin-3-ylcarbamoyl-
}-methyl)-3-trifluoromethyl-benzamide
##STR00142##
[0435] The title compound was prepared as a white solid by the
reductive amination of 4-(4-methylsulfanyl-phenyl)-cyclohex-3-enone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0436] .sup.1H NMR (CHLOROFORM-d) .delta.: 8.12 (s, 1H), 8.01 (d,
J=7.8 Hz, 1H), 7.77 (d, J=7.6 Hz, 1H), 7.56 (t, J=7.8 Hz, 1H),
7.25-7.32 (m, 2H), 7.17-7.23 (m, 2H), 5.98 (br. s., 1H), 4.57 (t,
J=6.1 Hz, 1H), 4.17 (m, 2H), 3.66 (d, J=8.1 Hz, 2H), 2.98-3.06 (m,
2H), 2.42-2.52 (m, 3H), 2.23-2.42 (m, 2H), 1.92 (br. s., 2H),
1.75-1.89 (m, 2H), 1.36-1.51 (m, 2H).
Step D
N-({1-[4-(4-Methanesulfonyl-phenyl)-cyclohex-3-enyl]-azetidin-3-ylcarbamoy-
l}-methyl)-3-trifluoromethyl-benzamide
##STR00143##
[0438] The title compound was prepared as a white solid from the
OXONE oxidation of
N-({1-[4-(4-methylsulfanyl-phenyl)-cyclohex-3-enyl]-azetidin-3-ylcarbamoy-
l}-methyl)-3-trifluoromethyl-benzamide (as prepared in the previous
step) using the procedure described in Step C of Example 14.
[0439] ESI-MS (m/z): Calcd. For
C.sub.26H.sub.28F.sub.3N.sub.3O.sub.4S: 535.22; found: 536.2
(M+H).
Step E
N-({1-[4-(4-Methanesulfonyl-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
##STR00144##
[0441] The title compound was prepared as a white solid from
N-({1-[4-(4-methanesulfonyl-phenyl)-cyclohex-3-enyl]-azetidin-3-ylcarbamo-
yl}-methyl)-3-trifluoromethyl-benzamide (as prepared in the
previous step) using the procedure described in Step G of Example
1.
[0442] .sup.1H NMR (CHLOROFORM-d) .delta.: 8.12 (s, 1H), 8.01 (d,
J=8.1 Hz, 1H), 7.82-7.89 (m, J=8.3 Hz, 1H), 7.79 (d, J=7.8 Hz, 1H),
7.59 (t, J=7.8 Hz, 1H), 7.48-7.54 (m, J=8.3 Hz, 2H), 7.42 (t, J=4.9
Hz, 1H), 4.42-4.59 (m, 1H), 4.16 (d, J=5.1 Hz, 2H), 3.95 (br. s.,
1H), 3.66-3.76 (m, 2H), 3.04 (s, 1H), 3.03 (s, 3H), 2.74 (d, J=12.6
Hz, 2H), 2.67 (br. s., 2H), 1.99-2.07 (m, 2H), 1.92 (d, J=13.4 Hz,
4H).
Example 30
N-{[1-(4-Hydroxy-4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-tr-
ifluoromethyl-benzamide
Step A
8-Phenyl-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00145##
[0444] The title compound was prepared as a white solid from
1-bromo-benzene and 1,4-dioxa-spiro[4.5]decan-8-one using the
procedure described in Step A of Example 1.
[0445] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.52 (d, J=6.6 Hz,
2H), 7.35 (t, J=7.0 Hz, 2H), 7.28 (t, J=6.8 Hz, 2H), 4.02 (m, 4H),
2.10 (m, 2H), 1.80 (d, J=8.2 Hz, 2H), 1.68 (d, J=8.2 Hz, 2H), 1.56
(d, J=9.5 Hz, 2H).
Step B
4-Hydroxy-4-phenyl-cyclohexanone
##STR00146##
[0447] The title compound was prepared as a white solid from
8-phenyl-1,4-dioxa-spiro[4.5]decan-8-ol (as prepared in the
previous step) using the procedure described in Step B of Example
1.
[0448] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.52 (d, J=6.6 Hz,
2H), 7.42 (t, J=6.5 Hz, 2H), 7.30 (d, J=6.3 Hz, 1H), 2.34 (m, 4H),
2.18 (m, 4H).
Step C
N-{[1-(4-Hydroxy-4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-tr-
ifluoromethyl-benzamide
##STR00147##
[0450] The title compound was prepared as a white solid by
reductive amination of 4-hydroxy-4-phenyl-cyclohexanone (as
prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0451] 30a: Less Polar Fraction from Silica Gel Column
[0452] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.10 (s, 1H), 8.01
(d, J=6.5 Hz, 1H), 7.79 (d, J=6.4 Hz, 1H), 7.58 (t, J=6.8 Hz, 1H),
7.50 (d, J=6.0 Hz, 2H), 7.45 (m, 1H), 7.35 (m, 2H), 7.26 (d, J=5.8
Hz, 1H), 7.22 (m, 1H), 6.96 (d, J=6.8 Hz, 1H), 4.53 (m, 1H), 4.15
(d, J=3.2 Hz, 2H), 3.70 (t, J=7.2 Hz, 2H), 2.89 (t, J=7.5 Hz, 2H),
2.25 (m, 2H), 1.80 (m, 2H), 1.55 (m, 2H), 1.40 (m, 2H).
[0453] 30b: More Polar Fraction from Silica Gel Column
[0454] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.01
(d, J=6.6 Hz, 1H), 7.78 (d, J=6.5 Hz, 1H), 7.61 (m, 1H), 7.52 (m,
3H), 7.30 (t, J=6.0 Hz, 3H), 7.22 (m, 3H), 4.52 (m, 1H), 4.20 (d,
J=3.2 Hz, 2H), 3.60 (t, J=7.0 Hz, 2H), 2.87 (t, J=7.50 Hz, 2H),
2.30 (s, 2H), 2.22 (m, 2H), 1.80 (m, 2H), 1.50 (m, 2H), 1.40 (m,
2H).
Example 31
N-{[1-(4-Benzo[1,3]dioxol-5-yl-4-hydroxy-cyclohexyl)-azetidin-3-ylcarbamoy-
l]-methyl}-3-trifluoromethyl-benzamide
##STR00148##
[0456] The title compound was prepared as a white solid by
reductive amination of
4-benzo[1,3]dioxol-5-yl-4-hydroxy-cyclohexanone (as prepared in
Example 1, Step B) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0457] 31a: Less Polar Fraction from Silica Gel Column
[0458] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.8 Hz, 1H), 7.80 (d, J=7.0 Hz, 2H), 7.58 (t, J=6.8 Hz, 1H),
7.45 (m, 1H), 7.01 9s, 1H), 6.92 (d, J=6.5 Hz, 1H), 6.88 (m, 1H),
6.75 (d, J=6.2 Hz, 1H), 5.92 (s, 2H), 4.53 (m, 1H), 4.18 (d, J=3.5
Hz, 2H), 3.60 (t, J=7.0 Hz, 2H), 2.95 (t, J=7.0 Hz, 2H), 2.32 (s,
br, 1H), 2.20 (m, 1H), 1.85 (m, 4H), 1.60 (m, 2H), 1.42 (m,
2H).
[0459] 31b: More Polar Fraction from Silica Gel Column
[0460] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.30 (s, br, 1H),
8.12 (s, 1H), 8.05 (d, J=6.5 Hz, 1H), 7.80 (d, J=6.6 Hz, 1H), 7.58
(t, J=6.8 Hz, 1H), 7.50 (m, 1H), 7.02 (s, 1H), 6.95 (d, J=6.8 Hz,
1H), 6.85 (s, 1H), 5.92 (s, 2H), 4.57 (m, 1H), 4.20 (d, J=4.6 Hz,
2H), 3.75 (t, J=7.5 Hz, 2H), 3.38 (t, J=7.5 Hz, 2H), 2.38 (m, 1H),
1.95 (m, 2H), 1.75 (m, 4H), 1.60 (m, 2H).
Example 32
N-({1-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-4-hydroxy-cyclohexyl]-azetidi-
n-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
Step A
8-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00149##
[0462] The title compound was prepared as a white solid from and
1,4-dioxa-spiro[4.5]decan-8-one (Aldrich) using the procedure
described in Step A of Example 1.
[0463] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.05 (s, 1H), 6.95
(d, J=7.1 Hz, 1H), 6.80 (d, J=7.0 Hz, 1H), 4.22 (s, 4H), 4.00 (m,
4H), 2.10 (m, 4H), 1.80 (m, 2H), 1.65 (d, J=7.5 Hz, 2H).
Step B
4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-4-hydroxy-cyclohexanone
##STR00150##
[0465] The title compound was prepared as a white solid from
8-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-1,4-dioxa-spiro[4.5]decan-8-ol
(as prepared in the previous step) using the procedure described in
Step B of Example 1.
[0466] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.01 (s, 1H), 6.98
(d, J=6.8 Hz, 1H), 6.85 (d, J=6.5 Hz, 1H), 4.28 (s, 4H), 2.90 (m,
2H), 2.30 (m, 2H), 2.25 (m, 2H), 2.15 (m, 2H).
Step C
N-({1-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-4-hydroxy-cyclohexyl]-azetidi-
n-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00151##
[0468] The title compound was prepared as a white solid by
reductive amination of
4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4-hydroxy-cyclohexanone (as
prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0469] 32a: Less Polar Isomer
[0470] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.15 (s, 1H),
8.07 (d, J=6.5 Hz, 1H), 7.78 (d, J=6.4 Hz, 1H), 7.59 (t, J=6.5 Hz,
1H), 6.90 (s, 1H), 6.88 (d, J=7.0 Hz, 2H), 6.66 (d, J=7.0 Hz, 1H),
4.35 (m, 1H), 4.12 (s, 4H), 3.95 (s, 2H), 3.70 (t, J=6.0 Hz, 2H),
3.12 (d, J=6.0 Hz, 2H), 2.45 (m, 1H), 2.16 (m, 2H), 1.85 (m, 2H),
1.55 (m, 2H), 1.30 (m, 2H).
[0471] 32b: More Polar Isomer
[0472] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.25 (s, 1H),
8.16 (d, J=6.0 Hz, 1H), 7.90 (d, J=6.0 Hz, 1H), 7.72 (t, J=6.0 Hz,
1H), 6.95 (s, 1H), 6.90 (d, J=6.0 Hz, 2H), 6.76 (t, J=6.5 Hz, 1H),
4.50 (m, 1H), 4.21 (s, 4H), 4.08 (s, 2H), 4.05 (t, J=6.0 Hz, 2H),
3.65 (d, J=6.0 Hz, 2H), 2.75 (m, 1H), 1.90 (m, 4H), 1.65 (m,
2H).
Example 33
N-({1-[4-(2,3-Dihydro-benzofuran-6-yl)-4-hydroxy-cyclohexyl]-azetidin-3-yl-
carbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00152##
[0474] The title compound was prepared as a white solid by
reductive amination of
4-(2,3-dihydro-benzofuran-6-yl)-4-hydroxy-cyclohexanone (as
prepared in Example 3, Step B) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0475] 33a: Less Polar Fraction from Silica Gel Column
[0476] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.8 Hz, 1H), 7.75 (m, 2H), 7.55 (t, J=6.8 Hz, 1H), 7.35 (d,
J=7.0 Hz, 1H), 7.23 (d, J=6.5 Hz, 1H), 6.72 (d, J=6.5 Hz, 1H), 4.55
(t, J=7.5 Hz, 2H), 4.53 (m, 1H), 4.20 (d, J=3.5 Hz, 2H), 3.60 (t,
J=7.0 Hz, 2H), 3.22 (t, J=7.0 Hz, 2H), 2.85 (t, J=7.0 Hz, 2H), 2.25
(m, 3H), 1.85 (m, 2H), 1.60 (m, 2H), 1.35 (m, 2H).
[0477] 33b: More Polar Fraction from Silica Gel Column
[0478] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.12 (s, 1H), 8.05
(d, J=6.5 Hz, 1H), 7.80 (d, J=6.6 Hz, 1H), 7.58 (t, J=6.8 Hz, 1H),
7.50 (m, 1H), 7.48 (d, J=5.6 hz, 1H), 7.35 9s, 1H), 7.20 (d, J=6.2
Hz, 1H), 6.72 (d, J=6.8 Hz, 1H), 4.55 (t, J=7.0 Hz, 2H), 4.52 (m,
1H), 4.20 (d, J=4.6 Hz, 2H), 3.64 (t, J=7.5 Hz, 2H), 3.21 9t, J=7.0
Hz, 2H), 3.06 (t, J=7.5 Hz, 2H), 2.35 (m, 1H), 2.02 (m, 1H), 1.85
(m, 4H), 1.75 (m, 2H), 1.65 (m, 2H).
Example 34
N-({1-[4-(3H-Benzoimidazol-5-yl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbam-
oyl}-methyl)-3-trifluoromethyl-benzamide
##STR00153##
[0480] The title compound was prepared as a white solid by
reductive amination of
4-(3H-benzoimidazol-5-yl)-4-hydroxy-cyclohexanone (as prepared in
Example 20, Step B) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0481] 34a: Less Polar Fraction from Silica Gel Column
[0482] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.21 (s, 1H),
8.12 (s, 1H), 7.88 (d, J=6.4 Hz, 1H), 7.75 (s, 1H), 7.63 (t, J=6.5
Hz, 1H), 7.42 (d, J=5.0 Hz, 1H), 7.10 (t, J=5.6 Hz, 1H), 6.88 (m,
1H), 4.47 (m, 1H), 4.05 (s, 2H), 3.65 (m, 2H), 3.08 (m, 2H), 2.85
(m, 1H), 2.30 (m, 2H), 1.95 (m, 2H), 1.68 (m, 2H), 1.32 (m,
2H).
[0483] 34b: More Polar Fraction from Silica Gel Column
[0484] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.25 (s, 1H),
8.15 (s, 1H), 7.95 (d, J=5.7 Hz, 1H), 7.82 (s, 1H), 7.75 (t, J=6.0
Hz, 1H), 7.50 (d, J=5.5 Hz, 1H), 7.18 (t, J=5.5 Hz, 1H), 6.95 (m,
1H), 4.60 (m, 1H), 4.15 (s, 2H), 3.80 (m, 2H), 3.15 (m, 2H), 2.63
(m, 1H), 2.05 (m, 4H), 1.78 (m, 4H).
Example 35
N-({1-[4-Hydroxy-4-(2-oxo-2,3-dihydro-benzooxazol-5-yl)-cyclohexyl]-azetid-
in-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00154##
[0486] The title compound was prepared as a white solid by
reductive amination of
5-(1-hydroxy-4-oxo-cyclohexyl)-3H-benzooxazol-2-one (as prepared in
Example 5, Step A) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0487] 35a: Less Polar Fraction from Silica Gel Column
[0488] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.22 (s, 1H),
8.12 (d, J=6.5 Hz, 1H), 7.85 (d, J=6.0 Hz, 1H), 7.70 (t, J=6.6 Hz,
1H), 7.31 (d, J=7.0 Hz, 2H), 7.14 (d, J=6.6 Hz, 1H), 4.51 (m, 1H),
4.10 (s, 2H), 3.85 (t, J=6.7 Hz, 2H), 3.20 (t, J=6.8 Hz, 2H), 2.75
(s, br, 1H), 2.24 (m, 2H), 1.95 (m, 2H), 1.62 (m, 2H), 1.45 (m,
2H).
[0489] 35b: More Polar Fraction from Silica Gel Column
[0490] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.15 (s, 1H),
8.20 (d, J=6.5 Hz, 1H), 7.88 (d, J=5.6 Hz, 1H), 7.75 (t, J=6.5 Hz,
1H), 7.28 (d, J=6.3 Hz, 2H), 7.17 (d, J=6.7 Hz, 1H), 4.68 (m, 1H),
4.42 (t, J=6.9 Hz, 2H), 4.25 (t, J=6.8 Hz, 2H), 4.10 (s, 2H), 3.32
(s, br, 1H), 1.98 (m, 6H), 1.85 (m, 2H).
Example 36
N-({1-[4-Hydroxy-4-(4-methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
##STR00155##
[0492] The title compound was prepared as a white solid by
reductive amination of 4-hydroxy-4-(4-methoxy-phenyl)-cyclohexanone
(as prepared in Example 7, Step B) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0493] 36a: Less Polar Fraction from Silica Gel Column
[0494] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.13 (s, 1H), 8.02
(d, J=6.4 Hz, 1H), 7.80 (d, J=6.7 Hz, 1H), 7.68 (m, 1H), 7.57 (t,
J=6.6 Hz, 1H), 7.41 (d, J=7.5 Hz, 2H), 7.31 (d, J=6.0 Hz, 1H), 6.86
(d, J=7.5 Hz, 2H), 4.51 (m, 1H), 4.20 (d, J=3.1 Hz, 2H), 3.80 (s,
3H), 3.65 (t, J=6.5 Hz, 2H), 2.92 (t, J=6.5 Hz, 2H), 2.30 (m, 2H),
1.85 (m, 2H), 1.71 (m, 2H), 1.45 (m, 2H).
[0495] 36b: More Polar Fraction from Silica Gel Column
[0496] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.05
(d, J=6.5 Hz, 1H), 7.78 (d, J=6.5 Hz, 1H), 7.58 (t, J=7.0 Hz, 1H),
7.52 (m, 1H), 7.40 (d, J=7.8 Hz, 2H), 7.20 (d, J=6.4 Hz, 1H), 6.85
(d, J=7.8 Hz, 2H), 4.55 (m, 1H), 4.15 (d, J=2.8 Hz, 2H), 3.75 (s,
3H), 3.62 (t, J=6.5 Hz, 2H), 3.10 (t, J=6.5 Hz, 2H), 2.05 (m, 2H),
1.80 (m, 2H), 1.72 (m, 2H), 1.55 (m, 2H).
Example 37
N-({1-[4-Hydroxy-4-(3-methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
Step A
8-(3-Methoxy-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00156##
[0498] The title compound was prepared as a white solid from
1-bromo-3-methoxy-benzene (Aldrich) and
1,4-dioxa-spiro[4.5]decan-8-one using the procedure described in
Step A of Example 1.
[0499] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.28 (t, J=7.1 Hz,
1H), 7.10 (m, 2H), 6.81 (d, J=6.8 Hz, 1H), 4.00 (s, 4H), 3.82 9s,
3H), 2.15 (m, 4H), 1.82 (m, 2H), 1.73 (m, 2H).
Step B
4-Hydroxy-4-(3-methoxy-phenyl)-cyclohexanone
##STR00157##
[0501] The title compound was prepared as a white solid from
8-(3-methoxy-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (as prepared in
the previous step) using the procedure described in Step B of
Example 1.
[0502] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.32 (t, J=6.5 Hz,
1H), 7.10 (d, J=6.4 Hz, 1H), 7.07 (s, 1H), 6.85 (d, J=6.5 Hz, 1H),
3.85 (s, 3H), 2.92 (m, 2H), 2.35 (m, 4H), 2.20 (m, 2H).
Step C
N-({1-[4-Hydroxy-4-(3-methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
##STR00158##
[0504] The title compound was prepared as a white solid by
reductive amination of 4-hydroxy-4-(3-methoxy-phenyl)-cyclohexanone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0505] 37a: Less Polar Fraction from Silica Gel Column
[0506] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.10 (s, 1H), 8.02
(d, J=6.0 Hz, 1H), 7.80 (d, J=6.5 Hz, 1H), 7.58 (t, J=7.0 Hz, 1H),
7.25 (d, J=6.7 Hz, 1H), 7.20 (s, 1H), 7.10 (d, J=5.8 Hz, 1H), 6.82
(d, J=6.5 Hz, 1H), 4.52 (m, 1H), 4.18 (d, J=3.0 Hz, 2H), 3.62 (t,
J=7.5 Hz, 2H), 2.91 (t, J=7.0 Hz, 2H), 2.32 (s, br, 1H), 2.20 (t,
J=8.0 Hz, 2H), 1.85 (t, J=7.5 Hz, 2H), 1.55 (m, 2H), 1.50 (m,
2H).
[0507] 37b: More Polar Fraction from Silica Gel Column
[0508] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.8 Hz, 1H), 7.78 (d, J=6.8 Hz, 1H), 7.60 (t, J=6.5 Hz, 1H),
7.45 (m, 1H), 7.25 (d, J=6.6 Hz, 1H), 7.20 (d, J=6.5 Hz, 1H), 7.02
(d, J=5.8 Hz, 1H), 6.80 (d, J=6.0 Hz, 1H), 4.56 (m, 1H), 4.19 (d,
J=3.0 Hz, 2H), 3.63 (t, J=6.8 Hz, 2H), 3.10 (t, J=6.8 Hz, 2H), 2.10
(m, 2H), 1.82 (m, 2H), 1.70 (m, 2H), 1.55 (m, 2H).
Example 38
N-({1-[4-Hydroxy-4-(3-methylsulfanyl-phenyl)-cyclohexyl]-azetidin-3-ylcarb-
amoyl}-methyl)-3-trifluoromethyl-benzamide
Step A
[0509]
{1-[4-Hydroxy-4-(3-methylsulfanyl-phenyl)-cyclohexyl]-azetidin-3-yl-
}-carbamic acid tent-butyl ester
##STR00159##
[0510] The title compound was prepared as a white solid from
4-hydroxy-4-(3-methylsulfanyl-phenyl)-cyclohexanone (as prepared in
Example 14, Step B) and azetidin-3-yl-carbamic acid tert-butyl
ester using the procedure described in Step D of Example 1.
Less Polar Fraction from Silica Gel Column
[0511] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.45 (s, 1H), 7.25
(d, J=6.0 Hz, 1H), 7.20 (t, J=6.5 Hz, 1H), 7.08 (d, J=6.5 Hz, 1H),
5.05 (s, br, 1H), 4.25 (m, 1H), 3.60 (t, J=6.8 Hz, 2H), 2.88 (t,
J=6.5 Hz, 2H), 2.52 (s, 3H), 2.50 (m, 1H), 2.25 (m, 2H), 2.20 (m,
2H), 1.80 (m, 2H), 1.65 (m, 2H), 1.42 (s, 9H).
More Polar Fraction from Silica Gel Column
[0512] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.42 (s, 1H), 7.28
(d, J=6.6 Hz, 1H), 7.25 (t, J=6.5 Hz, 1H), 7.11 (d, J=6.5 Hz, 1H),
5.05 (s, br, 1H), 4.26 (m, 1H), 3.65 (t, J=7.2 Hz, 2H), 2.92 (t,
J=7.0 Hz, 2H), 2.60 (s, 3H), 2.55 (m, 1H), 1.80 (m, 4H), 1.75 (m,
2H), 1.55 (m, 2H).
Step B
4-(3-Amino-azetidin-1-yl)-1-(3-methylsulfanyl-phenyl)-cyclohexanol
##STR00160##
[0514] The title compound was prepared as a white solid from
{1-[4-hydroxy-4-(3-methylsulfanyl-phenyl)-cyclohexyl]-azetidin-3-yl}-carb-
amic acid tert-butyl ester (as prepared in the previous step, less
polar fraction) using the procedure described in Step E of Example
1.
[0515] ESI-MS (m/z): Calcd. For C.sub.16H.sub.24N.sub.2OS, 292;
found: 293 (M+H).
Step C
N-({1-[4-Hydroxy-4-(3-methylsulfanyl-phenyl)-cyclohexyl]-azetidin-3-ylcarb-
amoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00161##
[0517] The title compound was prepared as a white solid from
4-(3-amino-azetidin-1-yl)-1-(3-methylsulfanyl-phenyl)-cyclohexanol
(as prepared in the previous step) using the procedure described in
Step F of Example 1.
[0518] 38a: Less Polar Isomer from Silica Gel Column
[0519] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.05 (s, 1H),
7.98 (d, J=6.5 Hz, 1H), 7.70 (d, J=6.4 Hz, 1H), 7.52 (t, J=6.5 Hz,
1H), 7.28 (s, 1H), 7.15 (d, J=7.0 Hz, 2H), 7.10 (t, J=7.0 Hz, 1H),
6.88 (d, J=7.0 Hz, 1H), 4.31 (m, 1H), 3.88 (s, 2H), 3.65 (t, J=6.0
Hz, 2H), 2.91 (d, J=6.0 Hz, 2H), 2.35 (m, 1H), 2.30 (s, 3H), 2.06
(m, 2H), 1.65 (m, 2H), 1.35 (m, 2H), 1.25 (m, 2H).
[0520] 38b: More Polar Isomer from Silica Gel Column
[0521] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.09 (s, 1H),
7.99 (d, J=6.0 Hz, 1H), 7.68 (d, J=6.2 Hz, 1H), 7.51 (t, J=6.5 Hz,
1H), 7.25 (s, 1H), 7.05 (m, 2H), 6.90 (d, J=7.0 Hz, 1H), 4.30 (m,
1H), 3.88 (s, 2H), 3.45 (t, J=6.0 Hz, 2H), 2.90 (d, J=6.0 Hz, 2H),
2.28 (s, 3H), 2.06 (m, 1H), 1.65 (m, 4H), 1.50 (m, 4H).
Example 39
N-({1-[4-(3-Dimethylamino-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarba-
moyl}-methyl)-3-trifluoromethyl-benzamide
Step A
8-(3-Dimethylamino-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00162##
[0523] The title compound was prepared as a white solid from
1-bromo-3-dimethylamino-benzene (Aldrich) and
1,4-dioxa-spiro[4.5]decan-8-one using the procedure described in
Step A of Example 1.
[0524] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.20 (t, J=7.5 Hz,
1H), 6.95 (s, 1H), 6.82 (d, J=6.5 Hz, 1H), 6.62 (d, J=6.5 Hz, 1H),
3.95 (s, 4H), 2.98 (s, 6H), 2.98 (s, 6H), 2.15 (m, 4H), 1.80 (m,
2H), 1.68 (m, 2H).
Step B
4-(3-Dimethylamino-phenyl)-4-hydroxy-cyclohexanone
##STR00163##
[0526] The title compound was prepared as a white solid from
8-(3-dimethylamino-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0527] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.23 (d, J=7.8 Hz,
1H), 6.95 (s, 1H), 6.84 (d, J=6.8 Hz, 1H), 6.69 (d, J=6.5 Hz, 1H),
2.98 (s, 6H), 2.90 (m, 2H), 2.32 (m, 4H), 2.20 (m, 2H).
Step C
N-({1-[4-(3-Dimethylamino-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarba-
moyl}-methyl)-3-trifluoromethyl-benzamide
##STR00164##
[0529] The title compound was prepared as a white solid by
reductive amination of
4-(3-dimethylamino-phenyl)-4-hydroxy-cyclohexanone (as prepared in
the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0530] 39a: Less Polar Fraction from Silica Gel Column
[0531] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.12 (s, 1H), 8.02
(d, J=6.5 Hz, 1H), 7.88 (m, 1H), 7.75 (t, J=6.6 Hz, 1H), 7.51 (m,
J=7.0 Hz, 2H), 7.20 (t, J=6.6 Hz, 1H), 6.98 (s, 1H), 6.85 (d, J=6.4
Hz, 1H), 6.62 (d, J=6.5 Hz, 1H), 4.51 (m, 1H), 4.15 (d, J=3.5 Hz,
2H), 3.58 (t, J=6.7 Hz, 2H), 2.95 (s, 6H), 2.86 (t, J=6.8 Hz, 2H),
2.40 (s, br, 1H), 2.24 (m, 2H), 1.80 (t, J=8.0 Hz, 2H), 1.52 (d,
J=8.2 Hz, 2H), 1.45 (m, 2H).
[0532] 39b: More Polar Fraction from Silica Gel Column
[0533] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.12 (s, 1H), 8.06
(d, J=6.5 Hz, 1H), 7.82 (d, J=5.6 Hz, 1H), 7.62 (t, J=6.5 Hz, 1H),
7.30 (m, 2H), 6.95 (s, 1H), 6.85 (d, J=6.7 Hz, 1H), 6.78 (d, J=6.0
Hz, 1H), 6.66 (d, J=6.5 Hz, 1H), 4.55 (m, 1H), 4.18 (d, J=4.5 Hz,
2H), 3.66 (t, J=6.9 Hz, 2H), 3.08 (t, J=6.8 Hz, 2H), 2.32 (s, br,
1H), 1.92 (m, 2H), 1.85 (m, 4H), 1.58 (m, 2H).
Example 40
N-({1-[4-(4-Hydroxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3--
trifluoromethyl-benzamide
Step A
8-[4-(tert-Butyl-dimethyl-silanyloxy)-phenyl]-1,4-dioxa-spiro[4.5]decan-8--
ol
##STR00165##
[0535] The title compound was prepared as a white solid from
(4-bromo-phenoxy)-tert-butyl-dimethyl-silane (Aldrich) and
1,4-dioxa-spiro[4.5]decan-8-one using the procedure described in
Step A of Example 1.
[0536] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.18 (d, J=6.8 Hz,
2H), 6.58 (d, J=7.0 Hz, 2H), 3.79 (m, 4H), 1.98 (m, 4H), 1.65 (d,
J=6.4 Hz, 2H), 1.50 (d, J=6.8 Hz, 2H), 0.80 (s, 9H), 0.05 (s,
6H).
Step B
4-[4-(tert-Butyl-dimethyl-silanyloxy)-phenyl]-4-hydroxy-cyclohexanone
##STR00166##
[0538] The title compound was prepared as a white solid from
8-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-1,4-dioxa-spiro[4.5]decan-8-
-ol (as prepared in the previous step) using the procedure
described in Step B of Example 1.
[0539] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.26 (d, J=6.5 Hz,
1H), 7.10 (d, J=6.4 Hz, 1H), 7.01 (s, 1H), 6.79 (d, J=6.8 Hz, 1H),
2.95 (m, 2H), 2.38 (m, 2H), 2.25 (m, 2H), 2.20 (m, 2H), 1.02 (s,
9H), 0.21 (s, 6H).
Step C
4-[4-(tert-Butyl-dimethyl-silanyloxy)-phenyl]-cyclohex-3-enone
##STR00167##
[0541] The title compound was prepared as a white solid from
dehydration of
4-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-4-hydroxy-cyclohexanone
(as prepared in the previous step) using the procedure described in
Step B of Example 5.
[0542] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.01 (t, J=6.4 Hz,
1H), 6.78 (d, J=6.6 Hz, 1H), 6.65 (s, 1H), 6.54 (d, J=6.7 Hz, 1H),
5.85 (m, 1H), 2.88 (s, 2H), 2.70 (t, J=7.2 Hz, 2H), 2.42 (t, J=7.5
Hz, 2H).
Step D
4-(4-Hydroxy-phenyl)-cyclohex-3-enone
##STR00168##
[0544]
4-[4-(tert-Butyl-dimethyl-silanyloxy)-phenyl]-cyclohex-3-enone (2.0
g, 6.62 mmol) in THF was treated with TBAF (1N in THF, 10 mL, 9.93
mmol) at room temperature. After 10 min., the solvent was removed
and the residue was partitioned between ethyl acetate and water.
The organic layer was washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered, and the filtrate concentrated in vacuo
to give colorless oil, which was purified on a silica gel column by
a CombiFlash.RTM. system using hexanes and ethyl acetate as eluent
(from pure hexanes to pure ethyl acetate) to afford the title
compound as a white solid.
[0545] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 7.28 (d, J=6.5
Hz, 2H), 6.75 (d, J=6.5 Hz, 2H), 5.95 (m, 1H), 3.01 (s, 2H), 2.80
(t, J=4.2 Hz, 2H), 2.55 (t, J=6.8 Hz, 2H).
Step E
4-(4-Hydroxy-phenyl)-cyclohexanone
##STR00169##
[0547] The title compound was prepared as a white solid from
4-(4-hydroxy-phenyl)-cyclohex-3-enone (as prepared in the previous
step) using the procedure described in Step C of Example 5.
[0548] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 7.05 (t, J=6.8
Hz, 2H), 6.70 (d, J=6.8 Hz, 2H), 2.90 (m, 1H), 2.55 (m, 2H), 2.30
(m, 2H), 2.08 (m, 2H, 1.90 (m, 2H).
Step F
N-({1-[4-(4-Hydroxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3--
trifluoromethyl-benzamide
##STR00170##
[0550] The title compound was prepared as a white solid by
reductive amination of 4-(4-Hydroxy-phenyl)-cyclohexanone (as
prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0551] 40a: Less Polar Isomer from Silica Gel Column
[0552] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.21 (s, 1H),
8.15 (d, J=6.5 Hz, 1H), 7.88 (d, J=6.4 Hz, 1H), 7.70 (t, J=6.5 Hz,
1H), 7.15 (d, J=7.0 Hz, 2H), 6.72 (d, J=7.0 Hz, 2H), 4.47 (m, 1H),
4.05 (s, 2H), 3.65 (m, 2H), 2.95 (m, 2H), 2.45 (m, 1H), 2.40 (s,
br, 1H), 1.75 (m, 4H), 1.50 (m, 4H).
[0553] 40b: More Polar Isomer from Silica Gel Column
[0554] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.11 (s, 1H),
8.08 (d, J=6.5 Hz, 1H), 7.82 (d, J=6.0 Hz, 1H), 7.60 (t, J=7.2 Hz,
1H), 6.95 (d, J=7.2 Hz, 2H), 6.62 (d, J=6.5 Hz, 1H), 4.35 (m, 1H),
3.95 (s, 2H), 3.72 (t, J=6.5 Hz, 2H), 3.15 (t, J=6.2 Hz, 2H), 3.01
(m, 1H), 2.25 (m, 1H), 1.90 (m, 4H), 1.35 (m, 2H), 1.12 (m,
2H).
Example 41
N-[(1-{4-[4-(2-Dimethylamino-ethoxy)-phenyl]-cyclohexyl}-azetidin-3-ylcarb-
amoyl)-methyl]-3-trifluoromethyl-benzamide
Step A
4-[4-(2-Dimethylamino-ethoxy)-phenyl]-cyclohexanone
##STR00171##
[0556] Into a solution of 4-(4-hydroxy-phenyl)cyclohexanone (as
prepared in Example 40, Step E, 2.4 g, 12.6 mmol),
N,N-dimethylethanolamine (Aldrich, 3.37 g, 37.8 mmol) and
triphenylphosphine (Aldrich, 9.91 g, 37.8 mmol) in THF (100 mL) at
0.degree. C. was added dropwise a solution of diisopropyl
azodicarboxylate (7.44 mL, 37.8 mmol) in THF (15 mL) under Ar. The
resulting solution was stirred at 0.degree. C. for 1 h and at room
temperature overnight. The solvent was removed and the residue was
partitioned between ethyl acetate and water. The organic layer was
washed with brine, dried over anhydrous Na.sub.2SO.sub.4, filtered,
and the filtrate concentrated in vacuo to give a colorless oil,
which was purified on a silica gel column by a CombiFlash.RTM.
system using hexanes and ethyl acetate as eluent (from pure hexanes
to pure ethyl acetate) to afford the title compound as a white
solid.
[0557] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.13-7.21 (2H,
dd), 6.81-6.86 (2H, dd), 4.01-4.06 (2H, m), 3.51 (1H, m), 2.69-2.73
(2H, m), 2.47-2.50 (2H, m), 2.32-2.34 (4H, m), 2.24 (6H, s),
1.67-1.73 (2H, m).
Step B
N-[(1-{4-[4-(2-Dimethylamino-ethoxy)-phenyl]-cyclohexyl}-azetidin-3-ylcarb-
amoyl)-methyl]-3-trifluoromethyl-benzamide
##STR00172##
[0559] The title compound was prepared from
4-[4-(2-dimethylamino-ethoxy)-phenyl]-cyclohexanone (as prepared in
the previous step) according to the general reductive amination
procedure in Step C of Example 4.
[0560] A mixture of 4:1 ratio of two isomers was detected from LC.
ESI-MS (m/z): Calcd. For C.sub.29H.sub.37F.sub.3N.sub.4O.sub.3,
546; found: 547 [M+H].
Example 42
N-({1-[4-Hydroxy-4-(4-hydroxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
Step A
4-Hydroxy-4-(4-hydroxy-phenyl)-cyclohexanone
##STR00173##
[0562] The title compound was prepared as a white solid by TBAF
de-protection of
4-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-4-hydroxy-cyclohexanone
using the procedure described in Step D of Example 40.
[0563] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.25 (t, J=6.5 Hz,
1H), 7.08 (s, 1H), 7.05 (d, J=6.0 Hz, 1H), 6.78 (d, J=6.4 Hz, 1H),
2.95 (m, 2H), 2.35 (m, 2H), 2.30 (m, 2H), 2.18 (m, 2H).
Step B
N-({1-[4-Hydroxy-4-(4-hydroxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
##STR00174##
[0565] The title compound was prepared as a white solid by
reductive amination of 4-hydroxy-4-(4-hydroxy-phenyl)-cyclohexanone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0566] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.20 (s, 1H),
8.10 (d, J=6.5 Hz, 1H), 7.85 (d, J=6.4 Hz, 1H), 7.62 (t, J=6.5 Hz,
1H), 7.10 (t, J=6.5 Hz, 1H), 6.98 (d, J=6.5 Hz, 2H), 6.58 (d, J=7.0
Hz, 2H), 4.45 (m, 1H), 4.01 (s, 2H), 3.72 (t, J=6.0 Hz, 2H), 3.12
(d, J=6.0 Hz, 2H), 2.55 (m, 1H), 2.26 (m, 2H), 1.85 (m, 2H), 1.48
(m, 2H), 1.31 (m, 2H).
Example 43
3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cyclohex-
yl)-phenoxy]-aceticacid methyl ester
##STR00175##
[0568]
N-({1-[4-(4-Hydroxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-met-
hyl)-3-trifluoromethyl-benzamide (as prepared in Example 40, less
polar isomer, 250 mg, 0.53 mmol) in DMF (5 mL) was treated with
Cs.sub.2CO.sub.3 (260 mg, 0.80 mmol) followed by bromo-acetic acid
methyl ester (Aldrich, 92 mg, 0.60 mmol) at room temperature. The
reaction was gently heated at 60.degree. C. for 4 hours and then
allowed to cool. The solid was filtered off and DMF was removed in
vacuo. The residue was partitioned between water and DCM. The
aqueous layer was extracted 3 times with a chloroform/IPA
"cocktail" (.about.3:1, v/v). The combined organic layers were
dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to
give the crude product, which was then purified by a
CombiFlash.RTM. system using ethyl acetate and 7N NH.sub.3 in MeOH
as eluent (from pure ethyl acetate to 5% 7N NH.sub.3 in MeOH in
ethyl acetate) to afford the title compound as a white solid.
[0569] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.5 Hz, 1H), 7.80 (d, J=6.5 Hz, 1H), 7.60 (t, J=6.5 Hz, 1H),
7.42 (m, 1H), 7.15 (d, J=7.0 Hz, 2H), 6.90 (d, J=5.6 Hz, 1H), 6.80
(d, J=7.0 Hz, 2H), 4.60 (s, 2H), 4.52 (m, 1H), 4.22 (d, J=3.5 Hz,
2H), 3.80 (s, 3H), 3.60 (t, J=7.0 Hz, 2H), 2.85 (t, J=7.0 Hz, 2H),
2.45 (m, 1H), 2.30 (s, br, 1H), 1.85 (2H), 1.70 (m, 2H), 1.55 (m,
2H), 1.44 (m, 2H).
Example 44
3-[2-(3-Trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cyclohex-
yl)-phenoxy]-aceticacid
##STR00176##
[0571] The title compound was prepared as a white solid by
hydrolysis of
3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetidin-1-yl}-cyclohe-
xyl)-phenoxy]-aceticacid methyl ester (as prepared in Example 43)
using the procedure described in Example 10.
[0572] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.15 (s, 1H),
8.02 (d, J=6.5 Hz, 1H), 7.78 (d, J=6.4 Hz, 1H), 7.60 (t, J=6.5 Hz,
1H), 7.05 (d, J=7.0 Hz, 2H), 6.72 (d, J=7.0 Hz, 2H), 4.41 (m, 1H),
4.25 (s, 2H), 4.00 (s, 2H), 3.60 (m, 2H), 2.98 (m, 2H), 2.45 (m,
1H), 1.65 (m, 4H), 1.50 (m, 4H).
Example 45
4-(1-Hydroxy-4-{3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetidi-
n-1-yl}-cyclohexyl)-benzoic acid
##STR00177##
[0574] The title compound was prepared as a white solid by
reductive amination of 4-(1-hydroxy-4-oxo-cyclohexyl)-benzoic acid
methyl ester (as prepared in Example 9, Step B) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4 followed by base catalyzed hydrolysis of the
ester using the procedure described in Example 10.
[0575] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.20 (s, 1H),
8.08 (d, J=6.5 Hz, 1H), 7.85 (d, J=6.4 Hz, 2H), 7.80 (d, J=6.3 Hz,
1H), 7.65 (t, J=6.5 Hz, 1H), 7.40 (d, J=7.0 Hz, 2H), 4.51 (m, 1H),
4.20 (s, 2H), 4.00 (s, 3H), 3.85 (m, 2H), 3.20 (m, 2H), 2.85 (m,
1H), 2.20 (m, 2H), 1.98 (m, 2H), 1.65 (m, 2H), 1.50 (m, 2H).
Example 46
N-({1-[4-Hydroxy-4-(3-hydroxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
Step A
tert-Butyl-dimethyl-silanyloxy)-phenyl]-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00178##
[0577] The title compound was prepared as a white solid from and
1,4-dioxa-spiro[4.5]decan-8-one (Aldrich) using the procedure
described in Step A of Example 1.
[0578] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.20 (t, J=6.6 Hz,
1H), 7.11 (d, J=6.0 Hz, 1H), 7.04 (s, 1H), 6.76 (d, J=6.0 Hz, 1H),
3.00 (m, 4H), 2.10 (t, J=8.5 Hz, 4H), 1.80 (d, J=6.8 Hz, 2H), 1.72
(d, J=6.6 Hz, 2H), 0.98 (s, 9H), 0.21 (s, 6H).
Step B
4-[3-(tert-Butyl-dimethyl-silanyloxy)-phenyl]-4-hydroxy-cyclohexanone
##STR00179##
[0580] The title compound was prepared as a white solid from using
the procedure described in Step B of Example 1.
[0581] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.25 (t, J=6.6 Hz,
1H), 7.08 (d, J=6.3 Hz, 1H), 7.05 (d, J=2.2 Hz, 1H), 6.75 (d, J=6.0
Hz, 1H0, 2.90 (m, 2H), 2.35 (m, 2H), 2.30 (m, 2H), 2.12 (m, 2H),
1.05 (s, 9H), 0.20 (s, 6H).
Step C
4-Hydroxy-4-(3-hydroxy-phenyl)-cyclohexanone
##STR00180##
[0583] The title compound was prepared as a white solid by TBAF
de-protection of
4-[3-(tert-butyl-dimethyl-silanyloxy)-phenyl]-4-hydroxy-cyclohexanone
(as prepared in the previous step) using the procedure described in
Step D of Example 40.
[0584] ESI-MS (m/z): Calcd. For C.sub.12H.sub.14O.sub.3, 206;
found: 207 (M+H).
Step D
N-({1-[4-Hydroxy-4-(3-hydroxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
##STR00181##
[0586] The title compound was prepared as a white solid by
reductive amination of 4-hydroxy-4-(3-hydroxy-phenyl)-cyclohexanone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0587] 46a: Less Polar Isomer from Silica Gel Column
[0588] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.15 (s, 1H),
8.08 (d, J=6.5 Hz, 1H), 7.78 (d, J=6.4 Hz, 1H), 7.60 (t, J=6.5 Hz,
1H), 7.10 (t, J=7.0 Hz, 1H), 6.92 (d, J=4.0 Hz, 2H), 6.59 (d, J=5.2
Hz, 1H), 4.41 (m, 1H), 4.00 (s, 2H), 3.60 (t, J=6.5 Hz, 2H), 2.98
(t, J=6.5 Hz, 2H), 2.35 (m, 1H), 2.17 (m, 2H), 1.85 (m, 2H), 1.50
(m, 2H), 1.32 (m, 2H).
[0589] 46b: More Polar Isomer from Silica Gel Column
[0590] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.17 (s, 1H),
8.09 (d, J=6.6 Hz, 1H), 7.80 (d, J=6.8 Hz, 1H), 7.65 (t, J=6.5 Hz,
1H), 7.05 (t, J=6.8 Hz, 1H), 6.88 (s, 1H), 6.72 (s, 1H), 6.55 (d,
J=6.0 Hz, 1H), 4.45 (m, 1H), 4.05 (s, 2H), 3.68 (t, J=7.0 Hz, 2H),
3.10 (t, J=7.0 Hz, 2H), 2.25 (m, 1H), 1.75 (m, 4H), 1.64 (m, 2H),
1.54 (m, 2H).
Example 47
N-({1-[4-(4-Fluoro-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-m-
ethyl)-3-trifluoromethyl-benzamide
Step A
8-(4-Fluoro-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00182##
[0592] The title compound was prepared as a white solid from
4-fluoro-phenyl-bromide (Aldrich) and
1,4-dioxa-spiro[4.5]decan-8-one using the procedure described in
Step A of Example 1.
[0593] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.45 (dd, J=8.5,
6.0 Hz, 2H), 6.98 (dd, J=8.8, 6.2 Hz, 2H), 4.00 (m, 4H), 2.10 (m,
4H), 1.82 (m, 2H), 1.65 (m, 2H).
Step B
4-(4-Fluoro-phenyl)-4-hydroxy-cyclohexanone
##STR00183##
[0595] The title compound was prepared as a white solid from
8-(4-fluoro-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (as prepared in
the previous step) using the procedure described in Step B of
Example 1.
[0596] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.50 (dd, J=8.0,
6.2 Hz, 2H), 7.05 (dd, J=8.5, 6.2 Hz, 2H), 2.95 (m, 2H), 2.35 (m,
2H), 2.20 (m, 2H), 2.03 (m, 2H).
Step C
N-({1-[4-(4-Fluoro-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-m-
ethyl)-3-trifluoromethyl-benzamide
##STR00184##
[0598] The title compound was prepared as a white solid by
reductive amination of 4-(4-fluoro-phenyl)-4-hydroxy-cyclohexanone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0599] 47a: Less Polar Isomer from Silica Gel Column
[0600] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (s, 1H), 8.05
(d, J=6.8 Hz, 1H), 7.80 (t, J=5.6 Hz, 1H), 7.77 (d, J=6.8 Hz, 1H),
7.51 (t, J=7.7 Hz, 2H), 7.92 (t, J=7.8 Hz, 2H), 4.51 (m, 1H), 4.15
(d, J=3.5 Hz, 2H), 3.60 (t, J=6.8 Hz, 2H), 2.96 (t, J=6.8 Hz, 2H),
2.30 (s, 1H), 2.24 (t, J=8.5 Hz, 2H), 1.85 (t, J=8.0 Hz, 2H), 1.52
(d, J=8.2 Hz, 2H), 1.42 (m, 2H).
[0601] 47b: More Polar Isomer from Silica Gel Column
[0602] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.0 Hz, 1H), 7.85 (t, J=4.3 Hz, 1H), 7.72 (m, 1H), 7.53 (d,
J=7.0 Hz, 1H), 7.50 (m, J=8.5, 6.5 Hz, 2H), 7.01 (t, J=6.8 Hz, 2H),
4.44 (m, 1H), 4.18 (d, J=3.2 Hz, 2H), 3.55 (t, J=7.4 Hz, 2H), 3.10
(t, J=7.0 Hz, 2H), 2.10 (m, 2H), 1.85-1.48 (m, 6H).
Example 48
N-({1-[4-(3-Cyano-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
##STR00185##
[0604] The title compounds were prepared as white solids by
reductive amination of 3-[1-hydroxy-4-oxo-cyclohexyl)-benzonitrile
(as prepared Example 8, Step B) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0605] 48a: Less Polar Isomer from Silica Gel Column
[0606] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (s, 1H), 8.05
(d, J=6.8 Hz, 1H), 7.85 (s, 1H), 7.80 (t, J=6.6 Hz, 1H), 7.58 (t,
J=6.2 Hz, 1H), 7.51 (d, J=6.7 Hz, 1H), 7.42 (t, J=6.8 Hz, 1H), 7.30
(s, br, 1H), 6.85 (s, br, 1H), 4.55 (m, 1H), 4.21 (d, J=3.5 Hz,
2H), 3.65 (t, J=6.8 Hz, 2H), 2.90 (m, 2H), 2.45 (m, 1H), 2.20 (t,
J=8.5 Hz, 2H), 1.85 (t, J=8.0 Hz, 2H), 1.48 (m, 4H).
[0607] 48b: More Polar Isomer from Silica Gel Column
[0608] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (s, 1H), 8.05
(d, J=6.0 Hz, 1H), 7.85 (t, J=5.8 Hz, 1H), 7.75 (d, J=6.6 Hz, 1H),
7.56 (d, J=7.0 Hz, 1H), 7.50 (m, J=7.5, 6.0 Hz, 2H), 7.42 (t, J=6.2
Hz, 1H), 7.21 (s, 1H), 4.54 (m, 1H), 4.18 (d, J=3.2 Hz, 2H), 3.68
(t, J=7.4 Hz, 2H), 3.10 (t, J=7.0 Hz, 2H), 2.20 (m, 2H), 1.85-1.66
(m, 4H), 1.55 (m, 2H).
Example 49
N-[(1-{4-Hydroxy-4-[3-(1H-tetrazol-5-yl)-phenyl]-cyclohexyl}-azetidin-3-yl-
carbamoyl)-methyl]-3-trifluoromethyl-benzamide
##STR00186##
[0610] TMSN.sub.3 (Fluka, 50 mg, 0.42 mmol), TBAF (Aldrich, 1.0 N
in THF, 0.5 mL, 0.5 mmol) and
N-({1-[4-(3-cyano-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-m-
ethyl)-3-trifluoromethyl-benzamide (as prepared in Example 48, less
polar isomer, 70 mg, 0.14 mmol) were dissolved in THF (2 mL) and
water (0.5 mL) mixed solvent. The reaction mixture was subjected to
microwave irradiation at 120.degree. C. for 20 min. The crude
reaction mixture was loaded on a silica gel column using a
CombiFlash.RTM. system using ethyl acetate and 7N NH.sub.3 in MeOH
as eluent (from pure ethyl acetate to 5% 7N NH.sub.3 in MeOH in
ethyl acetate) to afford the title compound as a white solid.
[0611] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.08 (s, 1H), 8.02
(d, J=6.5 Hz, 1H), 7.85 (s, 1H), 7.80 (t, J=6.0 Hz, 1H), 7.52 (m,
2H), 7.41 (t, J=6.2 Hz, 1H), 7.01 (d, J=6.0 Hz, 1H), 4.52 (m, 1H),
4.18 (d, J=2.8 Hz, 2H), 3.55 (t, J=6.8 Hz, 2H), 2.90 (t, J=6.5 Hz,
2H), 2.65 (m, 2H), 2.20 (m, 2H), 2.00 (m, 2H), 1.65 (m, 2H).
Example 50
[4-(1-Hydroxy-4-{3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetid-
in-1-yl}-cyclohexyl)-phenyl]-carbamic acid tert-butyl ester
Step A
[4-(1-Hydroxy-4-oxo-cyclohexyl)-phenyl]-carbamic acid tert-butyl
ester
##STR00187##
[0613] The title compound was prepared as a white solid from
[4-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-phenyl]-carbamic acid
tert-butyl ester using the procedure described in Step B of Example
1.
[0614] ESI-MS (m/z): Calcd. For C.sub.17H.sub.23NO.sub.4, 305;
found: 306 (M+H).
Step B
[4-(1-Hydroxy-4-{3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetid-
in-1-yl}-cyclohexyl)-phenyl]-carbamic acid tert-butyl ester
##STR00188##
[0616] The title compound was prepared as a white solid by
reductive amination of
[4-(1-hydroxy-4-oxo-cyclohexyl)-phenyl]-carbamic acid tert-butyl
ester (as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0617] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.24 (s, 1H),
8.15 (d, J=6.5 Hz, 1H), 7.88 (d, J=6.0 Hz, 1H), 7.70 (t, J=7.2 Hz,
1H), 7.45 (d, J=6.2 Hz, 2H), 7.30 (d, J=7.0 Hz, 2H), 4.45 (m, 1H),
4.05 (s, 2H), 3.65 (t, J=7.5 Hz, 2H), 2.98 (t, J=7.2 Hz, 2H), 2.45
(m, 1H), 2.25 (m, 2H), 1.87 (m, 2H), 1.52 (m, 2H), 1.64 (m, 2H),
1.58 (s, 9H), 1.32 (m, 2H).
Example 51
N-({1-[4-(3-Ethynyl-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
Step A
8-(3-Trimethylsilanylethynyl-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00189##
[0619] The title compound was prepared as a white solid from
(4-bromo-phenylethynyl)-trimethyl-silane (Aldrich) and
1,4-dioxa-spiro[4.5]decan-8-one using the procedure described in
Step A of Example 1.
[0620] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.65 (s, 1H), 7.50
(d, J=6.1 Hz, 1H), 7.35 (d, J=6.0 Hz, 1H), 7.28 (t, J=6.4 Hz, 1H),
4.05 (s, 4H), 2.20 (m, 4H), 1.85 (m, 2H), 1.71 (m, 2H).
Step B
4-Hydroxy-4-(3-trimethylsilanylethynyl-phenyl)-cyclohexanone
##STR00190##
[0622] The title compound was prepared as a white solid from
8-(3-trimethylsilanylethynyl-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
(as prepared in the previous step) using the procedure described in
Step B of Example 1.
[0623] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.65 (s, 1H), 7.46
(d, J=6.0 Hz, 1H), 7.40 (d, J=5.8 Hz, 1H), 7.31 (t, J=6.1 Hz, 1H),
2.98 (m, 2H), 2.35 (m, 2H), 2.30 (m, 2H), 2.20 (m, 2H), 2.10 (s,
1H).
Step C
N-({1-[4-(3-Ethynyl-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
##STR00191##
[0625] The title compound was prepared as a white solid by
reductive amination of
4-hydroxy-4-(3-trimethylsilanylethynyl-phenyl)-cyclohexanone (as
prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4 followed by a TBAF work-up using the procedure
described in Step D of Example 40.
[0626] 51a: Less Polar Isomer from Silica Gel Column
[0627] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (s, 1H), 8.02
(d, J=6.7 Hz, 1H), 7.78 (m, 2H), 7.34 (m, 2H), 7.25 (d, J=6.8 Hz,
1H), 7.10 (d, J=6.5 Hz, 1H), 4.52 (m, 1H), 4.20 (d, J=3.0 Hz, 2H),
3.60 (t, J=7.8 Hz, 2H), 2.90 (t, J=7.5 Hz, 2H), 2.30 (m, 2H), 2.25
(s, br, 1H), 1.80 (m, 2H), 1.55 (m, 2H), 1.40 (m, 2H).
[0628] 51b: More Polar Isomer from Silica Gel Column
[0629] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.00
(d, J=6.4 Hz, 1H), 7.77 (d, J=6.5 Hz, 1H), 7.55 (m, 1H), 7.45 (d,
J=6.3 Hz, 1H), 7.31 (d, J=6.6 Hz, 1H), 7.20 (d, J=6.4 Hz, 1H), 4.55
(m, 1H), 4.20 (d, J=3.2 Hz, 2H), 3.62 (t, J=7.5 Hz, 2H), 3.02 (t,
J=7.5 Hz, 2H), 1.85 (m, 3H), 1.70 (s, br, 3H), 1.80 (m, 1H), 1.50
(m, 2H).
Example 52
N-({1-[4-(3-Ethyl-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
##STR00192##
[0631] The title compound was prepared as a white solid by
hydrogenation of
N-({1-[4-(3-ethynyl-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamo-
yl}-methyl)-3-trifluoromethyl-benzamide (as prepared in Example 51,
less polar isomer) using the procedure described in Step G of
Example 1.
[0632] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.21 (s, 1H),
8.15 (d, J=6.5 Hz, 1H), 7.86 (d, J=6.0 Hz, 1H), 7.70 (t, J=7.2 Hz,
1H), 7.35 (s, 1H), 7.30 (d, J=6.2 Hz, 1H), 7.20 (t, J=7.0 Hz, 1H),
7.05 (d, J=5.6 Hz, 1H), 4.45 (m, 1H), 4.05 (s, 2H), 3.65 (t, J=7.5
Hz, 2H), 2.98 (t, J=7.2 Hz, 2H), 2.65 (q, J=7.2 Hz, 2H), 2.45 (m,
1H), 2.25 (m, 2H), 1.87 (m, 2H), 1.52 (m, 2H), 1.34 (m, 2H), 1.20
(t, J=7.2 Hz, 3H).
Example 53
N-({1-[4-(4-Chloro-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-m-
ethyl)-3-trifluoromethyl-benzamide
Step A
8-(4-Chloro-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00193##
[0634] The title compound was prepared as a white solid from
4-bromochlorobenzene (Aldrich) and 1,4-dioxa-spiro[4.5]decan-8-one
using the procedure described in Step A of Example 1.
[0635] .sup.1H NMR (CHLOROFORM-d) .delta.: 7.46 (d, J=8.6 Hz, 2H),
7.30 (d, J=8.3 Hz, 2H), 3.98 (t, J=4.3 Hz, 4H), 2.51 (t, J=7.1 Hz,
1H), 2.07-2.22 (m, 2H), 1.97-2.07 (m, 2H), 1.78 (d, J=14.7 Hz, 2H),
1.69 (d, J=10.6 Hz, 2H).
Step B
4-(4-Chloro-phenyl)-4-hydroxy-cyclohexanone
##STR00194##
[0637] The title compound was prepared as a white solid from the
de-protection of 8-(4-chloro-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
(as prepared in the previous step) using the procedure described in
Step B of Example 1.
[0638] .sup.1H NMR (CHLOROFORM-d) .delta.: 7.42-7.50 (m, 2H),
7.31-7.40 (m, 2H), 2.38 (br. s., 2H), 2.28 (s, 2H), 2.18 (d, J=2.3
Hz, 2H).
Step C
N-({1-[4-(4-Chloro-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-m-
ethyl)-3-trifluoromethyl-benzamide
##STR00195##
[0640] The title compound was prepared as a white solid by
reductive amination of 4-(4-chloro-phenyl)-4-hydroxy-cyclohexanone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0641] .sup.1H NMR (CHLOROFORM-d) .delta.: 8.12 (s, 1H), 8.00 (d,
J=7.8 Hz, 1H), 7.89 (t, J=5.1 Hz, 1H), 7.75 (d, J=7.8 Hz, 1H),
7.45-7.57 (m, 2H), 7.43 (d, J=8.6 Hz, 1H), 7.27 (d, J=8.6 Hz, 1H),
4.43-4.55 (m, 1H), 4.16 (d, J=5.1 Hz, 2H), 3.58 (t, J=7.3 Hz, 2H),
2.51 (br s., 1H), 2.09-2.20 (m, 2H), 1.73-1.84 (m, 4H), 1.32-1.51
(m, 4H).
Example 54
N-({1-[4-(4-Dimethylamino-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarba-
moyl}-methyl)-3-trifluoromethyl-benzamide
Step A
8-(4-Dimethylamino-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00196##
[0643] The title compound was prepared as a white solid from
4-bromodimethylamine (Aldrich) and 1,4-dioxa-spiro[4.5]decan-8-one
using the procedure described in Step A of Example 1.
[0644] .sup.1H NMR (CHLOROFORM-d) .delta.: 7.38 (d, J=8.6 Hz, 2H),
7.18-7.26 (m, 2H), 2.82-2.90 (m, 4H), 2.63 (s, 2H), 2.42-2.52 (m,
6H), 2.24 (s, 2H), 2.14-2.19 (m, 2H), 2.01 (s, 2H).
Step B
4-(4-Dimethylamino-phenyl)-4-hydroxy-cyclohexanone
##STR00197##
[0646] The title compound was prepared as a white solid from the
de-protection of
8-(4-dimethylamino-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0647] .sup.1H NMR (CHLOROFORM-d) .delta.: 7.31-7.44 (m, J=9.1 Hz,
2H), 6.67-6.77 (m, J=8.8
[0648] Hz, 2H), 2.95 (s, 6H), 2.83-2.92 (m, 2H), 2.28-2.36 (m, 2H),
2.25 (d, J=4.5 Hz, 2H), 2.14-2.22 (m, 2H).
Step C
N-({1-[4-(4-Dimethylamino-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarba-
moyl}-methyl)-3-trifluoromethyl-benzamide
##STR00198##
[0650] The title compound was prepared as a white solid by
reductive amination of
4-(4-dimethylamino-phenyl)-4-hydroxy-cyclohexanone (as prepared in
the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0651] 54a: Less Polar Isomer from Silica Gel Column
[0652] .sup.1H NMR (CHLOROFORM-d) .delta.: 8.12 (d, J=4.3 Hz, 1H),
8.01 (t, J=6.9 Hz, 1H), 7.77 (d, J=7.6 Hz, 1H), 7.57 (td, J=7.8,
3.3 Hz, 1H), 7.34 (d, J=8.8 Hz, 1H), 7.37 (d, J=8.8 Hz, 1H),
6.84-6.95 (m, 1H), 6.70 (s, 1H), 4.44 (br s., 1H), 3.57 (t, J=7.3
Hz, 2H), 2.93 (d, J=2.8 Hz, 2H), 2.55 (br s., 2H), 2.16-2.30 (m,
6H), 1.72-1.87 (m, 4H), 1.53-1.61 (m, 2H), 1.29-1.42 (m, 2H).
[0653] 54b: More Polar Isomer from Silica Gel Column
[0654] .sup.1H NMR (CHLOROFORM-d) .delta.: 8.20 (s, 1H), 8.10 (d,
J=7.6 Hz, 1H), 7.81 (d, J=7.6 Hz, 1H), 7.63 (t, J=7.8 Hz, 1H), 7.43
(s, 2H), 7.25-7.38 (m, J=8.8 Hz, 1H), 6.64-6.82 (m, J=8.8 Hz, 1H),
4.49 (t, J=6.4 Hz, 2H), 4.06 (s, 1H), 3.66 (t, J=7.7 Hz, 2H),
3.01-3.13 (m, 2H), 2.86-2.95 (m, 6H), 2.55 (br s, 1H), 1.63-1.90
(m, 4H), 1.48-1.61 (m, 4H).
Example 55
N-({1-[4-(4-benzamide)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methy-
l)-3-trifluoromethyl-benzamide
Step A
4-(8-Hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-benzamide
##STR00199##
[0656] The title compound was prepared as a white solid from
4-bromobenzamide (Aldrich) and 1,4-dioxa-spiro[4.5]decan-8-one
using the procedure described in Step A of Example 1.
[0657] .sup.1H NMR (MeOH) .delta.: 7.77-7.90 (m, J=8.3 Hz, 2H),
7.50-7.63 (m, J=8.3 Hz, 2H), 4.01 (s, 4H), 2.05-2.23 (m, 4H),
1.77-1.88 (m, 2H), 1.63-1.73 (m, 2H).
Step B
4-(1-Hydroxy-4-oxo-cyclohexyl)-benzamide
##STR00200##
[0659] The title compound was prepared as a white solid from the
de-protection of
4-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-benzamide (as prepared
in the previous step) using the procedure described in Step B of
Example 1.
[0660] .sup.1H NMR (MeOH) .delta.: 7.79-7.95 (m, 2H), 7.58-7.68 (m,
2H), 2.94 (td, J=15.3, 6.6 Hz, 2H), 2.31 (s, 4H), 2.12 (s, 2H).
Step C
N-({1-[4-(4-benzamide)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-methy-
l)-3-trifluoromethyl-benzamide
##STR00201##
[0662] The title compounds were prepared as white solids by
reductive amination of 4-(1-hydroxy-4-oxo-cyclohexyl)-benzamide (as
prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0663] 55a: Less Polar Isomer from Silica Gel Column
[0664] .sup.1H NMR (CHLOROFORM-d) .delta.: 8.18 (d, J=9.9 Hz, 1H),
8.10 (d, J=7.8 Hz, 1H), 7.71-7.81 (m, 2H), 7.47-7.66 (m, 2H),
6.89-7.09 (m, 2H), 4.29 (dd, J=16.7, 5.8 Hz, 1H), 4.12 (q, J=7.1
Hz, 2H), 3.99 (d, J=6.3 Hz, 2H), 3.66 (d, J=4.3 Hz, 2H), 2.62-2.78
(m, 1H), 2.07-2.25 (m, 2H), 1.99-2.06 (m, 2H), 1.81 (br. s., 2H),
1.70 (d, J=11.1 Hz, 2H).
[0665] 55b: More Polar Isomer from Silica Gel Column
[0666] .sup.1H NMR (CHLOROFORM-d) .delta.: 8.08-8.17 (m, 1H),
7.93-8.07 (m, 1H), 7.77 (d, J=5.8 Hz, 2H), 7.55-7.65 (m, 2H), 7.40
(br. s., 1H), 6.78-6.91 (m, 1H), 4.44 (br s, 1H), 4.06-4.15 (m,
2H), 3.58 (t, J=7.7 Hz, 2H), 2.26-2.38 (m, 1H), 2.10-2.24 (m, 2H),
1.73 (t, J=4.9 Hz, 2H), 1.63 (d, J=3.5 Hz, 2H), 1.26-1.33 (m,
4H).
Example 56
N-({1-[4-Hydroxy-4-(2-methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
Step A
8-(2-Methoxy-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00202##
[0668] The title compound was prepared as a white solid from
2-bromoanisole (Aldrich) and 1,4-dioxa-spiro[4.5]decan-8-one using
the procedure described in Step A of Example 1.
[0669] .sup.1H NMR (CHLOROFORM-d) .delta.: 7.31 (dd, J=7.7, 1.6 Hz,
1H), 7.19-7.26 (m, 1H), 6.89-6.98 (m, 2H), 3.96 (dd, J=6.7, 4.2 Hz,
4H), 3.89 (s, 3H), 2.50 (t, J=7.1 Hz, 2H), 2.13-2.26 (m, 2H),
2.05-2.12 (m, 4H), 2.00 (t, J=7.1 Hz, 2H).
Step B
4-Hydroxy-4-(2-methoxy-phenyl)-cyclohexanone
##STR00203##
[0671] The title compound was prepared as a white solid from the
de-protection of
8-(2-methoxy-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (as prepared in
the previous step) using the procedure described in Step B of
Example 1.
[0672] .sup.1H NMR (CHLOROFORM-d) .delta.: 7.32 (dd, J=8.0, 1.6 Hz,
1H), 7.26 (td, J=7.8, 1.5 Hz, 1H), 6.91-7.00 (m, 2H), 3.89 (s, 3H),
2.80-3.02 (m, 2H), 2.19-2.39 (m, 6H).
Step C
N-({1-[4-Hydroxy-4-(2-methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}--
methyl)-3-trifluoromethyl-benzamide
##STR00204##
[0674] The title compound was prepared as a white solid by
reductive amination of 4-hydroxy-4-(2-methoxy-phenyl)-cyclohexanone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0675] 56a: Less Polar Isomer from Silica Gel Column
[0676] .sup.1H NMR (CHLOROFORM-d) .delta.: 8.11 (s, 1H), 8.00 (d,
J=7.8 Hz, 1H), 7.76 (d, J=7.8 Hz, 1H), 7.60 (t, J=4.8 Hz, 1H), 7.55
(t, J=7.8 Hz, 1H), 7.31 (d, J=7.6 Hz, 1H), 7.14-7.26 (m, 1H),
6.82-7.01 (m, 1H), 4.38-4.62 (m, 1H), 4.12-4.25 (m, 4H), 2.85 (t,
J=6.9 Hz, 3H), 2.25 (t, J=3.7 Hz, 1H), 2.08-2.22 (m, 2H), 1.81-1.96
(m, 4H), 1.75 (d, J=13.1 Hz, 2H), 1.34-1.49 (m, 2H).
[0677] 56b: More Polar Isomer from Silica Gel Column
[0678] .sup.1H NMR (CHLOROFORM-d) .delta.: 8.13 (s, 1H), 8.03 (d,
J=7.8 Hz, 1H), 7.77 (d, J=7.6 Hz, 1H), 7.58 (t, J=7.8 Hz, 1H), 7.36
(t, J=5.1 Hz, 1H), 7.17-7.31 (m, 2H), 6.90-7.01 (m, 1H), 4.26 (d,
J=5.8 Hz, 1H), 4.20 (dd, J=12.1, 5.1 Hz, 2H), 3.78 (dd, J=11.1, 4.0
Hz, 2H), 3.06 (dd, J=12.6, 5.6 Hz, 1H), 2.86-2.80 (m, 3H),
2.41-2.57 (m, 2H), 2.10 (d, J=12.9 Hz, 2H), 1.91 (d, J=11.1 Hz,
2H), 1.81 (d, J=11.4 Hz, 2H), 1.74 (d, J=19.2 Hz, 2H).
Example 57
N-({1-[4-(3-Fluoro-4-methoxy-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylca-
rbamoyl}-methyl)-3-trifluoromethyl-benzamide
Step A
8-(3-Fluoro-4-methoxy-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00205##
[0680] The title compound was prepared as a white solid from
4-bromo-2-fluoro-anisole (Aldrich) and
1,4-dioxa-spiro[4.5]decan-8-one using the procedure described in
Step A of Example 1.
[0681] .sup.1H NMR (MeOH) .delta.: 7.05-7.11 (m, 2H), 6.86-6.98 (m,
1H), 3.86 (s, 4H), 3.74 (s, 3H), 1.86-2.01 (m, 4H), 1.60-1.68 (m,
2H), 1.47-1.57 (m, 2H).
Step B
4-(3-Fluoro-4-methoxy-phenyl)-4-hydroxy-cyclohexanone
##STR00206##
[0683] The title compound was prepared as a white solid from the
de-protection of
8-(3-fluoro-4-methoxy-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0684] .sup.1H NMR (MeOH) .delta.: 7.21 (d, J=2.3 Hz, 1H),
7.12-7.19 (m, 1H), 6.94 (t, J=8.6 Hz, 1H), 3.21 (s, 3H), 2.76 (d,
J=6.3 Hz, 2H), 2.06-2.23 (m, 4H), 1.98 (d, J=6.6 Hz, 2H).
Step C
N-({1-[4-(3-Fluoro-4-methoxy-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylca-
rbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00207##
[0686] The title compound was prepared as a white solid by
reductive amination of 4-hydroxy-4-(4-hydroxy-phenyl)-cyclohexanone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0687] 57a: Less Polar Isomer from Silica Gel Column
[0688] .sup.1H NMR (MeOH) .delta.: 8.12 (s, 1H), 7.97-8.09 (m, 1H),
7.77 (d, J=7.1 Hz, 1H), 7.53-7.65 (m, 1H), 7.11-7.22 (m, 2H),
6.86-6.98 (m, 1H), 4.53 (br s, 1H), 4.38 (t, J=7.1 Hz, 2H), 3.75
(s, 3H), 3.57 (t, J=7.7 Hz, 2H), 2.88 (t, J=7.6 Hz, 2H), 2.27 (br.
s., 1H), 1.98-2.17 (m, 2H), 1.66-1.82 (m, 2H), 1.41 (d, J=17.9 Hz,
2H), 1.21-1.34 (m, 2H).
[0689] 57b: More Polar Isomer from Silica Gel Column
[0690] .sup.1H NMR (MeOH) .delta.: 8.13 (s, 1H), 8.06 (d, J=7.8 Hz,
1H), 7.77 (d, J=7.8 Hz, 1H), 7.60 (t, J=7.8 Hz, 1H), 7.03-7.21 (m,
2H), 6.85-7.00 (m, 1H), 4.30 (s, 1H), 3.89-4.07 (m, 4H), 3.74 (s,
3H), 3.60 (d, J=6.1 Hz, 2H), 2.92 (dd, J=12.9, 4.5 Hz, 1H),
2.71-2.85 (m, 2H), 2.61 (br. s., 2H), 1.57-1.82 (m, 2H), 1.18-1.37
(m, 2H).
Example 58
N-({1-[4-(3-Amino-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
Step A
[3-(8-Hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-phenyl]-carbamic acid
tert-butyl ester
##STR00208##
[0692] The title compound was prepared as a white solid from
N-Boc-3-bromoanaline (Aldrich) and 1,4-dioxa-spiro[4.5]decan-8-one
using the procedure described in Step A of Example 1.
[0693] .sup.1H NMR (MeOH) .delta.: 7.54 (s, 1H), 7.26-7.32 (m, 1H),
7.23 (t, J=7.8 Hz, 1H), 7.10-7.19 (m, 1H), 3.99 (s, 4H), 2.00-2.21
(m, 4H), 1.78 (d, J=11.4 Hz, 2H), 1.66 (d, J=10.9 Hz, 2H), 1.54 (s,
9H).
Step B
[3-(1-Hydroxy-4-oxo-cyclohexyl)-phenyl]-carbamic acid tert-butyl
ester
##STR00209##
[0695] The title compound was prepared as a white solid from the
de-protection of
[3-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-phenyl]-carbamic acid
tert-butyl ester (as prepared in the previous step) using the
procedure described in Step B of Example 1.
[0696] .sup.1H NMR (MeOH) .delta.: 7.61 (s, 1H), 7.14-7.41 (m, 3H),
2.88 (d, J=8.8 Hz, 2H), 2.22-2.32 (m, 2H), 2.17 (s, 2H), 2.06-2.15
(m, 2H), 1.54 (s, 9H).
Step C
[3-(1-Hydroxy-4-{3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azetid-
in-1-yl}-cyclohexyl)-phenyl]-carbamic acid tent-butyl ester
##STR00210##
[0698] The title compound was prepared as a white solid by
reductive amination of
[3-(1-hydroxy-4-oxo-cyclohexyl)-phenyl]-carbamic acid tert-butyl
ester (as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
Less Polar Isomer from Silica Gel Column
[0699] .sup.1H NMR (MeOH) .delta.: 8.24 (s, 1H), 8.16 (d, J=8.3 Hz,
1H), 7.89 (d, J=8.6 Hz, 1H), 7.68-7.77 (m, 1H), 7.53-7.63 (m, 1H),
7.16-7.36 (m, 3H), 4.66 (br s., 1H), 4.48 (t, J=7.1 Hz, 2H), 3.67
(t, J=7.6 Hz, 2H), 2.99 (t, J=7.7 Hz, 2H), 2.37 (br. s., 1H),
2.23-2.32 (m, 2H), 1.80-1.93 (m, 2H), 1.58-1.67 (m, 2H), 1.52 (s,
9H), 1.32-1.46 (m, 2H).
More Polar Isomer from Silica Gel Column
[0700] .sup.1H NMR (MeOH) .delta.: 8.13 (s, 1H), 8.05 (d, J=7.8 Hz,
1H), 7.78 (d, J=8.1 Hz, 1H), 7.60 (t, J=7.8 Hz, 1H), 7.44 (s, 1H),
6.99-7.18 (m, 3H), 4.66 (br s, 1H), 4.42 (t, J=7.2 Hz, 2H), 3.75
(t, J=8.2 Hz, 2H), 2.32-2.44 (m, 1H), 2.22 (br s, 2H), 1.79-1.85
(m, 2H), 1.60-1.68 (m, 4H), 1.45-1.59 (m, 2H), 1.42 (s, 9H).
Step D
N-({1-[4-(3-Amino-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
##STR00211##
[0702] To a solution of
[3-(1-Hydroxy-4-{3-[2-(3-trifluoromethyl-benzoylamino)-acetylamino]-azeti-
din-1-yl}-cyclohexyl)-phenyl]-carbamic acid tert-butyl ester (as
prepared in the previous step, 25 mg) in DCM (1 mL) was added 4N
HCl (200 .mu.L). The reaction was stirred at RT and concentrated in
vacuo resulting in the title compound.
[0703] 58a: From Less Polar Isomer of Step C
[0704] .sup.1H NMR (MeOH) .delta.: 8.16 (s, 1H), 8.09 (d, J=7.8 Hz,
1H), 7.81 (d, J=7.8 Hz, 1H), 7.64 (t, J=7.8 Hz, 1H), 6.97-7.05 (m,
1H), 6.88 (t, J=1.9 Hz, 1H), 6.78-6.86 (m, 1H), 6.55 (d, J=10.1 Hz,
1H), 3.95-4.00 (m, 1H), 3.56-3.64 (m, 4H), 2.92 (t, J=7.7 Hz, 2H),
2.30 (d, J=3.8 Hz, 1H), 2.12-2.25 (m, 2H), 1.73-1.84 (m, 2H),
1.40-1.53 (m, 2H), 1.26-1.40 (m, 2H).
[0705] 58b: From More Polar Isomer of Step C
[0706] .sup.1H NMR (MeOH) .delta.: 8.14 (s, 1H), 8.08 (d, J=7.8 Hz,
1H), 7.79 (d, J=7.8 Hz, 1H), 7.62 (t, J=7.7 Hz, 1H), 7.49-7.57 (m,
2H), 7.38-7.48 (m, 1H), 7.18 (d, J=7.8 Hz, 1H), 4.20 (br s, 1H),
3.39 (br. s., 4H), 2.92 (t, J=7.7 Hz, 2H), 2.30 (d, J=3.8 Hz, 1H),
1.65-1.95 (m, 8H).
Example 59
N-{[1-(4-Hydroxy-4-p-tolyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-t-
rifluoromethyl-benzamide
Step A
8-p-Tolyl-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00212##
[0708] The title compound was prepared as a white solid from
4-bromotoluene (Aldrich) and 1,4-dioxa-spiro[4.5]decan-8-one using
the procedure described in Step A of Example 1. .sup.1H NMR (MeOH)
.delta.: 7.31-7.45 (m, J=8.3 Hz, 2H), 7.09-7.21 (m, J=8.1 Hz, 2H),
3.99 (s, 4H), 2.32 (s, 3H), 1.96-2.18 (m, 4H), 1.77 (d, J=11.4 Hz,
2H), 1.59-1.71 (m, 2H).
Step B
4-Hydroxy-4-p-tolyl-cyclohexanone
##STR00213##
[0710] The title compound was prepared as a white solid from the
de-protection of 8-p-tolyl-1,4-dioxa-spiro[4.5]decan-8-ol (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0711] .sup.1H NMR (MeOH) .delta.: 7.44 (d, J=8.1 Hz, 2H), 7.17 (d,
J=7.8 Hz, 2H), 2.81-2.97 (m, 3H), 2.22-2.38 (m, 4H), 2.11 (dd,
J=14.3, 3.2 Hz, 2H).
Step C
N-{[1-(4-Hydroxy-4-p-tolyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-t-
rifluoromethyl-benzamide
##STR00214##
[0713] The title compound was prepared as a white solid by
reductive amination of 4-hydroxy-4-p-tolyl-cyclohexanone (as
prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0714] .sup.1H NMR (MeOH) .delta.: 8.19-8.29 (m, 1H), 8.09-8.17 (m,
1H), 7.82-7.93 (m, 1H), 7.71 (t, J=7.2 Hz, 1H), 7.38-7.51 (m, 2H),
7.11-7.25 (m, 2H), 4.08-4.14 (m, 1H), 4.01-4.08 (m, 2H), 3.67 (t,
J=7.7 Hz, 2H), 2.89-3.06 (m, 2H), 2.35 (d, J=8.1 Hz, 1H), 2.32 (s,
3H), 2.14-2.30 (m, 2H), 2.03 (s, 2H), 1.76-1.93 (m, 2H), 1.43-1.65
(m, 2H).
Example 60
N-{[1-(4-Hydroxy-4-m-tolyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-t-
rifluoromethyl-benzamide
Step A
8-m-Tolyl-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00215##
[0716] The title compound was prepared as a white solid from
3-bromotoluene (Aldrich) and 1,4-dioxa-spiro[4.5]decan-8-one using
the procedure described in Step A of Example 1.
[0717] .sup.1H NMR (MeOH) .delta.: 7.33 (s, 1H), 7.28 (d, J=7.8 Hz,
1H), 7.20 (t, J=7.7 Hz, 1H), 7.04 (d, J=7.3 Hz, 1H), 3.98 (s, 4H),
2.06-2.20 (m, 4H), 1.97-2.06 (m, 3H), 1.76 (d, J=11.4 Hz, 2H), 1.66
(d, J=10.6 Hz, 2H).
Step B
4-Hydroxy-4-m-tolyl-cyclohexanone
##STR00216##
[0719] The title compound was prepared as a white solid from the
de-protection of 8-m-tolyl-1,4-dioxa-spiro[4.5]decan-8-ol (as
prepared in the previous step) using the procedure described in
Step B of Example 1.
[0720] .sup.1H NMR (MeOH) .delta.: 7.39 (s, 1H), 7.33 (s, 1H), 7.23
(t, J=7.6 Hz, 1H), 7.07 (d, J=7.6
[0721] Hz, 1H), 2.90 (d, J=6.3 Hz, 2H), 2.70 (s, 3H), 2.34-2.39 (m,
4H), 2.24-2.33 (m, 2H), 2.06-2.16 (m, 2H).
Step C
N-{[1-(4-Hydroxy-4-m-tolyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-t-
rifluoromethyl-benzamide
##STR00217##
[0723] The title compound was prepared as a white solid by
reductive amination of 4-hydroxy-4-m-tolyl-cyclohexanone (as
prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0724] .sup.1H NMR (MeOH) .delta.: 8.25 (s, 1H), 8.18 (d, J=7.8 Hz,
1H), 7.89 (d, J=8.3 Hz, 1H), 7.69-7.78 (m, 1H), 7.32 (s, 1H), 7.27
(d, J=7.8 Hz, 1H), 7.19 (t, J=7.6 Hz, 1H), 7.03 (d, J=7.3 Hz, 1H),
4.21 (br s, 1H), 3.72 (d, J=6.8 Hz, 4H), 2.96-3.05 (m, 2H),
2.77-2.94 (m, 1H), 2.35 (s, 3H), 1.87 (d, J=13.6 Hz, 4H), 1.67-1.83
(m, 4H).
Example 61
N-({1-[4-Hydroxy-4-(3-methanesulfonylamino-phenyl)-cyclohexyl]-azetidin-3--
ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00218##
[0726] The title compound was prepared as a white solid by
mesylation of
N-({1-[4-(3-amino-phenyl)-4-hydroxy-cyclohexyl]-azetidin-3-ylcarbamoyl}-m-
ethyl)-3-trifluoromethyl-benzamide (as prepared in Example 58)
using the procedure described in Example 16.
[0727] ESI-MS (m/z): Calcd. For
C.sub.26H.sub.31F.sub.3N.sub.4O.sub.5S, 568; found: 569 (M+H).
Example 62
N-({1-[4-(1,3-Dimethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-4-hydroxy--
cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
Step A
5-(8-Hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-1,3-dimethyl-1,3-dihydro-benzoi-
midazol-2-one
##STR00219##
[0729] The title compound was prepared as a white solid from
5-bromo-1,3-dimethyl-1,3-dihydro-benzoimidazol-2-one (prepared by
methylation of 5-bromo-1,3-dihydro-benzoimidazol-2-one from
Pharmlab) and 1,4-dioxa-spiro[4.5]decan-8-one using the procedure
described in Step A of Example 1.
[0730] .sup.1H NMR (MeOH) .delta.: 7.21-7.36 (m, 2H), 7.03 (d,
J=8.1 Hz, 1H), 4.02 (br s, 4H), 3.43 (d, J=9.1 Hz, 6H), 2.08-2.33
(m, 4H), 1.83 (d, J=10.1 Hz, 2H), 1.70 (d, J=9.6 Hz, 2H)
Step B
5-(1-Hydroxy-4-oxo-cyclohexyl)-1,3-dimethyl-1,3-dihydro-benzoimidazol-2-on-
e
##STR00220##
[0732] The title compound was prepared as a white solid from the
de-protection of
5-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-1,3-dimethyl-1,3-dihydro-benzo-
imidazol-2-one (as prepared in the previous step) using the
procedure described in Step B of Example 1.
[0733] .sup.1H NMR (CHLOROFORM-d) .delta.: 7.21 (dd, J=8.1, 1.8 Hz,
1H), 7.16 (d, J=1.5 Hz, 1H), 6.88 (d, J=8.1 Hz, 1H), 3.42 (d, J=3.5
Hz, 3H), 3.34 (d, J=5.8 Hz, 3H), 2.89-3.05 (m, 2H), 2.38 (d, J=16.7
Hz, 2H), 2.27 (d, J=3.5 Hz, 4H)
Step C
N-({1-[4-(1,3-Dimethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-4-hydroxy--
cyclohexyl]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00221##
[0735] The title compound was prepared as a white solid by
reductive amination of
5-(1-hydroxy-4-oxo-cyclohexyl)-1,3-dimethyl-1,3-dihydro-benzoimidazol-2-o-
ne (as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0736] .sup.1H NMR (MeOH) .delta.: 8.12 (s, 1H), 8.04 (d, J=7.8 Hz,
1H), 7.77 (d, J=7.8 Hz, 1H), 7.59 (t, J=7.8 Hz, 1H), 7.25 (s, 1H),
7.04-7.14 (m, 1H), 6.95-7.02 (m, 1H), 4.40 (t, J=7.1 Hz, 1H),
3.89-3.95 (m, 2H), 3.59 (t, J=7.8 Hz, 2H), 3.30 (s, 6H), 2.88 (t,
J=7.7 Hz, 2H), 2.26-2.36 (m, 1H), 2.08-2.22 (m, 2H), 1.74-1.83 (m,
2H), 1.42-1.52 (m, 2H), 1.33 (dd, J=13.5, 4.9 Hz, 2H).
Example 63
N-({1-[4-Hydroxy-4-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-5-yl)-cyclohexy-
l]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
Step A
5-(8-Hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-3-methyl-3H-benzooxazol-2-one
##STR00222##
[0738] The title compound was prepared as a white solid from
5-bromo-3-methyl-3H-benzooxazol-2-one (prepared by methylation of
5-bromo-3H-benzooxazol-2-one from Aldrich) and
1,4-dioxa-spiro[4.5]decan-8-one using the procedure described in
Step A of Example 1.
[0739] .sup.1H NMR (CHLOROFORM-d) .delta.: 7.23-7.31 (m, 1H), 7.18
(s, 1H), 7.07-7.14 (m, 1H), 3.99 (s, 4H), 3.43 (s, 3H), 2.04-2.22
(m, 4H), 1.83 (d, J=10.1 Hz, 2H), 1.70 (d, J=9.3 Hz, 2H)
Step B
5-(1-Hydroxy-4-oxo-cyclohexyl)-3-methyl-3H-benzooxazol-2-one
##STR00223##
[0741] The title compound was prepared as a white solid from the
de-protection of
5-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-3-methyl-3H-benzooxazol-2-one
(as prepared in the previous step) using the procedure described in
Step B of Example 1.
[0742] .sup.1H NMR (MeOH) .delta.: 7.31-7.38 (m, 2H), 7.20 (d,
J=8.3 Hz, 1H), 3.43 (s, 3H), 2.84-3.01 (m, 2H), 2.24-2.44 (m, 4H),
2.15 (d, J=11.9 Hz, 2H)
Step C
N-({1-[4-Hydroxy-4-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-5-yl)-cyclohexy-
l]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00224##
[0744] The title compound was prepared as a white solid by
reductive amination of
5-(1-hydroxy-4-oxo-cyclohexyl)-3-methyl-3H-benzooxazol-2-one (as
prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0745] 63a: Less Polar Isomer from Silica Gel Column
[0746] .sup.1H NMR (MeOH) .delta.: 8.23 (s, 1H), 8.16 (d, J=7.8 Hz,
1H), 7.87 (d, J=7.8 Hz, 1H), 7.70 (t, J=7.8 Hz, 1H), 7.38 (s, 2H),
7.18 (d, J=9.1 Hz, 1H), 4.52 (quin, J=7.1 Hz, 1H), 4.00-4.07 (m,
2H), 3.71 (t, J=7.7 Hz, 2H), 3.42 (s, 3H), 2.98 (t, J=7.8 Hz, 2H),
2.22 (t, J=10.6 Hz, 1H), 1.99-2.06 (m, 2H), 1.84-1.94 (m, 2H),
1.43-1.57 (m, 4H).
[0747] 63b: More Polar Isomer from Silica Gel Column
[0748] .sup.1H NMR (MeOH) .delta.: 8.24 (s, 1H), 8.17 (d, J=7.8 Hz,
1H), 7.88 (d, J=8.1 Hz, 1H), 7.71 (t, J=7.8 Hz, 1H), 7.24-7.35 (m,
2H), 7.18 (d, J=8.6 Hz, 1H), 4.50 (t, J=7.1 Hz, 1H), 4.07 (s, 2H),
3.71 (t, J=7.8 Hz, 2H), 3.41 (s, 3H), 3.10 (t, J=7.8 Hz, 2H),
2.19-2.34 (m, 1H), 1.78-1.93 (m, 4H), 1.67-1.76 (m, 2H), 1.50-1.67
(m, 2H)
Example 64
N-({1-[4-Hydroxy-4-(3-methyl-3H-benzoimidazol-5-yl)-cyclohexyl]-azetidin-3-
-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
Step A
8-(3-Methyl-3H-benzoimidazol-5-yl)-1,4-dioxa-spiro[4.5]decan-8-ol
##STR00225##
[0750] The title compound was prepared as a white solid from
5-bromo-1-methyl-1H-benzoimidazole (prepared by methylation of
5-bromo-1H-benzoimidazole) and 1,4-dioxa-spiro[4.5]decan-8-one
using the procedure described in Step A of Example 1.
[0751] .sup.1H NMR (MeOH) .delta.: 7.85 (s, 1H), 7.70 (s, 1H), 7.62
(d, J=8.6 Hz, 1H), 7.45 (d, J=8.6 Hz, 1H), 3.91 (d, J=5.3 Hz, 4H),
3.33 (d, J=5.1 Hz, 3H), 2.17-2.32 (m, 2H), 2.07-2.17 (m, 2H), 1.85
(d, J=12.1 Hz, 2H), 1.69 (d, J=15.7 Hz, 2H)
Step B
4-Hydroxy-4-(3-methyl-3H-benzoimidazol-5-yl)-cyclohexanone
##STR00226##
[0753] The title compound was prepared as a white solid from the
de-protection of
8-(3-methyl-3H-benzoimidazol-5-yl)-1,4-dioxa-spiro[4.5]decan-8-ol
(as prepared in the previous step) using the procedure described in
Step B of Example 1.
[0754] .sup.1H NMR (MeOH) .delta.: 7.66 (s, 1H), 7.53 (d, J=8.6 Hz,
1H), 7.37-7.47 (m, 2H), 3.80 (d, J=6.6 Hz, 4H), 3.20 (s, 3H),
2.76-2.90 (m, 2H), 2.25-2.40 (m, 2H), 2.21 (d, J=17.4 Hz, 2H), 2.07
(d, J=12.6 Hz, 2H).
Step C
N-({1-[4-Hydroxy-4-(3-methyl-3H-benzoimidazol-5-yl)-cyclohexyl]-azetidin-3-
-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00227##
[0756] The title compound was prepared as a white solid by
reductive amination of
4-hydroxy-4-(3-methyl-3H-benzoimidazol-5-yl)-cyclohexanone (as
prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0757] .sup.1H NMR (MeOH) .delta.: 8.24 (s, 1H), 8.16 (d, J=7.8 Hz,
1H), 8.10 (s, 1H), 7.83-7.94 (m, 1H), 7.67-7.79 (m, 1H), 7.49-7.67
(m, 2H), 4.50 (t, J=8.6 Hz, 1H), 4.03-4.09 (m, 2H), 3.85-3.95 (m,
2H), 3.33 (s, 3H), 2.96-3.04 (m, 1H), 2.40 (d, J=7.3 Hz, 2H),
2.28-2.37 (m, 2H), 1.89-1.98 (m, 2H), 1.57-1.71 (m, 2H), 1.36-1.53
(m, 2H).
Example 65
N-({1-[4-(3-Ethyl-2-oxo-2,3-dihydro-benzooxazol-5-yl)-4-hydroxy-cyclohexyl-
]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
Step A
3-Ethyl-5-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-3H-benzooxazol-2-one
##STR00228##
[0759] The title compound was prepared as a white solid from
5-bromo-3-ethyl-3H-benzooxazol-2-one (prepared by ethylation of
5-bromo-3H-benzooxazol-2-one) and 1,4-dioxa-spiro[4.5]decan-8-one
using the procedure described in Step A of Example 1. .sup.1H NMR
(MeOH) .delta.: 7.37 (s, 1H), 7.31 (dd, J=8.3, 1.8 Hz, 1H), 7.21
(d, J=8.3 Hz, 1H), 3.99-4.04 (m, 3H), 3.94 (q, J=7.3 Hz, 2H), 3.33
(dt, J=3.1, 1.6 Hz, 4H), 2.04-2.24 (m, 4H), 1.79 (d, J=11.9 Hz,
2H), 1.68 (d, J=11.4 Hz, 2H)
Step B
3-Ethyl-5-(1-hydroxy-4-oxo-cyclohexyl)-3H-benzooxazol-2-one
##STR00229##
[0761] The title compound was prepared as a white solid from the
de-protection of
3-ethyl-5-(8-hydroxy-1,4-dioxa-spiro[4.5]dec-8-yl)-3H-benzooxazol-2-one
using the procedure described in Step B of Example 1.
[0762] ESI-MS (m/z): Calcd. For C.sub.15H.sub.17NO.sub.4: 275.1;
found: 276.2 (M+H).
Step C
N-({1-[4-(3-Ethyl-2-oxo-2,3-dihydro-benzooxazol-5-yl)-4-hydroxy-cyclohexyl-
]-azetidin-3-ylcarbamoyl}-methyl)-3-trifluoromethyl-benzamide
##STR00230##
[0764] The title compound was prepared as a white solid by
reductive amination of
3-ethyl-5-(1-hydroxy-4-oxo-cyclohexyl)-3H-benzooxazol-2-one (as
prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0765] 65a: Less Polar Isomer from Silica Gel Column
[0766] .sup.1H NMR (MeOH) .delta.: 8.24 (s, 1H), 8.16 (d, J=7.8 Hz,
1H), 7.87 (d, J=7.8 Hz, 1H), 7.70 (t, J=8.0 Hz, 1H), 7.42 (s, 1H),
7.38 (d, J=6.6 Hz, 1H), 7.19 (d, J=8.6 Hz, 1H), 4.47-4.60 (m, 1H),
4.07 (br s, 2H), 3.93 (q, J=7.2 Hz, 2H), 3.71 (t, J=7.7 Hz, 2H),
2.98 (t, J=7.8 Hz, 2H), 2.40-2.49 (m, 1H), 2.15-2.31 (m, 2H),
1.80-1.94 (m, 2H), 1.44-1.59 (m, 4H), 1.37 (t, J=7.2 Hz, 3H).
[0767] 65b: More Polar Isomer from Silica Gel Column
[0768] .sup.1H NMR (MeOH) .delta.: 8.25 (s, 1H), 8.17 (d, J=7.8 Hz,
1H), 7.89 (d, J=7.8 Hz, 1H), 7.72 (t, J=7.8 Hz, 1H), 7.36 (d, J=1.5
Hz, 1H), 7.28 (dd, J=8.3, 1.8 Hz, 1H), 7.20 (d, J=8.6 Hz, 1H), 4.50
(quin, J=7.1 Hz, 1H), 4.07 (s, 2H), 3.93 (q, J=7.3 Hz, 2H), 3.72
(t, J=7.8 Hz, 2H), 3.10 (t, J=7.8 Hz, 2H), 2.23-2.35 (m, 1H),
1.78-1.92 (m, 4H), 1.70-1.78 (m, 2H), 1.55-1.68 (m, 2H), 1.37 (t,
J=7.2 Hz, 3H).
Example 66
2-Fluoro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-tri-
fluoromethyl-benzamide
Step A
[1-(4-Phenyl-cyclohexyl)-azetidin-3-yl]-carbamic acid tert-butyl
ester
##STR00231##
[0770] The title compound was prepared as a white solid by
reductive amination of 4-phenyl-cyclohexanone and
azetidin-3-yl-carbamic acid tert-butyl ester using the procedure
described in Step D of Example 1.
Less Polar Fraction from Silica Gel Column Collected
[0771] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.23 (m, 4H), 7.15
(t, J=6.5 Hz, 1H), 4.90 (s, br, 1H), 4.28 (s, br, 1H), 3.55 (t,
J=6.4 Hz, 2H), 2.75 (s, br, 1H), 2.43 (m, 1H), 1.85 (m 2H), 1.71
(d, J=7.5 Hz, 2H), 1.64 (d, J=7.4 Hz, 2H), 1.55 (m, 2H), 1.53 (s,
9H).
Step B
(4-Phenyl-cyclohexyl)-azetidin-3-ylamine TFA salt
##STR00232##
[0773] The title compound was prepared as colorless oil from the
TFA de-protection of
[1-(4-phenyl-cyclohexyl)-azetidin-3-yl]-carbamic acid tert-butyl
ester (as prepared in the previous step) using the procedure
described in Step E of Example 1.
[0774] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.23 (m, 4H), 7.15
(m, 1H), 3.60 (t, J=6.5 Hz, 2H), 3.15 (m, 1H), 2.55 (t, J=6.5 Hz,
2H), 2.35 (m, 1H), 2.21 (m, 1H), 1.85 (m, 2H), 1.70 (m, 2H), 1.65
(m, 2H), 1.48 (m, 2H).
Step C
{[1-(4-Phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-carbamic
acid tert-butyl ester
##STR00233##
[0776] The title compound was prepared as a white solid from the
EDCI coupling of (4-phenyl-cyclohexyl)-azetidin-3-ylamine TFA salt
(as prepared in the previous step) and
tert-butoxycarbonylamino-acetic acid (Aldrich) using the procedure
described in Step F of Example 1.
[0777] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.25 (m, 4H), 7.18
(m, 1H), 5.21 (s, br, 1H), 4.52 (m, 1H), 4.05 (t, J=4.2 Hz, 2H),
3.58 (t, J=6.5 Hz, 2H), 2.80 (t, J=6.5 Hz, 2H), 2.60 (m, 1H), 2.33
(m 1H), 1.92 (m, 2H), 1.72 (m, 2H), 1.58 (m, 2H), 1.50 (m, 2H),
1.47 (s, 9H).
Step D
2-Amino-N-[1-(4-phenyl-cyclohexyl)-azetidin-3-yl]-acetamide TFA
salt
##STR00234##
[0779] The title compound was prepared as colorless oil from the
TFA de-protection of
{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-carbamic
acid tert-butyl ester (as prepared in the previous step) using the
procedure described in step E of Example 1. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta.: 7.00-7.29 (m, 5H), 4.51 (br. s., 1H), 4.27
(br. s., 2H), 4.03 (br. s., 2H), 3.84 (br. s., 2H), 3.31-3.57 (m,
1H), 2.53 (br. s., 1H), 1.84 (br. s., 4H), 1.71 (br. s., 4H)
Step E
2-Fluoro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-tri-
fluoromethyl-benzamide
##STR00235##
[0781] The title compound was prepared as a white solid from the
EDCI coupling of
2-amino-N-[1-(4-phenyl-cyclohexyl)-azetidin-3-yl]-acetamide TFA
salt (as prepared in the previous step) and
2-fluoro-5-trifluoromethyl-benzoic acid (Aldrich) using the
procedure described in Step F of Example 1.
[0782] ESI-MS (m/z): Calcd. for
C.sub.25H.sub.27F.sub.4N.sub.3O.sub.2, 477; found: 478 (M+H).
Example 67
4-Methoxy-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-tr-
ifluoromethyl-benzamide
##STR00236##
[0784] The title compound was prepared as a white solid from EDCI
coupling of
2-amino-N-[1-(4-phenyl-cyclohexyl)-azetidin-3-yl]-acetamide TFA
salt (as prepared in Step D of Example 66) and
4-methoxy-3-trifluoromethyl-benzoic acid (Aldrich) using the
procedure described in Step F of Example 1.
[0785] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (s, 1H), 8.02
(d, J=6.5 Hz, 1H), 7.25 (m, 4H), 7.16 (t, J=5.3 Hz, 1H), 7.01 (d,
J=6.0 Hz, 1H), 4.55 (m, 1H), 4.15 (d, J=3.5 Hz, 2H), 3.95 (s, 3H),
3.65 (t, J=3.1 Hz, 2H), 2.90 (t, J=3.6 Hz, 2H), 2.65 (m, 1H), 2.45
(m, 1H), 1.90 (m, 2H), 1.75 (m, 2H), 1.50 (m, 4H).
Example 68
2-Methoxy-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-tr-
ifluoromethyl-benzamide
##STR00237##
[0787]
2-Fluoro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl-
}-5-trifluoromethyl-benzamide (as prepared in Example 66, 50 mg,
0.11 mmol) was treated with NaOMe (0.5 M in MeOH, 600 .mu.L, 0.30
mmol) in MeOH (1 mL) at room temperature overnight. The solvent was
removed and the residue was purified on a silica gel column using a
CombiFlash.RTM. system using ethyl acetate and 7N NH.sub.3 in MeOH
as eluent (from pure ethyl acetate to 5% 7N NH.sub.3 in MeOH in
ethyl acetate) to afford the title compound as a white solid.
[0788] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.40 (s, 1H), 8.3
(d, J=5.2 Hz, 1H), 7.30 (m, 4H), 7.20 (m, 1H), 7.08 (d, J=6.2 Hz,
1H), 4.55 (m, 1H), 4.15 (d, J=4.5 Hz, 2H), 4.01 (s, 3H), 3.68 (m,
2H), 2.50 (m, 1H), 2.21 (s, 1H), 1.90 (m, 2H), 1.78 (m, 2H), 1.66
(m, 2H), 1.55 (m, 4H).
Example 69
2-Dimethylamino-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl-
}-5-trifluoromethyl-benzamide
##STR00238##
[0790]
2-Fluoro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl-
}-5-trifluoromethyl-benzamide (as prepared in Example 66, 50 mg,
0.11 mmol) was treated with dimethyl amine (Aldrich, 40 wt. % in
water, .about.2 mL) in a sealed tube under microwave irradiation at
120.degree. C. for 20 min. The solvent was removed and the residue
was purified on a silica gel column using a CombiFlash.RTM. system
using ethyl acetate and 7N NH.sub.3 in MeOH as eluent (from pure
ethyl acetate to 5% 7N NH.sub.3 in MeOH in ethyl acetate) to afford
the title compound as a white solid.
[0791] ESI-MS (m/z): Calcd. for
C.sub.27H.sub.33F.sub.3N.sub.4O.sub.2, 502; found: 503 (M+H).
Example 70
N-{[1-(4-Phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-2-pyrrolidin-1-
-yl-5-trifluoromethyl-benzamide
##STR00239##
[0793] The title compound was prepared as a white solid from
coupling of
2-fluoro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-tr-
ifluoromethyl-benzamide (as prepared in Example 66) and pyrrolidine
(Aldrich) using the procedure described in Example 69.
[0794] ESI-MS (m/z): Calcd. for
C.sub.29H.sub.35F.sub.3N.sub.4O.sub.2, 528; found: 529 (M+H).
Example 71
4-Fluoro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-tri-
fluoromethyl-benzamide
Step A
3-[2-(4-Fluoro-3-trifluoromethyl-benzoylamino)-acetylamino]-azetidine-1-ca-
rboxylic acid tert-butylester
##STR00240##
[0796] The title compounds were prepared as white solids from the
EDCI coupling of 3-amino-azetidine-1-carboxylic acid tert-butyl
ester (BetaPharma) and
(4-fluoro-3-trifluoromethyl-benzoylamino)-acetic acid (analog
synthesis by the procedure described in Organic Synthesis XII,
40-2, 1932) using the procedure described in Step F of Example
1.
[0797] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (d, J=4.5 Hz,
1H), 8.05 (m, 1H), 7.28 (d, J=5.5 Hz, 1H), 4.62 (m, 1H), 4.25 (t,
J=7.0 Hz, 2H), 4.15 (s, 2H), 3.82 (t, J=6.8 Hz, 2H), 1.35 (s,
9H).
Step B
N-(Azetidin-3-ylcarbamoylmethyl)-4-fluoro-3-trifluoromethyl-benzamide
TFA salt
##STR00241##
[0799] The title compound was prepared as colorless oil from the
TFA de-protection of
3-[2-(4-fluoro-3-trifluoromethyl-benzoylamino)-acetylamino]-azetidine-1-c-
arboxylic acid tert-butylester (as prepared in the previous step)
using the procedure described in Step E of Example 1.
[0800] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.: 8.12-8.29 (m,
1H), 7.54-7.72 (m, 1H), 7.11-7.30 (m, 1H), 4.55 (br s., 1H),
4.06-4.13 (m, 2H), 3.75-4.02 (m, 2H), 3.03-3.15 (m, 2H).
Step C
4-Fluoro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-tri-
fluoromethyl-benzamide
##STR00242##
[0802] The title compound was prepared as a white solid by
reductive amination of 4-phenyl-cyclohexanone (as prepared in the
previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-4-fluoro-3-trifluoromethyl-benzamide
using the procedure described in Step C of Example 4.
[0803] 71a: Less Polar Isomer from Silica Gel Column
[0804] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.28 (d, J=5.8
Hz, 1H), 8.21 (m, 1H), 7.45 (t, J=6.5 Hz, 1H), 7.25 (s, 4H), 7.12
(m, 1H), 4.51 (m, 1H), 4.05 (s, 2H), 3.72 (t, J=6.5 Hz, 2H), 2.98
(t, J=6.0 Hz, 2H), 2.55 (t, J=4.5 Hz, 1H), 2.40 (s, br, 1H), 1.96
(m, 2H), 1.75 (m, 2H), 1.52 (m, 4H).
[0805] 71b: More Polar Isomer from Silica Gel Column
[0806] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.30 (d, J=5.0
Hz, 1H), 8.20 (m, 1H), 7.46 (d, J=6.5 Hz, 1H), 7.28 (m, 4H), 7.10
(m, 1H), 4.46 (m, 1H), 4.05 (s, 2H), 3.68 (t, J=6.5 Hz, 2H), 3.05
(t, J=6.0 Hz, 2H), 2.46 (t, J=4.5 Hz, 1H), 2.22 (t, J=4.0 Hz, 1H),
1.96 (m, 4H), 1.55 (m, 2H), 1.18 (m, 2H).
Example 72
4-(2-Hydroxy-ethylamino)-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoy-
l]-methyl}-3-trifluoromethyl-benzamide
##STR00243##
[0808] The title compound was prepared as a white solid from the
coupling of
4-fluoro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-
-trifluoromethyl-benzamide (as prepared in Example 71) and
2-amino-ethanol (Aldrich) using the procedure described in Example
65.
[0809] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.11 (s, 1H),
7.98 (d, J=6.5 Hz, 1H), 7.38 (d, J=6.5 Hz, 1H), 7.20 (m, 4H), 7.10
(m, 1H), 6.95 (d, J=6.5 Hz, 1H), 4.58 (m, 1H), 4.10 (t, J=7.5 Hz,
2H), 4.05 (s, 2H), 3.85 (t, J=7.2 Hz, 2H), 3.78 (t, J=5.2 Hz, 2H),
3.40 (t, J=6.5 Hz, 2H), 3.22 (t, J=6.0 Hz, 1H), 2.55 (m, 1H), 2.35
(s, br, 1H), 1.86 (m, 4H), 1.62 (m, 4H).
Example 73
4-Nitro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trif-
luoromethyl-benzamide
##STR00244##
[0811] The title compound was prepared as a white solid from EDCI
coupling of
2-amino-N-[1-(4-phenyl-cyclohexyl)-azetidin-3-yl]-acetamide TFA
salt (as prepared in Step D of Example 66) and
4-nitro-3-trifluoromethyl-benzoic acid (Aldrich) using the
procedure described in Step F of Example 1.
[0812] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.01 (s, 1H), 7.78
(d, J=6.6 Hz, 1H), 7.30 (m, 5H), 7.18 (t, J=6.5 Hz, 1H), 6.80 (s,
1H), 6.71 (d, J=6.5 Hz, 1H), 6.55 (s, 1H), 4.52 (m, 1H), 4.10 (s,
2H), 3.60 (t, J=5.1 Hz, 2H), 2.90 (s, br, 2H), 2.55 (m, 1H), 2.30
(s, br, 1H), 1.90 (m, 2H), 1.70 (m, 2H), 1.55 (m, 4H).
Example 74
4-Amino-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trif-
luoromethyl-benzamide
##STR00245##
[0814] The title compound was prepared as a white solid from
hydrogenation of
4-nitro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3--
trifluoromethyl-benzamide (as prepared in Example 73) using the
procedure described in Step G of Example 1.
[0815] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 7.90 (s, 1H),
7.68 (d, J=6.5 Hz, 1H), 7.45 (d, J=6.5 Hz, 1H), 7.20 (m, 5H), 4.58
(m, 1H), 4.05 (s, 2H), 3.75 (t, J=6.5 Hz, 2H), 3.02 (t, J=6.0 Hz,
2H), 2.55 (m, 1H), 2.35 (s, br, 1H), 1.96 (m, 2H), 1.65 (m, 2H),
1.40 (m, 4H).
Example 75
N-{[1-(4-Phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3,5-bis-triflu-
oromethyl-benzamide
Step A
3-[2-(3,5-Bis-trifluoromethyl-benzoylamino)-acetylamino]-azetidine-1-carbo-
xylic acid tent-butyl ester
##STR00246##
[0817] The title compounds were prepared as white solids from the
EDCI coupling between 3-amino-azetidine-1-carboxylic acid
tert-butyl ester and (3,5-bistrifluoromethyl-benzoylamino)-acetic
acid (analog synthesis by following the procedure on Organic
Synthesis XII, 40-2, 1932) using the procedure described in Step F
of Example 1. ESI-MS (m/z): Calcd. For
C.sub.19H.sub.21F.sub.6N.sub.3O.sub.4, 469; found: 470 (M+H).
Step B
N-(Azetidin-3-ylcarbamoylmethyl)-3,5-bis-trifluoromethyl-benzamide
TFA salt
##STR00247##
[0819] The title compound was prepared as colorless oil from TFA
de-protection of
3-[2-(3,5-bis-trifluoromethyl-benzoylamino)-acetylamino]-azetidine-1-carb-
oxylic acid tert-butylester (as prepared in the previous step)
using the procedure described in Step E of Example 1.
[0820] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.28 (s, 2H), 8.05
(s, 1H), 4.63 (m, 1H), 4.40 (m, 2H), 4.15 (m, 2H), 3.88 (m,
2H).
Step C
N-{[1-(4-Phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3,5-bis-triflu-
oromethyl-benzamide
##STR00248##
[0822] The title compound was prepared as a white solid by
reductive amination of 4-phenyl-cyclohexanone (Aldrich) and
N-(azetidin-3-ylcarbamoylmethyl)-3,5-bistrifluoromethyl-benzamide
(as prepared in the previous step) using the procedure described in
Step C of Example 4.
[0823] 75a: Less Polar Isomer from Silica Gel Column
[0824] .sup.1H NMR (MeOH) .delta.: 8.51 (s, 2H), 8.20 (s, 1H), 7.26
(d, J=4.3 Hz, 4H), 7.05-7.19 (m, 1H), 4.53 (t, J=7.1 Hz, 1H), 4.08
(s, 2H), 3.77 (t, J=7.8 Hz, 2H), 3.09 (t, J=7.7 Hz, 2H), 2.45-2.66
(m, 2H), 1.87 (d, J=14.4 Hz, 2H), 1.75-1.82 (m, 2H), 1.41-1.67 (m,
4H).
[0825] 75b: More Polar Isomer from Silica Gel Column
[0826] .sup.1H NMR (MeOH) .delta.: 8.52 (s, 2H), 8.20 (s, 1H),
7.11-7.33 (m, 5H), 4.51 (t, J=7.1 Hz, 1H), 4.08 (s, 2H), 3.73 (t,
J=7.8 Hz, 2H), 3.04-3.20 (m, 2H), 2.17-2.35 (m, 2H), 1.82-2.00 (m,
4H), 1.38-1.62 (m, 2H), 1.08-1.19 (m, 2H).
Example 76
3-Fluoro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-tri-
fluoromethyl-benzamide
Step A
3-[2-(3-trifluoromethyl-5-fluoro-benzoylamino)-acetylamino]-azetidine-1-ca-
rboxylic acid tent-butyl ester
##STR00249##
[0828] The title compounds were prepared as white solids from the
EDCI coupling of 3-amino-azetidine-1-carboxylic acid tert-butyl
ester (BetaPharma) and
(5-fluoro-3-trifluoromethyl-benzoylamino)-acetic acid (analog
synthesis by the procedure described in Organic Synthesis XII,
40-2, 1932) using the procedure described in Step F of Example
1.
[0829] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.05 (s, 1H), 7.89
(d, J=7.5 Hz, 1H), 7.41 (d, J=7.2 Hz, 1H), 4.55 (m, 1H), 4.28 (t,
J=7.2 Hz, 2H), 4.15 (d, J=3.0 Hz, 2H), 3.80 (t, J=4.5 Hz, 2H), 1.45
(s, 9H).
Step B
N-(Azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-5-fluoro-benzamide
TFA salt
##STR00250##
[0831] The title compound was prepared as colorless oil from the
TFA de-protection of
3-[2-(5-fluoro-3-trifluoromethyl-benzoylamino)-acetylamino]-azetidine-1-c-
arboxylic acid tert-butylester (as prepared in the previous step)
using the procedure described in Step E of Example 1.
[0832] .sup.1H NMR (MeOH) .delta.: 8.06 (s, 1H), 7.91 (d, J=9.1 Hz,
1H), 7.65 (d, J=8.3 Hz, 1H), 4.52-4.71 (m, 1H), 4.21 (t, J=8.5 Hz,
2H), 4.08 (s, 2H), 3.86 (dd, J=9.1, 5.3 Hz, 2H)
Step C
3-Fluoro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-tri-
fluoromethyl-benzamide
##STR00251##
[0834] The title compound was prepared as a white solid by
reductive amination of 4-phenyl-cyclohexanone (Aldrich) and
N-(azetidin-3-ylcarbamoylmethyl)-5-fluoro-3-trifluoromethyl-benzamide
(as prepared in the previous step) using the procedure described in
Step C of Example 4.
[0835] 76a: Less Polar Isomer from Silica Gel Column
[0836] .sup.1H NMR (MeOH) .delta.: 8.09 (s, 1H), 7.93 (d, J=9.1 Hz,
1H), 7.69 (d, J=8.3 Hz, 1H), 7.26 (d, J=4.5 Hz, 4H), 7.06-7.19 (m,
1H), 4.51 (quin, J=7.0 Hz, 1H), 4.06 (s, 2H), 3.69 (t, J=7.7 Hz,
2H), 2.96 (t, J=7.7 Hz, 2H), 2.48-2.63 (m, 1H), 2.42 (t, J=3.4 Hz,
1H), 1.80-1.99 (m, 2H), 1.69-1.80 (m, 2H), 1.48-1.64 (m, 4H)
[0837] 76b: Less Polar Isomer from Silica Gel Column
[0838] .sup.1H NMR (MeOH) .delta.: 8.09 (s, 1H), 7.93 (d, J=9.3 Hz,
1H), 7.70 (d, J=8.3 Hz, 1H), 7.26 (d, J=4.5 Hz, 4H), 7.08-7.21 (m,
1H), 4.51 (quin, J=7.0 Hz, 1H), 4.06 (s, 2H), 3.62-3.76 (m, 2H),
2.96 (t, J=7.6 Hz, 2H), 2.50-2.66 (m, 1H), 2.42 (t, J=3.4 Hz, 1H),
1.80-1.94 (m, 2H), 1.62-1.80 (m, 2H), 1.57 (d, J=12.1 Hz, 4H)
Example 77
3-Bromo-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-trif-
luoromethyl-benzamide
##STR00252##
[0840] The title compound was prepared as a white solid from the
EDCI coupling of
2-amino-N-[1-(4-phenyl-cyclohexyl)-azetidin-3-yl]-acetamide TFA
salt (as prepared in Step D of Example 66) and
5-bromo-3-trifluoromethyl-benzoic acid (Aldrich) using the
procedure described in Step F of Example 1. .sup.1H NMR (MeOH)
.delta.: 8.35 (s, 1H), 8.21 (s, 1H), 8.07 (s, 1H), 7.27 (s, 4H),
7.13 (s, 1H), 4.41-4.61 (m, 1H), 4.05 (s, 2H), 3.70 (t, J=7.7 Hz,
2H), 2.90-3.06 (m, 2H), 2.51-2.64 (m, 1H), 2.37-2.47 (m, 1H),
1.81-1.95 (m, 2H), 1.75 (dd, J=13.4, 3.0 Hz, 2H), 1.49-1.64 (m,
4H), 0.80-1.06 (m, 1H).
Example 78
3-Nitro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-trif-
luoromethyl-benzamide
##STR00253##
[0842] The title compound was prepared as a white solid from the
EDCI coupling of
2-amino-N-[1-(4-phenyl-cyclohexyl)-azetidin-3-yl]-acetamide TFA
salt (as prepared in Step D of Example 66) and
5-nitro-3-trifluoromethyl-benzoic acid (Aldrich) using the
procedure described in Step F of Example 1.
[0843] .sup.1H NMR (MeOH) .delta.: 9.02 (s, 1H), 8.71 (s, 1H), 8.63
(s, 1H), 7.26 (d, J=4.3 Hz, 4H), 7.07-7.20 (m, 1H), 4.55 (t, J=7.2
Hz, 1H), 4.01-4.16 (m, 2H), 3.80 (t, J=7.7 Hz, 2H), 3.13 (t, J=5.9
Hz, 2H), 2.47-2.64 (m, 2H), 1.86 (d, J=8.1 Hz, 2H), 1.73-1.83 (m,
2H), 1.52-1.71 (m, 4H), 0.83-1.07 (m, 1H)
Example 79
3-Amino-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-trif-
luoromethyl-benzamide
##STR00254##
[0845] The title compound was prepared as a white solid from the
hydrogenation of
5-nitro-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-tri-
fluoromethyl-benzamide (as prepared in Example 78) using the
procedure described in Step G of Example 1.
[0846] .sup.1H NMR (MeOH) .delta.: 7.23 (s, 1H), 7.26 (s, 1H), 7.14
(d, J=4.3 Hz, 5H), 7.01-7.09 (m, 1H), 6.97 (s, 1H), 4.40 (quin,
J=7.1 Hz, 1H), 3.90 (s, 2H), 3.62 (t, J=7.6 Hz, 2H), 2.92 (t, J=7.1
Hz, 2H), 2.41-2.52 (m, 1H), 2.38 (br. s., 1H), 1.68-1.84 (m, 2H),
1.64 (d, J=10.6 Hz, 2H), 1.45 (s, 4H), 1.49 (s, 2H).
Example 80
3-Bis
methanesulfonly-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]--
methyl}-5-trifluoromethyl-benzamide
##STR00255##
[0848] The title compound was prepared as a white solid from
mesylation of
3-amino-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-tri-
fluoromethyl-benzamide (as prepared in Example 79) using the
procedure described in Examples 16 and 17.
[0849] .sup.1H NMR (MeOH) .delta.: 8.39 (s, 1H), 8.25 (s, 1H), 8.04
(s, 1H), 7.27 (s, 4H), 7.07-7.22 (m, 1H), 4.55 (s, 1H), 4.08 (s,
2H), 3.78 (t, J=7.6 Hz, 2H), 3.44-3.58 (m, 6H), 3.05-3.21 (m, 2H),
2.49-2.68 (m, 2H), 1.76-1.92 (m, 4H), 1.52-1.67 (m, 4H).
Example 81
3-Hydroxy-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-tr-
ifluoromethyl-benzamide
##STR00256##
[0851] The title compound was prepared as a white solid from the
EDCI coupling of
2-amino-N-[1-(4-phenyl-cyclohexyl)-azetidin-3-yl]-acetamide TFA
salt (as prepared in Step D of Example 66) and
5-hydroxy-3-trifluoromethyl-benzoic acid (Alfa Aesar) using the
procedure described in Step F of Example 1.
[0852] .sup.1H NMR (MeOH) .delta.: 8.11 (d, J=8.8 Hz, 1H), 7.98 (d,
J=9.3 Hz, 1H), 7.67-7.80 (m, 1H), 7.49-7.62 (m, 1H), 7.22-7.37 (m,
4H), 4.61 (s, 1H), 4.09-4.24 (m, 2H), 3.51 (br. s., 2H), 3.16 (s,
2H), 1.54-1.72 (m, 2H), 1.22-1.44 (m, 8H)
Example 82
3-(3-tert-Butyl-ureido)-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl-
]-methyl}-5-trifluoromethyl-benzamide
##STR00257##
[0854] The title compound was prepared as a white solid from
coupling of
3-amino-N-{[1-(4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-5-tri-
fluoromethyl-benzamide (as prepared in Example 79) with
t-butyl-isocynate (Aldrich) using the procedure described in
Example 18.
[0855] .sup.1H NMR (MeOH) .delta.: 7.78 (d, J=11.1 Hz, 1H), 7.55
(s, 1H), 7.15 (d, J=14.9 Hz, 1H), 7.05 (d, J=4.5 Hz, 4H), 6.88-6.99
(m, 1H), 4.22-4.38 (m, 1H), 3.82 (s, 2H), 3.52 (t, J=7.1 Hz, 2H),
2.71-2.90 (m, 2H), 2.32-2.44 (m, 1H), 2.27 (br. s., 1H), 1.66 (d,
J=11.4 Hz, 2H), 1.55 (d, J=12.6 Hz, 2H), 1.28-1.43 (m, 4H),
1.10-1.20 (m, 9H).
Example 83
N-{[1-(4-Fluoro-4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-tri-
fluoromethyl-benzamide
##STR00258##
[0857]
N-{[1-(4-Hydroxy-4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methy-
l}-3-trifluoromethyl-benzamide (as prepared in Example 30, 680 mg,
1.43 mmol) in DCM (5 mL) was treated with DAST (Aldrich, 418 .mu.L,
4.29 mmol) dropwise at -78.degree. C. for 4 hours. The reaction was
quenched with MeOH, warmed to room temperature and partitioned
between DCM and water. The organic layer was washed with brine,
dried over anhydrous Na.sub.2SO.sub.4, filtered, concentrated and
the residue was purified by a CombiFlash.RTM. system using ethyl
acetate and 7N NH.sub.3 in MeOH as eluent (from pure ethyl acetate
to 5% 7N NH.sub.3 in MeOH in ethyl acetate) to afford two title
compound as white solid: less polar isomer.
[0858] 83a: Less Polar Fraction from Silica Gel Column
[0859] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.12 (s, 1H), 8.05
(d, J=6.5 Hz, 1H), 7.80 (d, J=6.2 Hz, 1H), 7.60 (t, J=6.8 Hz, 1H),
7.50 (d, J=6.5 Hz, 1H), 7.35.about.7.22 (m, 4H), 6.85 (s, br, 1H),
4.58 (m, 1H), 4.20 (d, J=3.1 Hz, 2H), 3.68 (m, br, 2H), 2.95 (s,
br, 3H), 2.15 (m, 2H), 1.90 (m, 2H), 1.75 (m, 2H), 1.58 (m,
2H).
[0860] 83b: More Polar Fraction from Silica Gel Column
[0861] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.10 (s, 1H), 8.02
(d, J=6.0 Hz, 1H), 7.75 (d, J=6.0 Hz, 1H), 7.62 (m, 2H),
7.45.about.7.20 (m, 4H), 4.60 (m, 1H), 4.20 (d, J=3.0 Hz, 2H), 3.70
(m, br, 2H), 3.08 (s, br, 3H), 1.90.about.1.68 (m, 6H), 1.55 (m,
2H).
Example 84
N-{[1-(4-Amino-4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trif-
luoromethyl-benzamide
Step A
2-Methyl-propane-2-sulfinic acid
(1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide
##STR00259##
[0863] To a solution of 1,4-dioxa-spiro[4.5]decan-8-one (Aldrich,
4.07 g, 26.1 mmol) and 2-methyl-propane-2-sulfinic acid amide
(Aldrich, 3.16 g, 26.1 mmol) in THF (20 mL) was added Ti(OEt).sub.4
(Aldrich, 10.8 mL, 52.2 mmol) at room temperature. The reaction was
stirred overnight and quenched with .about.5 mL water until
precipitation completed. The solid was filtered off and washed with
additional ethyl acetate. The combined filtrate was dried over
anhydrous Na.sub.2SO.sub.4, filtered, concentrated and the residue
was purified by a CombiFlash.RTM. system using hexanes and ethyl
acetate as eluent (from pure hexanes to pure ethyl acetate) to
afford the title compound as colorless oil.
[0864] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 4.01 (s, 4H), 3.10
(m, 1H), 2.93 (m, 1H), 2.65 (t, J=6.0 Hz, 2H), 1.95 (m, 4H), 1.21
(s, 9H).
Step B
4-Amino-4-phenyl-cyclohexanone
##STR00260##
[0866] A solution of phenyl magnesium bromide (Aldrich, 1.0 N in
THF, 5.7 mL, 5.70 mmol) was added into the solution of
2-methyl-propane-2-sulfinic acid
(1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide (as prepared in the
previous step, 1.23 g, 4.75 mmol) in THF (10 mL) at 0.degree. C.
After addition, the reaction was slowly warmed to room temperature
over 2 hours. 1N HCl (5 mL) was added, and the reaction was stirred
overnight. The reaction was quenched with saturated sodium
bicarbonate. The solvent was removed in vacuo and the residue was
partitioned between DCM and water. The organic layer was washed
with brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to afford the title compound as colorless oil.
[0867] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.50.about.7.25
(m, 5H), 2.90 (m, 2H), 2.35 (m, 4H), 2.10 (m, 2H), 1.82 (s, br,
2H).
Step C
N-{[1-(4-Amino-4-phenyl-cyclohexyl)-azetidin-3-ylcarbamoyl]-methyl}-3-trif-
luoromethyl-benzamide
##STR00261##
[0869] The title compound was prepared as a white solid by
reductive amination of 4-amino-4-phenyl-cyclohexanone (as prepared
in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0870] 84a: Less Polar Isomer from Silica Gel Column
[0871] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.18 (s, 1H),
8.10 (d, J=6.5 Hz, 1H), 7.85 (d, J=7.0 Hz, 1H), 7.72 (t, J=6.0 Hz,
2H), 7.65 (d, J=6.0 Hz, 2H), 7.38 (t, J=6.0 Hz, 2H), 7.25 (m, 1H),
4.37 (m, 1H), 3.98 (s, 2H), 3.62 (m, 2H), 3.04 (m, 2H), 2.70 (m,
br, 1H), 2.30 (m, 2H), 1.85 (m, 2H), 1.65 (m, 2H), 1.50 (m,
2H).
[0872] 84b: More Polar Isomer from Silica Gel Column
[0873] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.22 (s, 1H),
8.15 (d, J=6.2 Hz, 1H), 7.88 (d, J=7.0 Hz, 1H), 7.70 (t, J=6.5 Hz,
1H), 7.62 (d, J=7.0 Hz, 2H), 7.48 (t, J=7.0 Hz, 2H), 7.32 (m, 1H),
4.34 (m, 1H), 4.02 (s, 2H), 3.69 (t, J=7.0 Hz, 2H), 3.11 (t, J=7.2
Hz, 2H), 2.75 (m, br, 1H), 2.35 (m, 1H), 1.90 (m, 6H), 1.18 (m,
2H).
Example 85
N-{[1-(4-Amino-4-benzo[1,3]dioxol-5-yl-cyclohexyl)-azetidin-3-ylcarbamoyl]-
-methyl}-3-trifluoromethyl-benzamide
Step A
4-Amino-4-benzo[1,3]-dioxol-5-yl-cyclohexanone
##STR00262##
[0875] The title compound was prepared as a white solid from
addition of 3,4-methylenedioxo-phenyl magnesium bromide (Aldrich)
to 2-methyl-propane-2-sulfinic acid
(1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide (as prepared in Example
84, Step A) followed by hydrolysis using the procedure described in
Step B of Example 84.
[0876] ESI-MS (m/z): Calcd. For C.sub.13H.sub.15NO.sub.3, 233;
found: 234 (M+H).
Step B
[0877]
N-{[1-(4-Amino-4-benzo[1,3]-dioxol-5-yl-cyclohexyl)-azetidin-3-ylca-
rbamoyl]-methyl}-3-trifluoromethyl-benzamide
##STR00263##
[0878] The title compound was prepared as a white solid by
reductive amination of
4-amino-4-benzo[1,3]dioxol-5-yl-cyclohexanone (as prepared in the
previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0879] 85a: Less Polar Isomer from Silica Gel Column
[0880] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.21 (s, 1H),
8.15 (d, J=5.6 Hz, 1H), 7.88 (d, J=5.0 Hz, 1H), 7.71 (t, J=6.5 Hz,
1H), 7.15 (s, 1H), 7.12 (d, J=6.0 Hz, 1H), 6.91 (d, J=6.5 Hz, 1H),
6.02 (s, 2H), 4.35 (m, 1H), 4.02 (s, 2H), 3.70 (t, J=6.0 Hz, 2H),
3.15 (d, J=6.0 Hz, 2H), 2.72 (m, 2H), 2.35 (m, 1H), 1.90 (m, 4H),
1.25 (m, 2H).
[0881] 85b: More Polar Isomer from Silica Gel Column
[0882] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.22 (s, 1H),
8.18 (d, J=6.0 Hz, 1H), 7.90 (d, J=6.0 Hz, 1H), 7.70 (t, J=6.8 Hz,
1H), 7.13 (s, 1H), 7.10 (d, J=6.0 Hz, 1H), 6.88 (d, J=6.6 Hz, 1H),
6.01 (s, 2H), 4.50 (m, 1H), 4.10 (s, 2H), 3.88 (t, J=7.0 Hz, 2H),
3.29 (d, J=7.0 Hz, 2H), 2.45 (m, 1H), 2.25 (m, 2H), 2.10 (m, 2H),
1.85 (m, 2H), 1.55 (m, 2H).
Example 86
N-({1-[4-Amino-4-(4-methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
Step A
4-Amino-4-(4-methoxy-phenyl)-cyclohexanone
##STR00264##
[0884] The title compound was prepared as a white solid from
addition of 4-methoxy-phenyl magnesium bromide (Aldrich) to
2-methyl-propane-2-sulfinic acid
(1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide (as prepared in Example
84, Step A) followed by the hydrolysis using the procedure
described in Step B of Example 84.
[0885] ESI-MS (m/z): Calcd. For C.sub.13H.sub.17NO.sub.2, 219;
found: 220 (M+H).
Step B
N-({1-[4-Amino-4-(4-methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
##STR00265##
[0887] The title compound was prepared as a white solid by
reductive amination of 4-amino-4-(4-methoxy-phenyl)-cyclohexanone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0888] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.22 (s, 1H),
8.11 (d, J=6.2 Hz, 1H), 7.85 (d, J=7.0 Hz, 1H), 7.70 (t, J=6.5 Hz,
1H), 7.54 (d, J=7.0 Hz, 2H), 7.02 (d, J=7.0 Hz, 2H), 4.52 (m, 1H),
4.08 (s, 2H), 3.95 (s, 3H), 3.69 (t, J=7.0 Hz, 2H), 3.15 (t, J=7.2
Hz, 2H), 2.62 (m, 1H), 1.80 (m, 2H), 1.75 (m, 2H), 1.55 (m,
4H).
Example 87
N-({1-[4-Amino-4-(3-methoxy-phenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-me-
thyl)-3-trifluoromethyl-benzamide
Step A
4-Amino-4-(3-methoxy-phenyl)-cyclohexanone
##STR00266##
[0890] The title compound was prepared as a white solid from
addition of 3-methoxy-phenyl magnesium bromide (Aldrich) to
2-methyl-propane-2-sulfinic acid
(1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide (as prepared in Example
84, Step A) followed by hydrolysis using the procedure described in
Step B of Example 84.
[0891] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 7.20 (t, J=5.6
Hz, 1H), 7.05 (s, 1H), 6.98 (m, 1H), 6.71 (d, J=6.5 Hz, 1H), 3.65
(s, 3H), 2.60 (m, 2H), 2.35 (m, 2H), 2.21 (m, 2H), 1.95 (m,
2H).
Step B
N-({1-[4-Amino-4-(3-methoxyphenyl)-cyclohexyl]-azetidin-3-ylcarbamoyl}-met-
hyl)-3-trifluoromethyl-benzamide
##STR00267##
[0893] The title compound was prepared as a white solid by
reductive amination of 4-amino-4-(3-methoxy-phenyl)-cyclohexanone
(as prepared in the previous step) and
N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide (as
prepared in step B of Example 4) using the procedure described in
Step C of Example 4.
[0894] 86a: Less Polar Isomer from Silica Gel Column
[0895] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.25 (s, 1H),
8.18 (d, J=5.6 Hz, 1H), 7.88 (d, J=5.0 Hz, 1H), 7.71 (t, J=6.5 Hz,
1H), 7.28 (t, J=6.0 Hz, 1H), 7.12 (d, J=6.0 Hz, 1H), 7.10 (s, 1H),
6.81 (d, J=6.5 Hz, 1H), 4.35 (m, 1H), 4.02 (s, 2H), 3.81 (s, 3H),
3.60 (t, J=6.0 Hz, 2H), 3.02 (d, J=6.0 Hz, 2H), 2.45 (m, 2H), 2.30
(m, 1H), 1.83 (m, 2H), 1.65 (m, 2H), 1.12 (m, 2H).
[0896] 86b: More Polar Isomer from Silica Gel Column
[0897] .sup.1H NMR (400 MHz, d.sub.4-MeOH) .delta. 8.15 (s, 1H),
8.05 (d, J=6.6 Hz, 1H), 7.80 (d, J=6.0 Hz, 1H), 7.62 (t, J=6.5 Hz,
1H), 7.30 (t, J=6.2 Hz, 1H), 7.08 (d, J=6.5 Hz, 1H), 7.05 (s, 1H),
6.91 (d, J=6.5 Hz, 1H), 4.55 (m, 1H), 4.23 (t, J=7.0 Hz, 2H), 4.02
(s, 2H), 3.85 (t, J=7.0 Hz, 2H), 3.75 (s, 3H), 3.10 (m, 1H), 2.28
(m, 2H), 2.15 (m, 2H), 1.98 (m, 2H), 1.65 (m, 2H).
Example 88
In Vitro Biological Data
[0898] Compounds of the invention were subjected to various
representative biological tests. The results of these tests are
intended to illustrate the invention in a non-limiting fashion.
[0899] MCP-1 Receptor Binding Assay in THP-1 Cells
[0900] Human monocytic cell line THP-1 cells were obtained from
American Type Culture Collection (Manassas, Va., USA). The THP-1
cells were grown in RPMI-1640 (RPMI: Roswell Park Memorial
Institute Medium-cell culture growth media) supplemented with 10%
fetal bovine serum in a humidified 5% CO.sub.2 atmosphere at
37.degree. C. The cell density was maintained between
0.5.times.10.sup.6cells/mL.
[0901] THP-1 (cells were incubated with 0.5 nM .sup.125I labeled
MCP-1 (Perkin-Elmer Life Sciences, Inc. Boston, Mass.) in the
presence of varying concentrations of either unlabeled MCP-1 (R
& D Systems, Minneapolis, Minn.) or test compound for 2 hours
at 30.degree. C. in a 96 well plate. Cells were then harvested onto
a filter plate, dried, and 20 .mu.L of Microscint 20 was added to
each well. Plates were counted in a TopCount NXT, Microplate
Scintillation & Luminescence Counter (Perkin-Elmer Life
Sciences, Inc. Boston, Mass.). Blank values (buffer only) were
subtracted from all values and drug treated values were compared to
vehicle treated values. 1 .mu.M cold MCP-1 was used for nonspecific
binding.
[0902] Table 1 lists IC.sub.50 values for inhibition of MCP-1
binding to CCR2 obtained for test compounds of the invention. Where
an IC.sub.50 value was not obtained for a particular compound, the
percent inhibition is provided at a test concentration of 25
.mu.M.
TABLE-US-00001 TABLE 1 Inhibition of MCP-1 Binding IC.sub.50
Example CCR2 Binding (nM) 1a 1.2 2a 390 3a 45 4a 33 5a 9 6a 200 7a
50 8a 85 9 80 10 70 11a 135 12 220 13 61 14a 440 15 337 16 100 17
27 18 >25,000 19 130 20a 27 21a 30 22 8,600 23 260 24a 340 25
320 26 70 27 86 28 200 29 280 30a 36 31a 46 32a 63 33a 25 34a 310
35a 190 36a 21 37a 69 38a 190 39a 15 40a 21 41 160 42 130 43 38 44
124 45 6,900 46a 110 47a 206 48a 413 49 810 50 230 51a 228 52 160
53 240 54a 62 55a 5,300 56a 5,200 57a 33 58a 52 59 100 60 100 61
130 62 82 63a 150 64 110 65a 150 66 620 67 600 68 740 69 240 70
1,700 71a 200 72 400 73 490 74 46 75a 4,700 76a 220 77 380 78 1,000
79 23 80 420 81 11,000 82 50 83a 120 84a 240 85a 280 86 320 87a
330
Example 90
Animals
[0903] Mouse CCR2 knock-out/human CCR2 knock-in mice were generated
using targeted 129Sv/Evbrd embryonic stem cell clones injected into
C57BL/6 mice. Expression of the hCCR2 transcript was confirmed by
quantitative reverse transcription-polymerase chain reaction
performed on spleen and blood total RNA from homozygous hCCR2
knock-in mice. Backcrossing into C57BL/6 genetic background
continued to the eighth generation. Transgenic mice were housed in
a specific-pathogen-free, temperature-controlled facility that
maintained a 12-hour light/12-hour dark cycle. Mice had free access
to water and food. Experimental procedures were carried out in
accordance with institutional standards for animal care and were
approved by the institute's animal care and use committee.
Example 91
Murine In Vivo Cell Migration Assay
[0904] Animals were orally dosed with vehicle or CCR2 antagonists
at 3, 10 and 30 mg/kg bid. Animals underwent anesthesia and
laparotomy. A distal loop of small bowel (5 cm in length) was
gently eventrated onto moist sterile gauze. Synthetic human MCP-1
(1 mg/100 ml sterile PBS) or PBS alone was administered drop-wise
onto the serosa of the eventrated loop. A suture knot was placed
into the mesentery to mark the terminus of the treated area.
Twenty-four hours later, the animal was sacrificed and the segment
of bowel plus the adjacent region was removed. The tissue was
opened along the mesenteric border, pinned flat and the mucosa
removed. The remaining muscle layer was fixed briefly in 100% EtOH
and then stained using Hanker-Yates reagent to detect
myeloperoxidase-containing immune cells. At 30 mpk, P.O. bid, a
compound is deemed efficacious if the inhibition of cell migration
reaches 30% compared with vehicle-treated animals. The compounds of
Example #1 and Example #30 were found to be efficacious in blocking
cell migration.
Example 92
Thiolycollate-Induced Peritonitis in Mice
[0905] Animals were orally dosed with vehicle or CCR2 antagonists
at 30 mg/kg bid). One hour later, the animals were
intraperiponeally injected with sterile thioglycollate (25 mL/kg,
ip, Sigma) for induction of peritonitis. Animals were orally
treated twice daily with vehicle or CCR2 antagonists. At 72-hour
time point, perinoteal cavities were lavaged with 10 mL of sterile
saline. Total cell counts in the peritoneal lavage fluid were
performed using a microscope and cell differentiation was performed
using cytospin analysis after Giemsa staining (Hema Tek 2000).
Percent inhibition of the thioglycollate-induced peritonitis was
calculated by comparing the change in number of leukocytes of CCR2
antagonist treated mice to the vehicle-treated mice. At 30 mpk,
p.o. bid, the compounds of Example #1 and Example #30 were shown to
have >50% inhibition of thioglycollate-induced peritonitis.
Example 93
MCP-1-Induced Monocyte Recruitment to Airway of Mice
[0906] Animals are orally treated with vehicle or CCR2 antagonists
at 3, 10, and 30 mg/kg po bid). One hour later, the animals are
intranasally dosed with 4 .mu.g of MCP-1 in sterile saline. The
animals are orally treated twice daily with vehicle or CCR2
antagonists. After 48 h, mice are euthanized by intraperitoneal
injection of anesthesia solution (Sleepaway-Sodium pentobarbital).
Whole bronchoalveolar lavage (BAL) is performed using 1.4 ml of
ice-cold PBS containing 3 mM EDTA. Total cell counts in the BAL
lavage fluid are performed using a microscope and cell
differentiation is performed using cytospin analysis after Giemsa
staining (Hema Tek 2000). Percent inhibition is calculated by
comparing the change in number of total leukocyte counts (including
monocytes/macrophages and lymphocytes) of compound-treated mice to
the vehicle-treated mice. Compounds are deemed efficacious if
percent inhibition reaches 30%.
Example 94
High-Fat Diet Induced Obesity and Insulin Resistance in Mice
[0907] Obesity was induced by a high-fat diet that derived
approximately 60% calories from lipids (D-12492; Research Diets
Inc.) in animals for 10-24 weeks at age of 7 weeks. Prior to age 7
weeks, animals were fed a standard pellet diet, in which 5% of
calories were provided as fat. Obese animals were randomized by
body weight and fat mass. The obese animals were orally treated
with vehicle or CCR2 antagonists at 30 mg/kg, po bid. Body weight
and food intake and fasting blood glucose levels were monitored.
Body mass was determined by a NMR analyzer (Burker MiniSpec).
Insulin tolerance test was carried out in animals that were fasted
for 3 hours. After an intraperitoneal bolus injection of
recombinant human insulin (1.5 U/kg), blood glucose concentrations
were measured using a Glucometer before and 15, 30, 45, 60, 90 and
120 minutes after injection. Glucose tolerance tests were performed
after an overnight (17-hour) fast. Blood glucose concentrations
were measured before and after 15, 30, 60, 90, 120 minutes after an
oral dose of glucose dissolved in water (1 g/kg). Energy
expenditure analysis was monitored by a complete laboratory animal
monitor system. After 40 days treatment with vehicle or CCR2
antagonists, the animals were sacrificed by CO.sub.2 asphyxiation.
Percent of weight loss was calculated by comparing the body weight
changes of the compound-treated mice with the vehicle-treated mice.
At 30 mpk, p.o. bid, the compound of Example #30 was shown to
reduce body weight >8%.
Example 95
Mouse Model of Allergic Asthma
[0908] Animals were sensitized by intraperitoneal injection of 10
.mu.g chicken egg albumin (OVA) absorbed to 1 mg Imject.RTM. in 100
.mu.L phosphate-buffered saline (PBS) on days 0 and 5. Control
animals received PBS ip. OVA-immunized animals were challenged by
inhalation of 0.5% OVA aerosol for 10 minutes by an ultrasonic
nebulizer on days 12, 16 and 20. Control animals were challenged
with PBS in similar fashion. The OVA-sensitized animals received
vehicle (0.5% Methocel) or CCR2 antagonists orally at 3, 10, mg/kg
twice daily from days 9-20 and once daily on day 21, 2 hours before
sacrifice. Dexamethason (5 mg/kg) and Montelukast (1 mg/kg) were
given orally once a day. On day 21, 2 hours post the last dose of
CCR2 compounds, bronchial reactivity to aerosolized methacholine
was measured using a Buxco whole body plethysmograpgh. On day 21,
the animals were sacrificed. Bronchoalveolar lavage fluid was
collected (1 mL) and total cells counted. The numbers of
eosinophils, lymphocytes, monocytes and neutrophils were determined
using cytospin analysis after Giemsa staining (Hema Tek 2000).
Percent inhibition of total BAL leukocyte count (and eosinophil
count) was calculated by comparing the compound-treated mice with
vehicle-treated mice. Compounds are deemed efficacious if the
inhibition reaches 30%. At 10 mpk, p.o. bid, the compound of
Example #30 was shown to be efficacious in reduction of cell
count.
[0909] While the foregoing specification teaches the principles of
the present invention, with examples provided for the purpose of
illustration, it will be understood that the practice of the
invention encompasses all of the usual variations, adaptations
and/or modifications as come within the scope of the following
claims and their equivalents.
* * * * *